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ABSTRACT
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that
provides a molecular link between the coagulation and fibrinolytic systems. TAFI is
activated through proteolytic cleavage by thrombin and plasmin although they are
relatively weak activators. However, thrombin in complex with the endothelial cell
cofactor thrombomodulin (TM), or plasmin in the presence of glycosaminoglycans
(GAGs), such as heparin, are able to greatly accelerate the activation of TAFI to generate
the enzyme activated TAFI (TAFIa). Additionally, the presence of GAGs has been shown
to stabilize the enzyme, TAFIa, increasing its half-life. TAFIa possesses basic
carboxypeptidase activity which down-regulates fibrin clot lysis by removing carboxylterminal lysine and arginine residues from partially degraded fibrin thereby, attenuating
the positive feedback in the fibrinolytic cascade that is essential for plasminogen
activation. The work in this dissertation is focused on understanding the regulation of
TAFI activation and evaluating TAFIa activity. Through construction of mutant variants
of TAFI in putative interaction regions with TM and GAGs, we have identified important
regions on the TAFI structure that mediate the accelerated activation by the thrombin-TM
complex and the acceleration of plasmin-mediated TAFI activation by GAGs and the
stabilization of the TAFIa enzyme. We found that the region on TAFI that showed the
strongest TM dependence was focused around the activation domain of TAFI, which
would be near where the c-loop of EGF-3 of TM would contact TAFI. We also identified
residues on TAFI that could be part of a heparin binding site that allows GAGs to mediate
the acceleration of plasmin-mediated TAFI activation and stabilization of the TAFIa
enzyme. As well, we have designed a novel fluorescence based assay for the
measurement of the basic carboxypeptidase activity of TAFIa, which has significantly
increased sensitivity compared to the currently available carboxypeptidase B (CPB)
substrates. Taken together, the results of the studies described will aid in further
propelling the determination of the mechanism of TAFI activation by the respective
activators as well as provide a sensitive tool for monitoring the carboxypeptidase activity
of TAFIa.

v

DEDICATION

I dedicate this work to my parents, Munir and Suzan, and my brother Raymond for their
love and support

vi

ACKNOWLEDGEMENTS
First and foremost, I would like to sincerely thank my supervisor, Dr. Michael
Boffa for giving me the opportunity to work in his laboratory at the University of
Windsor. I am very grateful for his constant guidance, patience, and encouragement
throughout the years and the opportunities he has provided that has allowed me to reach
this level. I would also like to thank Dr. Marlys Koschinsky for all of her input, advice,
and support during my time as a graduate student which has been greatly appreciated.
Next, I would like to thank my committee members, Dr. Bulent Mutus, Dr. Otis
Vacratsis, Dr. Andrew Swan, and my external examiner, Dr. Patricia Liaw, for being on
my committee, the valuable suggestions and advice they provided in our meetings over
the years, and the time spent reading my dissertation. Thank you to all the professors in
the Biochemistry Department; Dr. Sirinart Ananvoranich, Dr. Bulent Mutus, Dr. Siyaram
Pandey, and Dr. Lana Lee, who have all contributed to my growth and knowledge and
allowed me to use all the equipment required for my research. Thank you to the support
staff in the Chemistry and Biochemistry department; Marlene Bezaire, Cathy Wilson,
Beth Kickham, Joe Lichaa, Jerry Vriesacker, and Alina Jaworska-Sobiesiak for answering
questions and all of their assistance over the years.
I would like to thank all current and past graduate students in the MBB and MLK
labs who have been a part of my graduate experience and who have made the last few
years so pleasant and memorable. Thank you to Dr. Rocco Romagnuolo, Corey Scipione,
Christina Rizzo, Anastassia Filipieva, and Zainab Bazzi for their assistance, friendship,
and support throughout the years. Thank you to Dr. Ronan San Juan for help setting up
the liquid nitrogen for preparing phospholipid vesicles. Thank you to Kara Picco for her
vii

assistance in generating preliminary results for Chapter 5 and Mousa Gawanmeh for his
assistance in completing the cloning for Chapter 3. Thank you to Dr. Joellen Lin and Dr.
Mathieu Garand for their advice and support, especially at the beginning of my graduate
studies. Thank you to Justin Garabon, Sera Sayegh, Matt Gemin, and Jackson Mcainey
for the coffee runs and endless jokes that always kept my spirits up. Thank you to Dr.
Nicole Ferric, Dr. Dragana Komnenov, Kristen, Tazeen, Branna, Jen, Zach, and Scott.
Also, I would like to thank everyone in the Biochemistry Department that has made my
experience so enjoyable and I am thankful for the friendships I have gained. Over the
years, spending many long hours and late nights in the lab you have all become an
extension of my family and for that I will forever be grateful. I wish them all the best in
their future endeavours.
I would like to thank my friends who have always been very understanding and
supportive. And last but not least, I would like to thank my family; my parents, Munir and
Suzan, and my brother, Raymond for their unconditional love, continuous support, and
encouragement throughout my university education and the completion of this
dissertation. I would not be where I am today without them.

viii

TABLE OF CONTENTS

DECLARATION OF CO-AUTHORSHIP AND PREVIOUS PUBLICATION ....... iii
ABSTRACT ....................................................................................................................... v
DEDICATION.................................................................................................................. vi
ACKNOWLEDGEMENTS ........................................................................................... vii
LIST OF TABLES ......................................................................................................... xiv
LIST OF FIGURES ........................................................................................................ xv
LIST OF ABBREVIATIONS ...................................................................................... xvii
Chapter 1 ........................................................................................................................... 1
General Introduction ........................................................................................................ 1
Chapter 1 General Introduction ..................................................................................... 1
1.1

Introduction ............................................................................................................ 2

1.2

Overview of Haemostasis ...................................................................................... 2

1.3

The Coagulation Cascade ...................................................................................... 5
1.3.1

1.4

The Anticoagulant pathway ....................................................................................... 13

The Fibrinolytic Cascade .................................................................................... 15
1.4.1

Antifibrinolytic pathways .......................................................................................... 17

1.5

The TAFI Pathway as a Link between Coagulation and Fibrinolysis ............ 18

1.6

TAFI ...................................................................................................................... 19
1.6.1

Properties and Expression of the TAFI Protein ......................................................... 20

1.6.2

Activation of TAFI..................................................................................................... 22

1.6.2.1

Thrombomodulin and TAFI activation .................................................................. 25

1.6.2.2

Plasmin as an activator of TAFI............................................................................. 27

1.6.2.3

Glycosaminoglycans and their effect on TAFI/TAFIa .......................................... 29

1.6.3

Inactivation of TAFI .................................................................................................. 33

1.7

The Function of TAFI in Fibrinolysis ................................................................ 36

1.8

The Physiological Role of TAFI .......................................................................... 40
ix

1.9

Measurement of TAFI ......................................................................................... 45

1.10

Rationale, Hypothesis and Objectives ................................................................ 47

1.11

References ............................................................................................................. 49

Identification of a Thrombomodulin Interaction Site on Thrombin-Activatable
Fibrinolysis Inhibitor that Mediates Accelerated Activation by Thrombin .............. 61
Chapter 2 Identification of a Thrombomodulin Interaction Site on ThrombinActivatable Fibrinolysis Inhibitor that Mediates Accelerated Activation by
Thrombin ......................................................................................................................... 61
2.1

Summary ............................................................................................................... 62

2.2

Introduction .......................................................................................................... 63

2.3

Experimental Procedures .................................................................................... 66

2.4

2.3.1

Materials..................................................................................................................... 66

2.3.2

Construction of TAFI Variants .................................................................................. 67

2.3.3

Expression and Purification of Recombinant TAFI Variants .................................... 68

2.3.4

Kinetics of activation of TAFI variants by thrombin-thrombomodulin complex ...... 68

2.3.5

Kinetics of activation of TAFI variants by thrombin ................................................. 69

2.3.6

Activation of TAFI variants by plasmin .................................................................... 69

2.3.7

Thermal Stability Assay of the TAFIa variants ......................................................... 70

2.3.8

Clot Lysis Assays ....................................................................................................... 70

2.3.9

Statistical Methods ..................................................................................................... 71

Results ................................................................................................................... 72
2.4.1

Construction, expression, and purification of TAFI variants ..................................... 72

2.4.2

Kinetics of activation of TAFI variants by thrombin in the presence of TM ............. 74

2.4.3

Kinetics of activation of TAFI variants by thrombin ................................................. 78

2.4.4

Activation of TAFI variants by plasmin .................................................................... 81

2.4.5

Thermal Stabilities of the TAFI variants ................................................................... 83

2.4.6

Antifibrinolytic potential of TAFI variants ................................................................ 85

2.5

Discussion.............................................................................................................. 88

2.6

Acknowledgements .............................................................................................. 92

2.7

Addendum ............................................................................................................ 92

2.8

References ............................................................................................................. 93
x

2.9

Supporting information ....................................................................................... 95

Chapter 3 ........................................................................................................................... 96
Role of residues 1 through 12 of the activation domain of TAFI in activation of TAFI by
thrombin-thrombomodulin ................................................................................................ 96
Chapter 3 Role of residues 1 through 12 of the activation domain of TAFI in
activation of TAFI by thrombin-thrombomodulin ...................................................... 96
3.1

Summary ............................................................................................................... 97

3.2

Introduction .......................................................................................................... 98

3.3

Experimental Procedures .................................................................................. 100

3.4

3.3.1

Materials................................................................................................................... 100

3.3.2

Construction of TAFI Activation Domain Deletion Mutants .................................. 101

3.3.3

Transient Transfection of TAFI Activation Domain Deletion Mutants ................... 102

3.3.4

Activation of TAFI Mutants and Western blot analysis .......................................... 103

3.3.5

RNA Extraction and DNase Treatment of RNA ...................................................... 104

3.3.6

Real-time quantitative RT-PCR ............................................................................... 104

Results ................................................................................................................. 106
3.4.1

Expression of N-terminal deletion TAFI variants .................................................... 106

3.5

Discussion............................................................................................................ 113

3.6

References ........................................................................................................... 118

Chapter 4 ....................................................................................................................... 120
Identification of Heparin Interaction Sites on Thrombin-Activatable Fibrinolysis
Inhibitor that Modulate Plasmin-mediated Activation, Thermal Stability and
Antifibrinolytic potential .............................................................................................. 120
Chapter 4 Identification of Heparin Interaction Sites on Thrombin-Activatable
Fibrinolysis Inhibitor that Modulate Plasmin-mediated Activation, Thermal
Stability and Antifibrinolytic potential ....................................................................... 120
4.1

Summary ............................................................................................................. 121

4.2

Introduction ........................................................................................................ 123

4.3

Experimental Procedures .................................................................................. 126
4.3.1

Materials................................................................................................................... 126

4.3.2

Construction of TAFI Variants ................................................................................ 127

4.3.3

Expression and purification of recombinant TAFI variants ..................................... 129
xi

4.4

4.3.4

Binding of TAFI to heparin...................................................................................... 130

4.3.5

Kinetics of activation of TAFI variants by plasmin ................................................. 130

4.3.6

Thermal stability of the TAFIa variants ................................................................... 131

4.3.7

Barium Adsorbed TAFI-Deficient Plasma............................................................... 132

4.3.8

Clot Lysis Assays ..................................................................................................... 132

4.3.9

Statistical Methods ................................................................................................... 133

Results ................................................................................................................. 134
4.4.1

Construction, expression, and purification of TAFI variants ................................... 134

4.4.2

Binding of TAFI variants to heparin-agarose .......................................................... 137

4.4.3 Kinetics of activation of TAFI variants by plasmin in the absence and presence of
heparin ……………………………………………………………………………………...139
4.4.4

Thermal Stabilities of the TAFI variants in the absence and presence of heparin ... 144

4.4.5

Antifibrinolytic potential of TAFI variants .............................................................. 148

4.5

Discussion............................................................................................................ 154

4.6

References ........................................................................................................... 159

Chapter 5 ....................................................................................................................... 161
A novel fluorescent assay for the measurement of activated Thrombin-Activatable
Fibrinolysis Inhibitor (TAFIa) activity ....................................................................... 161
Chapter 5 A novel fluorescent assay for the measurement of activated ThrombinActivatable Fibrinolysis Inhibitor (TAFIa) activity .................................................. 161
5.1

Summary ............................................................................................................. 162

5.2

Introduction ........................................................................................................ 164

5.3

Experimental Procedures .................................................................................. 166
5.3.1

Materials................................................................................................................... 166

5.3.2

Recombinant Wild-type TAFI and TAFI-CIIYQ .................................................... 167

5.3.3

Expression and Purification of Recombinant Wild-type TAFI and TAFI-CIIYQ ... 167

5.3.4

Spectrophotometric Measurements .......................................................................... 168

5.3.5

Screening quencher dyes of TAMRA-Gly-Ala-Gly-Arg substrate.......................... 169

5.3.6 Determination of the Effect of Chloride concentration on TAMRA-Gly-Ala-Gly-Arg
substrate and quencher interaction ....................................................................................... 170
5.3.7 Determination of the Effect of Evans Blue quencher concentration on detection of
enzymatic activity ................................................................................................................ 170
5.3.8

Thermal Stability and Activity of Wild-type TAFIa ................................................ 171
xii

5.3.9

Generating a Standard Curve for Measuring TAFIa Concentration ........................ 171

5.3.10 Measuring TAFI activation in real-time .................................................................. 172
5.3.11 Activity of TAFIa toward synthetic substrates ........................................................ 172

5.4

Results ................................................................................................................. 174
5.4.1

TAMRA-Gly-Ala-Gly-Arg substrate Assay Concept .............................................. 174

5.4.2

Spectral Properties of TAMRA-Gly-Ala-Gly-Arg substrate ................................... 176

5.4.3 Fluorescence quenching of TAMRA-Gly-Ala-Gly-Arg substrate by binding of
quencher ............................................................................................................................... 178
5.4.4 Influence of Chloride on TAMRA-Gly-Ala-Gly-Arg substrate and quencher
interaction ............................................................................................................................. 185
5.4.5

Influence of Evans Blue on detection of enzymatic activity .................................... 187

5.4.6

Standard Curves ....................................................................................................... 189

5.4.7 Thermal Stability and Enzymatic Activity of Wild-type TAFI in the absence or
presence of assay components.............................................................................................. 193
5.4.8

Monitoring Activation of TAFI in real-time ............................................................ 195

5.4.9

TAFIa activity toward synthetic substrates .............................................................. 197

5.5

Discussion............................................................................................................ 201

5.6

References ........................................................................................................... 206

Chapter 6 ....................................................................................................................... 208
General Discussion ........................................................................................................ 208
Chapter 6 General Discussion..................................................................................... 208
6.1

The interaction between TAFI and thrombomodulin .................................... 210

6.2

The interaction between TAFI and Heparin ................................................... 216

6.3

Monitoring TAFIa activity with a Fluorescence-based assay ........................ 222

6.4

Concluding Remarks ......................................................................................... 225

6.5

References ........................................................................................................... 227

VITA AUCTORIS ........................................................................................................ 231

xiii

LIST OF TABLES
Table 2-1. Kinetic Parameters for Activation of TAFI variants by thrombin-TM or
thrombin alone .................................................................................................................. 77
Table 2-2. Intrinsic Stability of TAFI variants ................................................................. 84
Supplementary Table 2-1. Primer sequences for construction of TAFI Variants .......... 95
Table 4-1. Primer sequences for mutagenesis of TAFI .................................................. 128
Table 4-2. Kinetic parameters for activation of TAFI variants by plasmin in the absence
of heparin ........................................................................................................................ 143
Table 4-3. Kinetic parameters for activation of TAFI variants by plasmin in the presence
of heparin ........................................................................................................................ 143
Table 4-4. Intrinsic Stability of TAFI variants in the absence and presence of heparin 145
Table 5-1. Dissociation constant and Hill constant between quencher and substrate .... 184
Table 5-2. Intrinsic Stability and activity of Wild-type TAFIa in the absence and presence
of assay components ....................................................................................................... 194
Table 5-3. TAFIa Activity toward substrates ................................................................. 200

xiv

LIST OF FIGURES
Figure 1-1. The coagulation and fibrinolysis systems. ...................................................... 7
Figure 1-2. Activation of TAFI and inactivation of TAFIa. ............................................ 24
Figure 1-3. Structure of thrombomodulin (TM). ............................................................. 26
Figure 1-4. The role of the TAFI pathway in fibrinolysis................................................ 38
Figure 2-1. Mutations analyzed in this study. .................................................................. 73
Figure 2-2. The kinetics of activation of TAFI variants by thrombin in the presence of
TM……………………………………………………………………………………….76
Figure 2-3. The kinetics of activation of TAFI variants by thrombin. ............................. 80
Figure 2-4. Plasmin-mediated activation of TAFI variants. ............................................ 82
Figure 2-5. The antifibrinolytic potential of TAFI variants in the presence of TM......... 87
Figure 3-1. TAFI amino-terminal deletion mutants. ...................................................... 108
Figure 3-2. Activation of TAFI amino-terminal deletion mutants................................. 110
Figure 3-3. Quantification of amino-terminal deletion mutants expression. ................. 112
Figure 3-4. Structure of the activation domain of TAFI. ............................................... 117
Figure 4-1. Putative glycosaminoglycan binding sites on TAFI. .................................. 135
Figure 4-2. Mutations of Potential heparin binding sites on TAFI. ............................... 136
Figure 4-3. Binding of TAFI variants to heparin-agarose.............................................. 138
Figure 4-4. Effect of heparin on the kinetics of activation of the TAFI variants by
plasmin. ........................................................................................................................... 142
Figure 4-5. Effect of heparin on the stabilities of the TAFIa variants. .......................... 147
Figure 4-6. Effect of heparin on the antifibrinolytic potential of the TAFI variants. .... 151
Figure 4-7. Effect of heparin on the anfibrinolytic potential of the TAFIa variants. ..... 153
Figure 5-1. Schematic representation of the fluorescent carboxypeptidase assay. ........ 175
xv

Figure 5-2. Spectral properties of TAMRA-Gly-Ala-Gly-Arg substrate. ..................... 177
Figure 5-3. Structure of components of the fluorescent assay. ...................................... 180
Figure 5-4. Visualization of Evans Blue titration with TAMRA-Gly-Ala-Gly-Arg
substrate. ......................................................................................................................... 181
Figure 5-5. Quencher titration of TAMRA-Gly-Ala-Gly-Arg substrate. ...................... 182
Figure 5-6. Hill plot of TAMRA-Gly-Ala-Gly-Arg substrate with quenchers. ............. 183
Figure 5-7. Effect of NaCl on TAMRA-Gly-Ala-Gly-Arg substrate and quencher
interaction. ...................................................................................................................... 186
Figure 5-8. Effect of Evans Blue on detection of enzymatic activity. ........................... 188
Figure 5-9. Standard fluorescence progress curves........................................................ 191
Figure 5-10. Standard curve plots. ................................................................................. 192
Figure 5-11. Activation of TAFI progress curve. .......................................................... 196
Figure 5-12. Enzymatic activity of wild-type TAFIa toward synthetic carboxypeptidase B
substrates. ........................................................................................................................ 199

xvi

LIST OF ABBREVIATIONS
Abbreviation

Definition

AAFK

anisylazoformyl-lysine

AAFR

anisylazoformyl-arginine

ε-ACA

ε-aminocaproic acid

ADP

adenosine diphosphate

APC

activated protein C

AT

antithrombin

BAP

barium adsorbed plasma

BHK

baby hamster kidney cells

cDNA

complement deoxyrinonucleic acid

CPB

carboxypeptidase B

CPR

carboxypeptidase R

CPU

carboxypeptidase U

DIC

disseminated intravascular coagulation

DMEM

dulbecco’s modified eagle medium

DTT

dithiothreitol

EDTA

ethylenediaminetetraacetic acid

EGF

epidermal growth factor

EPCR

endothelial protein C receptor

FDPs

fibrin degradation products

FV

coagulation factor V

FVa

activated coagulation factor V

FVII

coagulation factor VII

FVIIa

activated coagulation factor VIIa

FVIII

coagulation factor VIII

FVIIIa

activated coagulation factor VIIIa

FIX

coagulation factor IX

FIXa

activated coagulation factor IXa

FX

coagulation factor X

FXa

activated coagulation factor Xa

FXI

coagulation factor XI

FXIa

activated coagulation factor XIa

FXII

coagulation factor XII
xvii

FXIIa

activated coagulation factor XIIa

FXIII

coagulation factor XIII

FXIIIa

coagulation factor XIIIa

GAGs

glycosaminoglycans

GEMSA

2-guanidinoethylmercaptosuccinic acid

Gla

γ-carboxyglutamate residues

GlcA

β- D-glucuronic acid

GlcN

α-D-glucosamine

GP

glycoprotein

GP Ia/IIa

glycoprotein Ia/IIa receptors

GP Ib–IX-V

glycoprotein Ib–IX-V complex

HBS

HEPES-buffered saline

HBST

HEPES-buffered saline/0.01% (v/v) Tween 80

HEK293

human embryonic kidney cells

HEPES

N-(2-hydroxyethyl)-piperazine-N’-(2-ethansulfonic
acid)

Hipp-Arg, HR

hippuryl-L-arginine

6×His tag

hexa histidine tag

HPLC

high-performance liquid chromatography

IdoA

α-L-iduronic acid

kcat

maximum rate of enzyme catalysis per unit enzyme

kcat/KM

catalytic efficiency

KM

Michaelis-Menten constant

Kd

dissociation constant

LCI

leech carboxypeptidase inhibitor

LETS

Leiden Thrombophilia Study

LMWH

low molecular weight heparin

βME

2-mercaptoethanol

MERGEPTA

2-mercaptomethyl-3-guanindinoethylthiopropannoic
acid

NCS

newborn calf serum

NO

nitric oxide

Opti-MEM

reduced serum minimal essential medium

PAI-1

plasminogen activator inhibitor-1

PAR1, PAR4

protease-activated receptors
xviii

PC

protein C

PC/PS

phosphatidylcholine/phosphatidylserine

PGI2

prostacyclin

Plg

plasminogen

Plummer’s inhibitor

DL-2-mercaptomethyl-3guanidinoethylthiopropanoic acid

PMSF

phenylmethanesulfonyl fluoride

PPAck

D-phenylalanylprolylarginyl chloromethylketone

pro-pCPB

procarboxypeptidase B

PSF

penicillin/streptomyocin/fungizone

PTCI

potato tuber carboxypeptidase inhibitor

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel
electrophoresis

Serpins

serine protease inhibitors

TAFI

thrombin-activatable fibrinolysis inhibitor

TAFIa

activated TAFI

TAFIai

inactivated TAFIa

TAMRA

tetramethylrhodamine

TCI

tick carboxypeptidase inhibitor

TdP

TAFI-deficient plasma

TdBAP

TAFI-deficient barium adsorbed plasma

TF

tissue factor

TFPI

tissue factor pathway inhibitor

TM

thrombomodulin

tPA

tissue-type plasminogen activator

qRT-PCR

quantitative real-time reverse transcription
polymerase chain reaction

UH

unfractionated heparin

uPA

urokinase-type plasminogen activator

uPAR

urokinase-type plasminogen activator receptor

VFKck

D-Val-Phe-Lys chloromethylketone

vWF

von Willebrand factor

xix

Chapter 1
General Introduction

Chapter 1 General Introduction

1

1.1 Introduction
Haemostasis is a protective mechanism that prevents significant blood loss upon
vascular injury while maintaining the fluidity of blood elsewhere in the circulation [1, 2].
It involves the rapid and highly localized formation of a stable haemostatic plug to
efficiently seal the lesion in the vessel wall. Haemostasis involves a balance between the
opposing pathways of the coagulation cascade involved in fibrin clot formation and the
fibrinolytic cascade involved in clot dissolution. Each pathway comprises many different
components which require coordinated activity in addition to interplay between the
systems. The entire process is tightly regulated and ensures the clot is removed in a timely
manner following repair to the damaged tissue. These pathways are constantly active and
tightly controlled through a balance of anticoagulant and procoagulant activities.
Different stimuli can disturb and shift the balance which could either lead to inappropriate
clot formation or inability to form a stable clot causing thrombosis or excessive blood
loss, respectively [1-4].

1.2 Overview of Haemostasis
Haemostasis encompasses many complex processes, all occurring simultaneously, in
order to seal the rupture in the damaged blood vessel. This is accomplished by three
general components: the vascular wall, platelets, and the coagulation pathway [2].
Endothelial cells, lining the inner surface of the blood vessels, play an important role in
maintaining the haemostatic balance. The endothelium expresses various anticoagulant
and procoagulant molecules and their distribution varies throughout the vasculature [5].
Under normal physiological states, the balance is in favour of anticoagulant activities by
2

maintaining the blood in a fluid state and preventing clot formation. The

intact

endothelium mediates its anticoagulant activities by releasing vasodilatators (prostacyclin
(PGI2), nitric oxide (NO)), preventing platelet adhesion and activation (PGI2, NO, ectoadenosine

diphosphatase),

preventing

coagulation

(surface

expression

of

thrombomodulin, heparin-like molecules, endothelial protein C receptor (EPCR), and
secretion of tissue factor pathway inhibitor (TFPI)), and preventing fibrin deposition
(secreting tissue-type plasminogen activator (tPA)). Injury to the endothelium causes a
shift in the balance in favour of procoagulant activities to promote clot formation and
prevent excessive blood loss. The procoagulant activities include promoting platelet
adhesion and activation (producing von Willebrand factor (vWF)), enhancing coagulation
(induced by bacterial endotoxin or cytokines to express tissue factor (TF) and coagulation
factor V (FV)), and inhibiting clot dissolution (secreting plasminogen activator inhibitor1 (PAI-1) [5-9].
The endothelial cells are located at the interface between the flowing blood and the
sub-endothelial structures deep within the layers of the blood vessel wall. In normal
circumstances, plasma proteins, platelets and cellular elements suspended in flowing
blood never make sustained contact with the endothelial surface due to the anticoagulant
properties of healthy endothelium [1, 7]. The endothelium provides a protective layer
from the basement membrane and extracellular matrix located in the intimal layer
immediately beneath the endothelium. The extracellular matrix is composed of adhesive
proteins such as collagen, fibronectin, laminin, vitronectin, and vWF, allowing platelet
adhesion in the event of denudation or injury of the endothelium. In addition, the vessel
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wall contains TF which is a membrane protein located on smooth muscle cells,
fibroblasts, and macrophages that initiates blood coagulation [1].
Following vascular injury, the first step is immediate constriction of the damaged
blood vessels. Vasoconstriction temporarily decreases blood flow within the vessel to
immediately limit bleeding [6]. The lesion in the vessel wall results in exposure of the
subendothelial extracellular matrix allowing platelets to make contact with these
structures thereby triggering adhesion. Platelets possess many different receptors on their
surface, allowing them to bind to collagen or other adhesive proteins such as vWF. In
high shear conditions found in arteries and the microcirculation (blood velocity between
300-1600 s-1), vWF is essential for platelet adhesion to the sub-endothelium; vWF acts as
a bridge by binding to collagen and platelet membrane glycoprotein Ib–IX-V (GP Ib–IXV) complex [7, 10]. In low shear conditions as in veins (blood velocity approximately 20200 s-1) platelet adhesion is mediated through other platelet receptors, such as
glycoprotein Ia/IIa (GP Ia/IIa) and α2β1 integrin interaction with collagen [10]. Platelet
adhesion results in activation of the platelets causing a change in shape, from discoid
shape to formation of pseudopodia giving them a spikey appearance and allowing them to
spread out on the surface of the injury [11].
Platelet activation results in intracellular signalling which stimulates release of a
variety of substances from their granules. There are two types of platelet granules
important in haemostasis. Platelet alpha granules contain fibrinogen, fibronectin,
coagulation factors V and VIII (FVIII), platelet factor 4, and growth factors among other
substances. Platelet dense granules contain platelet activators or agonists such as
adenosine diphosphate (ADP), ionized calcium, and serotonin [12]. Release of these
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platelet agonists, in particular ADP, serves to recruit and activate additional platelets at
the injury site. This promotes platelet aggregation by allowing them to adhere to the layer
of platelets already present, eventually forming a loose platelet plug, the first haemostatic
structure. In addition, ADP mediated platelet activation induces a conformational change
of the platelet glycoprotein IIb/IIIa allowing activated platelets to form a high affinity
bond to fibrinogen as well as bind to vWF, fibronectin, and vitronectin. The platelets
ability to bind to fibrinogen, forming a bridge between adjacent activated platelets, allows
them to stick to one another and contributes to spreading the platelet aggregates over the
exposed subendothelium. The platelet plug temporarily reduces blood loss, but is not
enough to seal the lesion in the vessel wall. Since vasoconstriction and platelet plug
formation occur very rapidly they are often grouped together and referred to as primary
haemostasis. The next step of haemostasis known as the coagulation cascade or
secondary haemostasis is what reinforces and strengthens this platelet plug [7, 12].

1.3 The Coagulation Cascade
The coagulation pathway is a very intricate process and comprises a series of
zymogen to enzyme conversions. The coagulation pathway was initially represented as a
“cascade” or “waterfall” model which was an important advance in understanding the
complicated process [13, 14]. However, this model was found not to be representative of
in vivo clinical observations thus was refined as a cell-based model which is a better
predictor of the in vivo phenomena. The cell-based model emphasizes that different cell
surfaces serve to control and regulate the coagulation process. The cell-based coagulation
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model is viewed as occurring in three overlapping phases: initiation, amplification, and
propagation (Figure 1-1) [15].

6

Figure 1-1. The coagulation and fibrinolysis systems. The cell based model of
haemostasis consists of the initiation, amplification and the propagation phase. The
initiation pathway of coagulation, traditionally known as the extrinsic pathway, generates
a small amount of thrombin (IIa) that is able to convert the soluble plasma protein
fibrinogen into insoluble fibrin fibres to promote fibrin clot formation. The large burst of
thrombin produced by the intrinsic pathway consolidates the fibrin clot, partly through the
activation of thrombin-activatable fibrinolysis inhibitor (TAFI). When thrombin binds to
thrombomodulin (TM) forming a complex, it loses its procoagulant abilities and instead
functions as an anticoagulant or antifibrinolytic enzyme through its ability to activate
protein C (PC) or TAFI, respectively. Fibrin degradation is accomplished by plasmin (Pn)
which is formed through activation of plasminogen (Plg) by tissue plasminogen activator
(tPA) with the fibrin surface acting as an important cofactor. Partial degradation of fibrin
by plasmin results in a form of fibrin that exposes carboxyl-terminal lysine and arginine
residues. Exposure of the basic residues enhances the cofactor function of fibrin
promoting the positive feedback mechanism of plasminogen activation. TAFIa attenuates
this positive feedback by removing the carboxyl-terminal basic residues. Therefore, the
TAFI pathway inhibits plasminogen activation and down-regulates fibrinolysis. The
figure was adapted and modified from reference [3].
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The coagulation process begins when there is a breach in the vascular endothelium
and the flowing blood is exposed to the extravascular tissue, more specifically to cells
expressing TF. TF is an integral membrane protein expressed by fibroblasts,
macrophages, and smooth muscle cells and during inflammatory states is expressed by
activated endothelial cells and monocytes [16-18]. Activated factor VII (FVIIa)
circulating in the plasma, representing about 1% of the total and the remaining 99% as
FVII zymogen, rapidly binds to TF [19]. The TF-FVIIa complex activates the plasma
zymogens, factor IX (FIX) and factor X (FX), to their activate serine protease forms,
FIXa and FXa, on the cell surface. At high concentrations of TF, FX is activated by the
TF-FVIIa complex whereas at low concentrations of TF, FIX is mainly activated [20, 21].
The zymogen FVII is also able to bind to TF where then FIXa and FXa, in addition to
FVIIa, can feedback amplify the system by activating FVII bound to TF [22]. Factor Xa
is then able to interact with its cofactor FV on the cell surface and activate it. The
interaction of FXa-FVa complex with prothrombin forms the prothrombinase complex,
activating prothrombin to generate a small amount of thrombin. This pathway of
thrombin generation is called the initiation pathway and is traditionally known as the
extrinsic pathway of coagulation since it involves extravascular elements [15, 23].
Formation of the thrombin enzyme is key in coagulation as it has many important
functions in haemostasis including activation of platelets, conversion of the plasma
protein fibrinogen to fibrin which is involved in forming a fibrin net around the platelet
plug, and feedback amplification of the coagulation pathway [22]. The TF-FVIIa complex
functions on TF bearing cells and in close proximity to the partially activated platelet
surface at the site of injury. This localization is an important step in amplification of the
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procoaguant stimulus. The FX activated on TF bearing cells is quickly inhibited by
plasma protease inhibitors TFPI and antithrombin (AT) if it diffuses away from the cell
surface and into the blood. This is a vital and reoccurring theme in coagulation to localize
reactions to the surface of cells to protect them from inhibition. TFPI and AT can interact
with FXa directly inhibiting it; in addition, the TFPI-Xa complex can inhibit the TFFVIIa complex [24, 25]. Nevertheless, the remaining FXa on the TF bearing cell surface
is able to produce enough thrombin to fully activate the neighbouring platelets through
their protease-activated receptors (PAR1 and PAR4), increasing their adhesion, as well as
activate factors V, VIII, and XI (FXI) on the platelet surface [26-28]. Moreover, the
platelet receptor GP Ib–IX can not only bind vWF but also thrombin since both proteins
have distinct binding sites on the receptor therefore both can bind simultaneously [29].
This allows thrombin to activate coagulation factors directly on the platelet surface. For
example, FVIII exists in plasma bound to vWF as a noncovalent complex since FVIII is
highly unstable. When vWF binds to GP Ib–IX receptor, it brings FVIII in close
proximity to thrombin allowing it to activate FVIII resulting in dissociation of FVIIIa
from vWF [30, 31].
Activation of platelets allows a release of various substances from their granules
including ionized calcium, partially activated FV, and FVIII as previously mentioned.
Factor Xa and thrombin can fully activate FV released from platelets. Platelet activation
also results in exposure of negatively charged phospholipids on their membrane which
provide a surface for coagulation factors to assemble and localize their activity [15, 32].
Coagulation factors VII, IX, X and prothrombin interact with the negatively charged
phospholipid through their amino-terminal -carboxyglutamate (Gla) residues. These
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coagulation factors are referred to as vitamin K-dependent factors since they require
vitamin K for the proper synthesis of their Gla domain and calcium is essential for the
proper folding of the domain. Calcium also mediates the binding of the proteins to the
phospholipid surface through the interaction of one calcium ion with two -carboxyl
groups from the Gla domain [33]. In addition, activation of platelets exposes protein
receptors or binding sites on their surface for coagulation factors to interact with high
affinity [15, 34-37]. Another reoccurring mechanism in coagulation is the assembly of
complexes consisting of enzyme, substrate and cofactor on the cell surface to allow the
proper positioning of the enzyme-cofactor-substrate to enhance catalytic activity and
facilitate efficient activation. This localized assembly sets the stage for large amount of
thrombin generation on the platelet surface referred to as propagation [15].
The small amount of thrombin formed from the extrinsic pathway is sufficient to
form a fibrin net around the platelet plug, entrapping various blood cells to produce a
thrombus. However, this amount of thrombin is not enough to stabilize the fibrin clot.
The generation of large amounts of thrombin is necessary to protect the clot from
degradation and only takes place after the formation of the fibrin clot through feedback
amplification of the coagulation pathway [15, 22, 23]. This pathway of thrombin
generation is called the propagation phase or the intrinsic pathway since coagulation is
initiated by components within the vasculature.
The intrinsic pathway can initiate coagulation in vitro through the activation of
coagulation factor XII (FXII) upon contact with polyanionic surfaces such as glass or
kaolin in the so-called the contact pathway [38, 39]. The binding of FXII to negatively
charged surfaces leads to auto activation to form activated factor XIIa (FXIIa). Factor
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XIIa converts prekallikrein to kallikrein which in turn proteolytically cleaves highmolecular weight kininogen to release the vasodilator bradykinin. Additional FXII
activation occurs through a positive feedback loop following formation of kallikrein [38].
Factor FXII can also be activated through contact with pathophysiological activators such
as platelet polyphosphates, DNA, and RNA [40-42]. Generation of FXIIa as well as
kallikrein leads to activation of FXI to FXIa [38]. As previously mentioned, FXI can also
be activated directly by thrombin independent of the contact pathway components. In
fact, individuals with a deficiency of FXII or other proteins of the contact pathway
(prekallikrein or high-molecular weight kininogen) do not result in bleeding diathesis
which indicates the contact pathway is not vital for physiological haemostasis [43].
However, this pathway may be significant in the setting of iatrogenic thrombosis such as
occurs from indwelling catheters.
During the propagation phase, factor IXa that was activated on TF bearing cells is
able to diffuse to the activated platelet surface since it is not rapidly inhibited by AT or
other plasma protease inhibitors. Factor IX can also be directly activated on the platelet
surface by thrombin. Then, factor IXa can interact with its cofactor FVIIIa to form the
tenase complex, which activates FX to FXa [15, 27]. Formation of FXa by the tenase
complex is approximately 50-fold more efficient than that formed by the extrinsic
pathway [27, 44]. Factor Xa formed directly on the surface of the platelet allows it to
quickly form a complex with its cofactor FVa to assemble the prothrombinase complex
allowing a burst of thrombin formation close to the injury to allow stabilization of the
thrombus. Amplification of thrombin generation occurs through factor XI. Factor XIa that
was activated by thrombin on the platelet surface is able to directly activate FIX
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providing additional FIXa to enhance the formation of the tenase complex. Thus, the
coordinated assembly of the tenase and prothrombinase complex on the surface of
activated platelets sets the stage for large scale thrombin production within the fibrin clot
[15, 23].
Thrombin catalyzes the conversion of the soluble plasma protein, fibrinogen to fibrin,
an insoluble protein. Fibrinogen is important in promoting platelet aggregation during
primary haemostasis and fibrin is involved in forming a mesh around the platelet plug,
entrapping various blood cells to stabilize the haemostatic plug during secondary
haemostasis [1]. Fibrinogen is synthesized in the liver and is released into the
bloodstream at high concentrations (1.5-3 mg/mL). Its structure is elongated and consists
of three pairs of polypeptides called Aα, Bβ and γ that are linked together at their aminotermini through disulfide bonds. The fibrinogen structure consists of three connected
nodules: the central E nodule containing the amino-terminal residues of the polypeptides,
and two distal D nodules. Thrombin cleaves fibrinogen releasing fibrinopeptide A and
fibrinopeptide B from the amino-terminal central E nodule forming a fibrin monomer.
Cleavage unmasks polymerization sites in the E nodule that allows fibrin monomers to
interact laterally where the D nodule of one monomer can non-covalently interact with
the exposed polymerization site on the E nodule of another monomer. The fibrin dimers
then laterally associate to form protofibrils and polymerization continues to grow forming
fibrin fibres varying in length and forming branches creating a fibrin mesh around the
platelet plug [45]. The high concentration of thrombin generated inside the clot, activates
factor XIII (FXIII), which is a transglutaminase enzyme found in plasma and released
from the alpha granules of platelets. Factor XIIIa catalyzes isopeptide bonds between
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adjacent D nodules in fibrin, cross-linking the fibrin fibers providing structural stability to
the clot and increases the resistance of the clot to degradation [46, 47]. Activated FXIII
(FXIIIa) also cross-links many other plasma proteins to fibrin incorporating them into the
fibrin clot including fibronectin, α2-antiplasmin inhibitor [48], vWF [49], factor V [50],
thrombospondin [51], and thrombin-activatable fibrinolysis inhibitor (TAFI) [52].
The rate of thrombin formation greatly influences the architecture of the fibrin clot
and thus its stability. Studies have shown that fibrin clots formed during high rates of
thrombin generation produce thinner fibrin fibers that are tightly packed and less porous
and as a result were more resistant to degradation. On the other hand, low rates of
thrombin generation tend to produce thicker fibrin fibers that are loosely packed and more
porous and therefore susceptible to increased degradation [53].

1.3.1

The Anticoagulant pathway

The coagulation pathway is regulated at several stages during the progression of
thrombin formation by different protease inhibitors or interference with the cofactor
ability of some enzyme-substrate complexes. The anticoagulant pathways that regulate
coagulation include: TFPI, AT, and protein C (PC).
TFPI is a protein that is synthesized and secreted into the circulation primarily by
endothelial cells. TFPI is mostly found bound to heparan sulfate found on endothelial
cells and bound to lipoproteins in the plasma; a small concentration is also present in the
alpha granules of platelets. TFPI can inhibit FXa by directly binding to it and inactivating
it. The TFPI-FXa complex can then inhibit TF–FVIIa complex thereby preventing the
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activation of FX. TFPI can only inhibit the TF–FVIIa complex when in a complex with
FXa [54].
AT is a serpin-type protease inhibitor that is recognized by activated coagulation
plasma proteins FIXa, FXa, FXIa, and thrombin. AT can be found bound to
glycosaminoglycans (GAGs) present on the surface of endothelial cells. It is a suicide
substrate inhibitor that forms a 1:1 stable covalent complex with the activated coagulation
factor and in the presence of GAGs the inhibition is greatly accelerated [3, 55]. AT
inhibits free enzymes in plasma and is not able to inactivate enzymes in the tenase or
prothrombinase complex or thrombin bound to fibrin since their active sites are less
accessible even in the presence of GAGs [22].
Thrombomodulin (TM) is an integral membrane protein expressed on the cell surface
of all endothelial cells in the vasculature [4, 5]. Any generated thrombin that diffuses
from the fibrin clot is able to bind to TM located on intact endothelium. When thrombin
binds to TM forming a complex, thrombin loses its procoagulant activities such as
activation of platelets, activation of coagulation factors V, VIII, IX, XI, XIII, and
cleavage of fibrinogen. Instead, thrombin bound to TM functions as an anticoagulant
enzyme by activating the vitamin K-dependent PC to activated protein C (APC). The
activation of PC is localized to the endothelial surface through binding to an EPCR in
proximity to the thrombin-TM complex. APC with its cofactor, protein S, can cleave
cofactors FVa and FVIIIa inactivating them thereby down regulating thrombin
generation. APC can inactivate FVa and FVIIIa bound to the activated platelet surface as
well as when they are assembled in prothrombinase or tenase complex, respectively [22,
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56]. These anticoagulant pathways all aim to control and localize the coagulation pathway
to the site of vascular injury.

1.4 The Fibrinolytic Cascade
The conversion of the plasma protein fibrinogen to fibrin results in the formation of a
fibrin mesh around the platelet plug that provides the clot shape, strength, flexibility and
stability. The fibrin mesh surrounding the clot acts as a scaffold to support endothelial
cell growth and movement during wound healing [45]. The function of the fibrinolytic
cascade is to promote fibrin clot dissolution and recanalization of the vessel wall.
Fibrinolysis is analogous to the coagulation pathway in that it involves a series of
zymogen to enzyme conversions, feedback amplification, and inhibition at different
stages [1].
In normal circumstances, tPA is constitutively secreted into the circulation and is
immediately inhibited by PAI-1 with a very low concentration of free tPA remaining [8].
The fibrinolytic system becomes activated when FXa and thrombin are continually
released into the bloodstream stimulating the increased secretion of tPA from endothelial
cells [57-59]. Therefore, initiation of fibrinolysis is dependent on the balance of tPA
secretion and PAI-1. Another type of plasminogen activator is urokinase-type
plasminogen activator (uPA) but it is only produced by perturbed endothelial cells. In
addition, uPA is primarily involved in pericellular proteolysis during tissue remodelling
and cell migration through binding to its receptor (uPAR) on the cell surface. On the other
hand, tPA is mainly involved in dissolution of the fibrin clot through its ability to bind to
fibrin [60].
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Fibrinolysis begins when tPA and plasminogen bind to the fibrin surface. The
binding of plasminogen to fibrin is mediated by its kringle domains also called lysine
binding sites. tPA binds to fibrin via its finger domain and kringle domain 2. Fibrin
functions as a cofactor to enhance plasminogen activation by providing a surface for tPA
and plasminogen to bind forming a ternary complex consisting of tPA, plasminogen, and
fibrin. The fibrin surface increases the local concentration of tPA and plasminogen and
brings the active site of tPA in close proximity to the activation site of plasminogen. This
allows tPA to catalyze the conversion of the plasma zymogen plasminogen to the serine
protease plasmin. In the absence of fibrin, tPA mediated plasminogen activation is highly
inefficient [61, 62]. Plasmin is the terminal enzyme in fibrinolysis which cleaves the
fibrin mesh at basic residues within the coiled-coil regions linking the E and D domains,
thereby producing varying sizes of soluble fibrin degradation products (FDPs). As
plasmin digests the fibrin it exposes several carboxyl-terminal lysine and arginine
residues which function as high affinity binding sites for tPA [63, 64] and plasminogen,
accelerating fibrinolysis and stimulating positive feedback in the fibrinolytic cascade [6568].
Native plasminogen inherently possesses a closed conformation and binding to fibrin,
especially partially degraded fibrin with exposed carboxyl-terminal lysine residues,
causes a conformational change in plasminogen allowing tPA better access to its cleavage
site to yield plasmin [69]. Native plasminogen has a glutamic acid residue at its aminoterminus and is referred to as Glu-plasminogen. Plasmin can modify Glu-plasminogen by
removal of the amino-terminal “tail” domain resulting in a plasminogen molecule, called
Lys-plasminogen, with Lys77 at its amino-terminus. This conversion of Glu-plasminogen
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to Lys-plasminogen enhances the positive feedback by altering the structure of
plasminogen from a closed conformation to a more open conformation, exposing the tPA
cleavage site and making it a better substrate for plasminogen activators [69, 70]. In
addition, Lys-plasminogen’s open conformation allows it to bind to fibrin with higher
affinity than Glu-plasminogen [71-73]. tPA cleaves both Glu- and Lys-plasminogen in the
latent trypsin-like protease domain to generate Glu- and Lys-plasmin, respectively [60].

1.4.1

Antifibrinolytic pathways

The fibrinolysis pathway is regulated at many levels by different inhibitors.
Plasminogen activation is inhibited by PAI-1 by targeting the plasminogen activators tPA
and uPA. Plasma- and platelet-derived PAI-1 inhibits the plasminogen activators in the
circulation that diffuse away from the fibrin clot and is also capable of binding to the
fibrin surface and inhibit tPA mediated plasminogen activation thereby preventing
premature clot dissolution [74, 75]. Plasmin is primarily inhibited by α2-antiplasmin and
to a lesser extent by α2-macroglobulin [76, 77]. Plasma- and platelet-derived α2antiplasmin interact with plasmin by binding to its kringle domains therefore, plasmin
bound fibrin is protected from inhibition allowing the plasmin generated on the fibrin
surface to continue degradation [78-80]. However, factor XIIIa is able to cross-link α2antiplasmin to fibrin which prevents plasmin from binding and prevents fibrin
degradation [81]. Both PAI-1 and α2-antiplasmin are serpins that form a covalent complex
with their target protease [82]. Overall, the relative concentrations and localization of
plasminogen, plasminogen activators and inhibitors on the fibrin clot or in the vicinity
greatly influences the extent and of clot dissolution [1].
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1.5 The TAFI Pathway as a Link between Coagulation and Fibrinolysis
The coagulation and fibrinolytic systems may appear to be functioning independently
of one another, but in fact many different components within the two systems interact and
coordinate each other’s activity. The purpose of the coagulation pathway is the formation
of a stabilized fibrin clot through generation of the enzyme thrombin. Formation of the
fibrin clot is subsequently followed by dissolution of the clot through fibrinolysis by the
actions of the enzyme plasmin. Therefore, activation of the coagulation pathway and
formation of thrombin is coordinated with the activation of the fibrinolytic pathway and
formation of plasmin. For example, thrombin generated inside the clot can activate FXIII,
which forms covalent bonds between the fibrin fibers and cross-links α2-antiplasmin to
fibrin to provide structural stability to the clot and increase the resistance to fibrinolysis
[46-48]. Coagulation proteins such as thrombin and FXa have been found to stimulate the
increased secretion of tPA from endothelial cells thereby initiating fibrinolysis following
formation of the fibrin clot [57-59]. On the other hand, plasmin formation can down
regulate the coagulation pathway – and therefore thrombin formation – by proteolytically
inactivating FXa, converting it into a fibrinolysis cofactor that is able to bind to
plasminogen and accelerate plasmin generation by tPA [83-86]. In addition, plasmin
modified FVa is able to accelerate tPA mediated plasminogen activation [87].
Another factor involved in maintaining haemostasis is TAFI. TAFI can be cleaved by
thrombin [88] or thrombin in complex with TM [89] to activate TAFI. Plasmin is also
able to cleave and activate TAFI [90]. Activated TAFI (TAFIa) attenuates fibrinolysis by
interfering with the positive feedback mechanism of plasmin generation in the fibrinolytic

18

cascade. Therefore, TAFI is a molecular link between the coagulation and fibrinolysis
pathways since activation by thrombin down regulates fibrinolysis [91].

1.6 TAFI
TAFI was discovered by four separate laboratories independently and therefore has
been designated four different names. In 1989, Hendriks and coworkers first described the
presence of a basic carboxypeptidase present in serum but not plasma and appeared
following initiation of coagulation. Basic carboxypeptidases are hydrolytic enzymes that
remove carboxyl-terminal lysine and arginine residues from protein and peptide
substrates. They noticed the disappearance of the carboxypeptidase activity at 37°C and
thus named it unstable carboxypeptidase (carboxypeptidase U, CPU) [92-94]. At the same
time, Campbell and Okada identified an unstable carboxypeptidase in serum and found its
activity was specific to arginine containing substrates and was named arginine
carboxypeptidase (carboxypeptidase R, CPR) [95]. In 1991, Eaton and coworkers isolated
a plasminogen-binding carboxypeptidase protein from plasma using plasminogenSepharose affinity chromatography. They cloned the cDNA encoding the protein from a
human liver cDNA library and through sequence analysis found that it was homologous
to pancreatic procarboxypeptidase B and therefore named the protein plasma
procarboxypeptidase B (pro-pCPB) [96]. Bajzar and coworkers were initially trying to
understand the mechanism of the profibrinolytic effect of the anticoagulant APC. They
found that APC is not directly profibrinolytic but rather it prevents the formation of
thrombin which prevented activation of a substance that inhibits fibrinolysis [97, 98]. On
the basis of these observations they reported the isolation of the protein in 1995 and
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named it thrombin-activatable fibrinolysis inhibitor (TAFI) based on its function. Amino
acid sequence analysis indicated that TAFI was the same protein identified by Eaton and
coworkers as plasma pro-pCPB [88]. Also, amino acid sequence analysis of CPU and
CPR revealed that they are identical to pro-pCPB and TAFI [99, 100].

1.6.1

Properties and Expression of the TAFI Protein

TAFI circulates as a single-chain plasma zymogen in the bloodstream. TAFI is
encoded by the CPB2 gene which is located on chromosome 13q14.11 [100]. The CPB2
gene encodes a 423-amino acid primary translation product that is referred to as a preproenzyme. The first 22-amino acids of the amino-terminus form a signal peptide which
is cleaved off prior to secretion and the remaining 401-amino acid zymogen circulates in
the blood plasma [96]. The mature TAFI protein consists of two structural domains: a 92amino acid activation domain and a 309-amino acid catalytic domain. TAFI possesses a
predicted peptide molecular mass of 45,999 Da however, the activation domain is Nglycosylated at four sites (Asn22, Asn51, Asn63, Asn86) causing it to migrate on SDSPAGE as a ~60,000 Da protein. The glycosylation accounts for ~20% of the molecular
weight of plasma TAFI [101, 102].
Amino acid sequence analysis revealed that TAFI is homologous to the family of
zinc-containing metallocarboxypeptidases including pancreatic carboxypeptidase A1, A2,
B and mast cell carboxypeptidase A. The residues of zinc-dependent carboxypeptidases
involved in coordinating the zinc ion, substrate binding as well as catalysis are all
conserved in the TAFIa catalytic domain. The differentiating feature of these
carboxypeptidases is their specificity for the carboxyl-terminal amino acid of the
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substrate. Pancreatic carboxypeptidase B and TAFIa are specific for basic carboxylterminal amino acids whereas carboxypeptidases A are specific for aliphatic or aromatic
amino acids [96, 103].
The bound Zn2+ in the active site of TAFI is coordinated to His159, Glu162 and
His288. The residues involved in substrate binding are Arg235, Tyr341 and Asp348.
Residue Asp348, found at the bottom of the channel (S1’ subsite), is involved in forming
a salt bridge with the basic side chain in the substrate (P1’ residue), while residues
Arg235 and Tyr341 assist in fixing the carboxyl-terminal group of the substrate. The key
residue involved in substrate catalysis is Glu363. Residue Glu363 along with Zn2+
activate a water molecule to generate a hydroxyl nucleophile which attacks the carbonyl
carbon on the substrate. This is followed by proton transfer and formation of a tetrahedral
intermediate that subsequently collapses and breaks the peptide bond, resulting in the
release of the carboxyl-terminal basic residue and formation of a new carboxyl-terminus
[104].
The main source for the plasma pool of TAFI arises from expression of CPB2 in the
liver [103, 105]. The concentration of TAFI in plasma varies within the human population
ranging between 73 and 275 nM [106, 107]. TAFI protein has also been identified within
the alpha granules of platelets and is released upon platelet activation [108]. While the
platelet pool of TAFI accounts for less than 0.1% of TAFI present in the vasculature,
release of platelet-derived TAFI at the thrombosis site could have a significant impact on
fibrinolysis [108, 109].
CPB2 mRNA and TAFI protein expression has recently been shown in
megakaryocytes and macrophages, although it is significantly less than in hepatic cells
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[110]. The presence of TAFI in megakaryocytes suggests that platelet-derived TAFI is
synthesized by megakaryocytes. The role of the extra-hepatic pool of TAFI within
macrophages is not known at this time but suggests that the TAFI pathway may be
implicated in other processes besides fibrinolysis [110].

1.6.2

Activation of TAFI

The TAFI zymogen becomes activated through proteolytic cleavage of the activation
domain at Arg92 to form the active 35,000 Da TAFIa carboxypeptidase B-like enzyme
(Figure 1-2). This proteolytic cleavage results in the release of the activation domain and
allows exposure of the active site cleft of TAFIa enabling interactions between its
substrates to catalyze the removal of carboxyl-terminal arginine and lysine residues [88].
Thrombin and plasmin alone are capable of cleaving the Arg92-Ala93 scissile bond.
However they are both weak activators of TAFI, as they require high concentrations of
the enzymes and long incubations to form a sufficient amount of TAFIa [88, 96].
Thrombin in complex with the endothelial cell surface cofactor TM is capable of
significantly enhancing the activation of TAFI. The thrombin-TM complex increases the
catalytic efficiency (kcat/KM) of TAFI activation by over 1000-fold compared to thrombin
alone [89]. On the other hand, activation of TAFI by plasmin can be accelerated in the
presence of GAGs such a heparin. However, the catalytic efficiency of TAFI activation
by plasmin in the presence of heparin is still approximately 10-fold lower than by
thrombin-TM [90].
Based on this evidence it was assumed that the thrombin-TM complex is the
physiological activator of TAFI. However, an in vitro clot lysis assay revealed that the
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half-maximal effect of TAFIa on prolonging clot lysis time is attained at a concentration
of 1 nM. Activation of 1 nM of TAFI corresponds to less than 2% of the the plasma pool
of TAFI. These results suggest that even a small amount of TAFI activation is enough to
significantly inhibit the fibrinolytic cascade [89]. For example, the high concentration of
thrombin generated by amplification of the coagulation pathway through factor XI is
sufficient to activate TAFI in the absence of TM. In fact, a TAFIa mediated inhibition of
fibrinolysis has been demonstrated in vitro through clot lysis assays performed in the
absence of TM but with the existence of an intact factor XI-dependent pathway [88, 106].
Likewise, experiments in a rabbit thrombolysis model indicated that inhibition of FXIa
promotes thrombolysis in manner dependent on prevention of TAFI activation [111]. In
addition, thrombin-TM mediated activation of TAFI would only occur on the surface of
intact endothelium whereas sites of vascular injury that expose GAGs from the
subendothelial matrix may be expected to promote plasmin-mediated activation [90, 112,
113]. Therefore, TAFI activation in vivo can be achieved by thrombin, thrombin-TM, and
plasmin yet, the contribution of each of the activators to the TAFI pathway in vivo is
unknown. Activation of the TAFI pathway in vivo is likely dependent on the on the site of
thrombosis, the extent of activation of the coagulation and fibrinolytic cascades in
addition to the phenotype of the endothelium [5, 8].
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Figure 1-2. Activation of TAFI and inactivation of TAFIa. TAFI circulates as an
inactive zymogen in the bloodstream, and becomes activated during blood clotting or
fibrinolysis. The mature TAFI protein consists of a 92-amino acid activation domain
(black) which is N-glycosylated at four sites, and a 309-amino acid catalytic domain
(grey). TAFI becomes activated through cleavage at Arg92 by thrombin, thrombin-TM,
or plasmin forming activated TAFI (TAFIa). TAFIa is unstable at body temperature
possessing a half-life of approximately 8-15 minutes, and undergoes a conformational
change (to form TAFIai) that is associated with the disappearance of its enzymatic
activity. This conformational change also exposes residue Arg302 for cleavage by
thrombin and accelerates cleavage by plasmin at residues Arg302, Lys327 and Arg330.
The inset displays the location of Arg92 (red) and the side chains of residues in its
vicinity (cyan). The figure was adapted and modified from reference [104].
Crystallographic data are from reference [114]. (PDB accession #3D66)
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1.6.2.1 Thrombomodulin and TAFI activation
TM is a transmembrane protein expressed on the luminal endothelial surface lining
the blood vessels within the vasculature. TM is found in all vascular beds including
arteries, veins, and capillaries [4, 5, 115]. It is especially highly expressed in the
microvasculature which makes up more than 99% of the endothelial surface area [116].
TM is a 559 amino acid transmembrane glycoprotein and is divided into 10 structural
domains: an amino-terminal lectin-like domain (residues 1-222), six tandem epidermal
growth factor (EGF)-like domains connected by small interdomain peptides (residues
227-462), a serine/threonine-rich domain (residues 463-497), a transmembrane domain
(residues 498-521) and a short cytoplasmic tail (residues 522-559) (Figure 1-3) [115117]. In addition, soluble forms of TM are found circulating in the blood due to
proteolysis of the intact protein or damage to endothelial cells. Increased TM levels are
found in disorders linked to vascular damage including infections, sepsis, and
inflammation and have been recognized as a marker of disease [7, 9, 118-121].
Any thrombin generated at the injury site that diffuses into the blood either
encounters AT to rapidly inhibit the protease preventing it from cleaving fibrinogen in the
circulation or it binds to TM on the intact endothelium [15]. TM interacts with thrombin
forming a high affinity 1:1 complex which possesses anticoagulant and antifibrinolytic
properties. The thrombin-TM complex prevents the procoagulant functions of thrombin
by accelerating PC activation whereas the antifibrinolytic properties are promoted
through activation of TAFI and thereby down-regulating fibrinolysis [115, 116, 122,
123].
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Figure 1-3. Structure of thrombomodulin (TM). The structure of TM can be divided
into several domains. The extracellular amino-terminal domain of TM, which is directed
towards the circulating blood, consists of a lectin-like domain, followed by six tandemly
repeating epidermal growth factor (EGF)-like domains joined by small connecting
peptides, a serine/threonine-rich domain, a transmembrane domain and a short
cytoplasmic tail. The EGF domains 5 and 6 are primarily responsible for the interaction
with thrombin (indicated in blue). The smallest primary structure of TM capable of
efficiently activating Protein C requires the residues of EGF-4 through EGF-6 plus the six
residues connecting EGF-4 to EGF-3 (indicated in red) whereas TAFI requires residues of
the c-loop of EGF-3 through EGF-6 (indicated in yellow). The figure was adapted and
modified from reference [124].
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The structure of the thrombin-TM complex has been determined through X-ray
crystallography of human α-thrombin bound to the EGF-like domains 4, 5 and 6 on TM
[125]. Thrombin binds to TM EGF-5 and part of TM EGF-6 which is through interactions
with the lysine and arginine residues on the anion binding exosite I on thrombin [125127]. Additional structural elements of TM are required to allow efficient activation of
PC and TAFI by thrombin and, interestingly, these elements differ. The smallest primary
structure of TM capable of efficiently activating PC requires the residues of EGF-4
through EGF-6 plus the six residues connecting EGF-4 to EGF-3 whereas TAFI requires
residues of the c-loop of EGF-3 through EGF-6. A report of alanine scanning experiments
of residues within the c-loop of TM EGF-3 showed a 90% or greater reduction in TAFI
activation but no effect on PC activation [128]. Modeling of the PC structure with the
thrombin-TM complex showed that EGF-4 makes direct contact with the activation
peptide of PC, most notably involving three consecutive lysine residues in the activation
peptide [125]. Whether similar or analogous interactions occur between TM and TAFI is
unknown.

1.6.2.2 Plasmin as an activator of TAFI
Plasmin is the ultimate enzyme of the fibrinolytic pathway. It is formed by
conversion of the plasma zymogen plasminogen to the active serine protease, plasmin.
Plasminogen is a single chain glycoprotein that is primarily synthesized by the liver and
circulates in plasma at a concentration of 1.5 – 2 µM. Plasminogen activators cleave
plasminogen at the Arg561-Val562 bond to form the a two-chain plasmin protease. The
structure of plasmin consists of the heavy chain containing the five kringle domains
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(amino-terminal part of plasminogen) linked by a disulfide bond to a light chain
containing the serine protease catalytic domain (carboxyl-terminal part of plasminogen).
Kringle domains, also referred to as lysine binding sites, are triple loop structures
stabilized by three disulfide bonds. Plasmin contains two lysine binding kringle domains
(kringle 1 and 4) that exhibit high affinity to lysine and lysine analogs as well as internal
and carboxyl-terminal

lysine residues in

proteins.

The kringle

domains

of

plasminogen/plasmin mediate its interaction with fibrin, cell surface receptors, and other
proteins including its inhibitor α2-antiplasmin [60, 129, 130].
In addition to its roles in fibrin dissolution and promotion of positive feedback in the
fibrinolytic cascade, plasmin also functions as an activator of TAFI. Thus, plasmin is also
a negative regulator that attenuates plasmin generation in the fibrinolytic cascade by
interfering with the positive feedback mechanism through TAFIa. Plasmin is a very poor
activator of TAFI [60, 88]. An ideal plasmin substrate contains the following amino acids
surrounding the scissile bond for optimal catalysis: an arginine or lysine residue at the P1
position, an aromatic residue at the P2 position (immediately amino-terminal to the P1
residue), arginine, lysine, or serine at the P1’ position (immediately carboxyl-terminal to
the P1 residue), and an arginine, lysine, or glycine at the P2’ position. Plasmin is less
selective at the P3 position of the substrate [131]. The P2 position in TAFI is a proline
(Pro91) which makes TAFI a suboptimal substrate for plasmin. Additionally, the P1’ and
P2’ amino acid residues in TAFI are not solvent exposed and therefore are not able to
interact with plasmin [132]. However, the residues surrounding the cleavage site are not
the only determinants of substrate specificity [133]. Since the interaction of
plasmin/plasminogen with other proteins is mediated through their lysine binding kringle
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domains, this too may be the mode of interaction between plasmin and TAFI. Plasmin’s
kringle domains may interact with TAFI through its surface exposed lysine residues
[134]. At this time the structural basis for the interaction of plasmin with TAFI is
unknown.

1.6.2.3 Glycosaminoglycans and their effect on TAFI/TAFIa
GAGs are long, unbranched polysaccharide chains consisting of repeating
disaccharide units. The chains vary in length, and can contain between 80 to as many as
200 disaccharide units that occupy highly extended conformations. The disaccharide unit
consists of an amino sugar (N-acetylglucosamine or N-acetylgalactosamine) which is
usually sulfated and the second sugar is usually a uronic acid (glucuronic acid or iduronic
acid) or galactose. There are sulfate or carboxyl groups on most of their sugars, rendering
them highly negatively charged. GAGs are considered the most anionic molecules
produced by animal cells. There are four main groups of GAGs which are categorized by
their sugars, the type of linkage between the sugars, and the quantity and location of
sulfate groups: (l) hyaluronan, (2) chondroitin sulfate and dermatan sulfate, (3) heparan
sulfate and heparin, and (4) keratan sulfate. GAGs are found covalently linked to a core
protein and as a whole are referred to as proteoglycans [135, 136]. The structure of a
proteoglycan is highly variable in terms of the number and types of GAG chains, lengths,
and the proportion of sulfated and non-sulfated groups along the chains. Proteoglycans
are found on the luminal surface of endothelial cells as part of the glycocalyx, or in the
subendothelial extracellular matrix which can be exposed upon vascular injury [135, 137,
138].
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Two GAGs, heparan sulfate and heparin, have similar polysaccharide backbones but
differ in terms in their cellular localization and structural modifications. Nearly all animal
cells synthesize proteoglycans that contain heparan sulfate GAGs that are present on the
cell surface of the endothelium and the extracellular matrix. By contrast, heparin is
synthesized in cytoplasmic secretory granules by connective-tissue type mast cells [135,
139]. Heparan sulfate is found covalently attached to a variety of core proteins (syndecans
1-4, betaglycan, glypicans 1-6) whereas heparin is mainly attached to the serglycin core
protein [135]. They are both composed of alternating units of α-D-glucosamine (GlcN)
and uronic acid, β- D-glucuronic acid (GlcA) or α-L-iduronic acid (IdoA), that are
connected by (1→ 4) glycosidic linkages [135, 139]. Heparan sulfate and heparin differ in
terms of the extent of sulfation. In heparin, the GlcN sugar is predominantly N-sulfated
whereas the GlcN sugar in heparan sulfate varies containing both N-sulfated and Nacetylated and smaller amounts of N-unsubstituted sugars. Heparin is highly sulfated with
typically more than 80% sulfation containing 2.3-2.8 sulfates/disaccharide, while heparan
sulfate has less than 60% containing 0.6-1.5 sulfates/disaccharide. In addition, the
molecular weight of heparin varies between 7 to 20 kDa whereas heparan sulfate varies
between 10 to 70 kDa [135, 139, 140].
Due to the structural diversity of heparin and heparan sulfate they are able to bind
and interact with a variety of proteins to regulate their function. The interaction between
GAGs and their target protein is mediated through ionic interactions between the
negatively charged sulfate groups and the positively charged basic amino acid residues
(lysine, arginine, histidine in certain cases), respectively [139, 141]. In addition, hydrogen
bonding is possibly involved in the interaction between heparin binding to proteins. For
30

example, heparin binds to arginine residues more tightly than lysine residues due to the
stronger hydrogen bond between arginine’s guanidinylate side chain and the heparin
sulfate group as compared to the primary amino side chain of lysine residues [142]. The
basic residues on the protein structure can appear as linear arrangements or in spatial
folded clusters. Amino acid sequence alignments between various proteins known to bind
GAGs were analyzed in order to find a GAG binding consensus sequence which could be
used to identify potential GAG-binding regions in other proteins. Two GAG consensus
sequences were determined: –XBBXBX– and –XBBBXXBX–, where B and X represent
basic and hydrophobic residues, respectively [139, 141, 143]. The consensus sequences
were found to appear as both α-helical and β-strand conformations. For instance, the –
XBBXBX– sequence folded in β-strand conformation and the –XBBBXXBX– sequence
folded in α-helical conformation results in exposure of their basic amino acid residues
leaving the hydrophobic residues oriented toward the interior of the protein. In addition, a
third GAG binding consensus sequence –XBBBXXBBBXXBBX– has been identified in
vWF. The GAG binding consensus sequences can be helpful in identifying heparinbinding regions in proteins however, many proteins do not possess these sequences since
many factors determine the ability of GAGs to interact with proteins [141, 143]. The
specific folding conformation of the protein structure can bring distant basic residues in
the primary protein sequence closer together in clusters on the protein surface to enable
GAG binding. A minimum spacing of 20 Å of basic amino acids on the protein structure
was noted to bind GAGs in some proteins irrespective of tertiary structure. Apart from the
structure of the protein, the distribution and conformation of uronic acid residues and
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amount and position of sulfate groups on the GAGs can influence the interaction with
proteins [139, 144].
GAG-protein interactions are important in a variety of cellular functions including
the regulation of coagulation. AT is an important anticoagulant serine protease inhibitor
that is found circulating in plasma, bound to cell surface endothelial heparan sulfate or
exposed GAGs present in the extracellular matrix. AT inhibits the active coagulation
plasma proteins thrombin, FIXa, FXa, FXIa at a slow rate by forming an AT-protease
complex but, in the presence of GAGs, this inhibition is dramatically accelerated [3, 55].
Heparin is able to bind to AT inducing a conformational change that accelerates ATprotease complex formation and thus inhibition [145]. This function of heparin underlies
its role as an anticoagulant drug and as the template for related synthetic anticoagulants.
The minimum number of polysaccharide units required to bind to AT is a highly sulfated
pentasaccharide sequence. This binding is sufficient to accelerate FXa inhibition by AT
but a longer sequence of polysaccharides consisting of 16 or more residues is needed to
accelerate inactivation of thrombin as well as FIXa and FXIa [7, 139, 144]. Therefore, the
interaction of GAGs with proteins necessitates a minimum length requirement for binding
as well as function, and is specific to the GAG interacting protein. This underlies the
function of the anticoagulant drug Fondaparinux, which is a synthetic heparin compound
composed of a pentasaccharide sequence that exclusively accelerates the inhibition of
FXa [4]. Heparin is a widely used anticoagulant drug for deep vein thrombosis however
there are limitations such as short half-life, requirement for parenteral administration,
individual variation in responses to heparin treatment as well as risk of hemorrhagic
complications [146].
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GAGs have been found to play a role in regulation of fibrinolysis. The presence of
GAGs, such as heparin, has been found to regulate TAFI activation by accelerating its
activation by plasmin as well as stabilizing the TAFIa enzyme [90]. In the same study,
other GAGs including chondroitin sulfate, dextran sulfate, and heparan sulfate and
keratan sulfate at high concentrations have been found to stimulate plasmin-mediated
TAFI activation. Unfractionated heparin (UH) and low molecular weight heparin
(LMWH) were also examined and no difference was found between them [90].

1.6.3

Inactivation of TAFI

A characteristic that differentiates TAFIa from other carboxypeptidases is its intrinsic
instability. The intrinsic instability of TAFIa is temperature-dependent and causes the
activity of TAFIa to spontaneously decay. At body temperature TAFIa possesses a halflife of approximately 8-15 minutes. The half-life of TAFIa is increased to about 2 hours at
22°C and at 0°C TAFIa is stabilized [102]. In contrast to the proteases of the coagulation
and fibrinolytic pathways, no endogenous inhibitors of TAFIa have been described to this
point. However, proteinaceous inhibitors of TAFIa have been found in the secretions of
the leech Hirudo medicinalis [147] and the tick Rhipicephalus bursa [148] which would
be expected to promote continued fluidity of blood during feeding from a host. The
inactivation of TAFIa is associated with a dramatic structural change that results in a
significant decrease in the intrinsic fluorescence signal of the enzyme [102, 149]. The
intrinsic thermal instability of TAFIa is thought to be the regulatory mechanism of downregulation of TAFIa activity in vivo [102, 149].
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The crystal structures of human and bovine TAFI have provided insight into the
structural basis for the intrinsic instability of TAFIa [114, 150]. The crystal structure of
TAFI revealed that there is a highly dynamic region (residues 296-350) encompassing a
loop, a surface-exposed helix, and another surface-exposed loop in the catalytic domain
which is called the “dynamic flap” [114, 151]. Changes in conformation of the dynamic
flap can plausibly be linked to loss of TAFIa activity because the flap encompasses part
of the wall of the active site as well as the catalytically crucial Tyr341 and Asp348
residues. In the TAFI zymogen structure, the dynamic flap region is stabilized by
interacting with the activation domain through hydrophobic interactions between Val35
and Leu39 in the activation domain and Tyr341 in the dynamic flap. Proteolytic cleavage
of the activation domain by thrombin, thrombin-TM or plasmin releases the activation
domain and increases the mobility of the dynamic flap. Eventually, an irreversible
conformational change occurs in the dynamic flap, disrupting the catalytic site and
resulting in the loss of TAFIa activity [114, 150]. Mutagenesis studies have shown that
some residues mutated within this dynamic flap region greatly decrease the intrinsic
stability of TAFIa which in turn reduces the antifibrinolytic potential of the enzyme [149,
152].
The proteolytic cleavage of TAFIa was initially thought to be associated with the
inactivation of the enzyme. However, it has been shown that proteolytic cleavage of
TAFIa by thrombin can only occur following the thermal inactivation of TAFIa. The
conformational change in TAFIa exposes amino acid residue Arg302 causing it to be
cleaved by thrombin [149, 153]. On the other hand, plasmin has been shown to cleave
TAFIa at Arg302, Lys327 and Arg330 prior to its conformational change and thermal
34

inactivation of TAFIa can accelerate this cleavage [149, 154]. In addition, high
concentrations of plasmin have been shown to cleave TAFI at Lys327 and Arg330
forming a 45,000 Da TAFI species that upon further cleavage at Arg92 would not result
in the active enzyme. The ability of plasmin to cleave the TAFI zymogen and TAFIa prior
to its thermal inactivation may be a process to regulate the level of active TAFIa (Figure
1-2) [154].
Although TAFIa does not possess an endogenous inhibitor in vivo, many exogenous
inhibitors of TAFIa have been described based on its homology to the pancreatic
carboxypeptidases. Several reversible competitive inhibitors of TAFIa exist including the
lysine analog ε-aminocaproic acid (ε-ACA) and arginine analogs 2-mercaptomethyl-3guanindinoethylthiopropannoic

acid

(MERGEPTA)

and

2-

guanidinoethylmercaptosuccinic acid (GEMSA) [92, 102, 155]. Some naturally occurring
inhibitors include potato tuber carboxypeptidase inhibitor (PTCI) [156, 157], as well as
those from leech (LCI) [147] and tick (TCI) [148]. Since TAFIa is

a

metallocarboxypeptidase (it contains a zinc ion in its active site), it is therefore sensitive
to chelating agents such as ethylenediaminetetraacetic acid (EDTA) and o-phenanthroline
[92]. In addition, TAFI contains eight cysteine residues and, based on homology to the
pancreatic carboxypeptidase, six of the residues are involved in disulfide bonds within the
catalytic domain and therefore would be susceptible to reducing agents such as
dithiothreitol (DTT) and 2-mercaptoethanol (βME) [92, 96].
An important characteristic of the competitive inhibitors of TAFIa is that they are
also able to stabilize the conformation of TAFIa at saturating concentrations of the
inhibitor thereby preventing it from thermal decay [102, 158]. In addition, they are able to
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decrease the rate of proteolytic cleavage at Arg302 by preventing the structural change of
TAFIa that is associated with inactivation making it more susceptible proteolysis [153,
155]. Studies of the effect of competitive inhibitors on fibrinolysis in the context of lysis
assays revealed that the inhibitor can either promote or inhibit fibrinolysis, depending on
its concentration [158]. The inhibitors display a biphasic antifibrinolytic effect where high
concentrations of the inhibitor would bind all the available TAFIa and therefore promote
fibrinolysis. On the other hand, lower concentrations of the inhibitor would result in a
small concentration of TAFIa bound to the inhibitor, being stabilized and also released in
a time-resolved manner, thus causing prolongation of fibrinolysis [159].

1.7 The Function of TAFI in Fibrinolysis
TAFIa possesses basic carboxypeptidase activity, catalyzing the removal of carboxylterminal basic residues from protein and peptide substrates. The basic carboxypeptidase
activity of TAFIa is responsible for its antifibrinolytic activity through its ability to
remove carboxyl-terminal lysine and arginine residues from partially degraded fibrin
which are important for the development of positive feedback in the fibrinolytic cascade
(Figure 1-4) [160]. TAFIa suppresses the positive feedback mechanism of plasmin
generation through various mechanisms.
First, TAFIa interferes with the stimulation of plasminogen activation and thus the
mechanism of positive feedback. The fibrin surface functions as a cofactor by enhancing
plasminogen activation by tPA over 500-fold, thereby localizing plasmin formation to the
site of the fibrin clot [62, 161]. Plasmin cleavage of the fibrin mesh results in the
exposure of carboxyl-terminal basic residues, providing additional binding sites for tPA
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and plasminogen through their kringle domains. These resides enhance the cofactor
function of fibrin by approximately 3-fold, stimulating Glu-plasminogen activation [160,
162]. Additionally, the partially degraded fibrin promotes the conversion of Gluplasminogen to Lys-plasminogen, enhancing the positive feedback in the fibrinolytic
pathway [62, 161]. Lys-plasminogen is a better substrate for tPA due to its open
conformation, rendering the cleavage site more accessible for tPA, as well as its higher
binding affinity to the partially degraded fibrin [71-73]. TAFIa cleavage of these exposed
carboxyl-terminal basic residues on fibrin significantly all but eliminates the fibrin
cofactor activity for Glu-plasminogen activation along with down regulating the rate of
conversion of Glu-plasminogen to Lys-plasminogen [160, 163]. Overall, TAFIa
diminishes the positive feedback in plasminogen activation and substantially halts the
progression of fibrinolysis.
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Figure 1-4. The role of the TAFI pathway in fibrinolysis. The coagulation and
fibrinolytic pathways terminate in the formation of the enzymes thrombin and plasmin,
respectively. Thrombin cleaves the soluble plasma protein fibrinogen to facilitate the
formation of the insoluble fibrin clot. The fibrin surface functions as an essential cofactor
for tissue-type plasminogen activator (tPA)-mediated activation of plasminogen to
plasmin. Plasmin cleaves the fibrin fibers at specific lysine residues in the clot to form
soluble fibrin degradation products (FDPs) thereby leading to clot dissolution. Proteolysis
of fibrin by plasmin results in a form of fibrin (fibrin’) with enhanced cofactor activity,
relative to native fibrin, due to the newly-exposed carboxyl-terminal lysine residues.
Activated TAFI (TAFIa), possessing basic carboxypeptidase activity, efficiently removes
the carboxyl-terminal lysine residues from partially-degraded fibrin, thus yielding a form
of fibrin (fibrin’’) that possesses almost no cofactor activity. Thus, the TAFI pathway
attenuates fibrinolysis by interfering with positive feedback in the fibrinolytic cascade
that is necessary for the development of positive feedback in the fibrinolytic pathway.
The figure was adapted and modified from reference [104].
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Secondly, TAFIa suppresses fibrinolysis by eliminating the protective effect of
partially degraded fibrin on plasmin [164]. When plasmin is formed, it remains associated
with the fibrin surface through the exposed carboxyl-terminal basic residues by binding
through its kringle domains. This restricts the activity of plasmin to the fibrin clot thus
promoting fibrin clot dissolution [165]. Removal of the carboxyl-terminal basic residues
on the fibrin surface by TAFIa decreases the ability of plasmin to bind to partially
degraded fibrin allowing it to be more readily inhibited by circulating α2-antiplasmin.
TAFIa decreases the local concentration of plasmin on the fibrin surface which prolongs
the progression of fibrinolysis [166].
Finally, TAFIa down regulates fibrinolysis by decreasing the cooperative cleavage
mechanism of plasmin-mediated fibrin degradation [167, 168]. It has been demonstrated
that cleavage of all the fibrin chains is not required for complete fibrin clot dissolution.
Instead, fibrin is solubilized when the α, β and γ chains of neighbouring protomers are
cleaved resulting in the release of fibrin degradation products of various molecular
weights. When plasmin cleaves one of the α, β and γ chains, it exposes carboxyl-terminal
basic residues providing binding sites for additional plasmin. This increases the local
concentration of plasmin in these specific regions on fibrin allowing cleavage of the other
chains in the vicinity. When TAFa cleaves the carboxyl-terminal basic residues it
prevents cooperative cleavage of fibrin by plasmin. TAFIa prevents the accumulation of
plasmin on fibrin at specific sites and instead forces plasmin to cleave at additional
random sites on the fibrin meshwork, making more cleavages then necessary to achieve
fibrin dissolution [167, 168].
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The TAFI pathway plays an important role in regulating fibrinolysis and it has been
demonstrated through a threshold dependent mechanism [169, 170]. The basis of the
threshold dependent mechanism is as long as the TAFIa concentration remains at or
above the specific threshold value, fibrinolysis would be attenuated. When the TAFIa
concentration drops below the threshold value, the number of carboxyl-terminal basic
residues increases allowing the progression of fibrinolysis. The period of time TAFIa
remains at or above the threshold is influenced by the rate of TAFIa formation and its
intrinsic thermal instability [169, 170]. Mutagenesis studies have revealed that the
maximum prolongation of fibrinolysis is proportional to the half-life of the TAFIa
enzyme. Therefore, variants with an increased half-life possess a higher antifibrinolytic
potential [149, 152].

1.8 The Physiological Role of TAFI
Numerous in vitro studies have established that the TAFI pathway regulates
fibrinolysis [88, 90, 107, 171-174]. Studies utilizing in vitro clot lysis assays have shown
with increasing concentrations of TAFI the time to lyse a clot increases and eventually
reaches a plateau [89, 102]. The time to lyse a clot at saturation (10 nM TAFIa) is
approximately three-fold longer compared to in the absence of TAFIa. In fact, the
concentration of TAFIa needed to achieve the half-maximal prolongation of lysis time is
1 nM which represents less than 2% of the concentration of TAFI in plasma [89]. Thus,
only a small fraction of the available TAFI needs to be activated to have a significant
impact on fibrinolysis although, the degree at which TAFIa inhibits fibrinolysis is
dictated by a threshold dependent mechanism as previously discussed. As well, in vitro
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clot lysis assays where TAFI is depleted from plasma or addition of PTCI, a specific
TAFIa inhibitor, showed substantial decreases in clot lysis time [175].
The TAFI pathway has also been shown to modulate fibrinolysis in vivo as
demonstrated through many animal studies. One of the first studies that provided this
evidence came from a canine model with electrically induced thrombosis of the coronary
artery which showed an increase in TAFIa activity in plasma samples following
thrombosis and thrombolytic therapy with tPA. A relationship was observed between the
time to reperfusion and the concentration of TAFIa whereby the higher the concentration
of TAFIa, the longer the time for tPA to establish blood flow [176]. Another study
involving a rabbit thrombolysis model where factor XI or TAFI was inhibited resulted in
an almost two-fold increase in endogenous lysis of jugular vein clots [111]. This study
supports the in vitro studies indicating that an intact intrinsic pathway of coagulation is
vital for generating the high concentrations of thrombin that are required for efficient
TAFI activation which is involved in down-regulating fibrinolysis [106, 111, 177]. In
addition, several animal models of arterial and venous thrombolysis in which TAFI was
inhibited were shown to enhance thrombolysis by tPA and were able to reduce the
amount of tPA required to attain a similar amount of lysis [111, 178-181]. These studies
provide evidence for possible TAFIa inhibitors in enhancing the efficacy of tPA in
thrombolytic therapies.
The coagulation pathway plays an important role in the formation of a fibrin clot as
well as the stabilization of the clot through activation of TAFI. Any abnormalities in the
coagulation pathway caused by deficiency of coagulation factors will affect the activation
of TAFI and in turn the stabilization of the clot. For example, deficiency of coagulation
41

factors VIII or IX results in the serious bleeding disorders hemophilia A and B,
respectively, and deficiency of factor XI causes a milder form of hemophilia. In these
individuals, the initiation phase of coagulation is delayed at low tissue factor
concentrations and the large burst in thrombin formation from the propagation phase is
severely impaired [182, 183]. Furthermore, studies involving plasmas deficient in
intrinsic pathway coagulation factors VIII, IX, X, XI have shown premature lysis
compared to normal plasma and upon addition of TAFI, TM or the deficient factor the
coagulation deficiency is corrected [182, 184]. Therefore, the reduction in thrombin
formation through the intrinsic pathway results in a decrease in TAFI activation and a
decrease in its ability to suppress fibrinolysis and stabilize the fibrin clot. In this regard, it
has been proposed that the bleeding observed in hemophilia patients is the result of not
only an inability to form the clot but also the failure of TAFI to stabilize the clot [177,
182, 184].
On the other hand, abnormalities in the coagulation pathway due to elevated
coagulation factor concentrations are susceptible to an increased risk for thrombotic
disorders. For example, individuals with high levels of intrinsic coagulation factors
(FVIII, IX, XI) would lead to a prolonged and increased rate of thrombin formation and
an increased activation of TAFI resulting in inappropriate down-regulation of fibrinolysis.
Studies have shown that the risk of venous thrombosis is increased about two-fold with
elevated levels of coagulation factors VIII, IX, XI [185-187]. As well, the Leiden
Thrombophilia Study (LETS) showed that elevated plasma TAFI concentrations were
associated with a mild risk for venous thrombosis [188]. Individuals with high TAFI
levels compared to low TAFI levels were at a two-fold increased risk for recurrent venous
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thromboembolism and patients with both high TAFI levels and one of the coagulation
factors XI, VIII, and IX were at a three-fold increased risk [188, 189]. In addition,
individuals with factor V Leiden suffer from higher thrombotic tendencies due to the
increased formation of thrombin and increased TAFI activation. Factor V Leiden is a
factor V Arg506Gln mutation in the APC cleavage site that decreases the rate of
inactivation by APC. This results in increased thrombin formation and increased
activation of TAFI and consequently down-regulation of fibrinolysis [190, 191]. Any
defects in the coagulation system as described can lead to changes in the activation of
TAFI and the regulation of the fibrinolytic system.
To understand the function of the TAFI pathway in vivo, mouse strains in which the
TAFI gene has been inactivated by homologous recombination have been developed
[192-195]. The TAFI-deficient mice were normal in terms of embryonic development and
viability, fertility, and possessed no phenotypic abnormalities. In addition, haematological
parameters of the mice were comparable with their wild-type littermates, although clots
formed from the TAFI-deficient mice plasma rapidly lysed [192, 194]. The TAFIdeficient mice were subjected to acute haemostatic challenges to induce a phenotype
including models of venous and arterial thrombosis, thrombin-induced acute
thromboembolism, endotoxin-induced disseminated intravascular coagulation (DIC), tail
bleeding, and kaolin-induced writhing response however no differences were observed
compared to the wild-type mice [192]. However, after back-crossing TAFI-deficient mice
into a heterozygous plasminogen background, a role of TAFI in regulation of
plasminogen in vivo was observed in models of pulmonary embolism. In the mice with
heterozygous plasminogen and partial TAFI deficiency (Plg+/-, TAFI+/-) and complete
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TAFI deficiency (Plg+/-, TAFI-/-) fibrinolysis was enhanced in a pulmonary clot lysis
model compared to wild-type (Plg+/-, TAFI+/+) [196]. Following this study, many reports
have been published providing additional evidence for the role of TAFI in fibrinolysis in
vivo. For example, in a batroxobin-induced pulmonary embolism model, TAFI-deficient
mice exhibited lower fibrin retention in the lungs than wild-type mice [194]. In
agreement, another report demonstrated that bleomycin-induced lung fibrosis in mice
lacking TAFI resulted in significantly reduced fibrosis in the lungs suggesting that TAFI
promotes lung fibrosis by modulating plasmin generation and decreasing fibrin
degradation in the lungs [195]. In a FeCl3-induced vena cava thrombosis model TAFIdeficient mice resulted in a reduced thrombus formation; note that these mice also
exhibited an increase in tail bleeding time [197]. As well, an enhanced fibrinolytic
capacity was observed in TAFI-deficient mice and TAFI/PAI-1 double-knockout mice
compared to wild-type TAFI or PAI-1 mice in a mouse thromboembolism model which
indicates the importance of TAFI deficiency on the fibrinolytic pathway [198]. Further
investigation of the TAFI pathway in animal models will aid in understanding the role of
TAFI in hematologic diseases.
Our understanding is limited in terms of how the TAFI pathway is regulated in vivo.
Specifically, the relative contributions of thrombin, thrombin-TM and plasmin in
regulating the TAFI pathway in vivo is unknown. Thus far, only two studies attempted to
identify the physiological activator of TAFI in vivo [199, 200]. Bajzar and coworkers
used a baboon model of Escherichia coli-induced sepsis to study TAFI activation in vivo.
This study demonstrated that thrombin-TM is the predominant physiologic activator of
TAFI in a setting of severe sepsis [199]. Another study by Gils and coworkers utilized an
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antibody that inhibited plasmin-mediated TAFI activation in vitro and found that when
injected into a mouse thromboembolism model it resulted in decreased fibrin deposition
in the lungs indicating an acceleration of fibrinolysis. Therefore, in the thromboembolism
model plasmin would be the predominant physiologic activator of TAFI [200]. Which
activator predominates in vivo would depend on the complex interaction of a variety of
different factors. For instance, different vascular compartments differ in their
hemodynamic characteristics, phenotype of the endothelium, contribution of platelets, and
ratio of the volume of blood to surface area of the endothelium [5, 8]. The activation of
TAFI is likely a function of the site of thrombosis and the extent of activation of the
coagulation and fibrinolytic cascades which would depend on the relative concentrations
of different activators, inhibitors, and cofactors. As well, the regulation of TAFI
activation could be altered in different physiological and pathophysiological
circumstances such as in inflammatory disorders, coagulopathies, atherosclerotic disease,
and tumour angiogenesis and metastasis.

1.9 Measurement of TAFI
Many methods are available for measurement of the basic carboxypeptidase activity
of TAFI generated following activation. The small synthetic substrates hippurylarginine/hippuryl-lysine (Hipp-Arg/Hipp-Lys) can be monitored spectrophotometrically,
by high-performance liquid chromatography (HPLC), and by a colorimetric analysis
through chemical derivatization of the hippuric acid. While the detection limits for HPLC
measurement of Hipp-Arg/Hipp-Lys are very low, it is a discontinuous assay and thus not
suited to use in high-throughput settings. As well, the disadvantage of the colorimetric
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analysis is its time-consuming nature [201]. Another class of small synthetic substrates,
anisylazoformyl-arginine/anisylazoformyl-lysine (AAFR/AAFK), can be monitored
spectrophotometrically and are able to quantify TAFIa levels in a purified system [102,
132, 152]. Unfortunately, due to their low sensitivity, these substrates cannot be used to
detect TAFIa activity in plasma and would suffer from interference in detection due to the
turbidity resulting from the formation of a fibrin clot. Alternatively, functional assays
exist for the detection of TAFIa activity in plasma and involve its ability to remove
carboxyl-terminal basic residues from soluble FDPs. The functional TAFIa assays
measure TAFIa concentration indirectly through plasminogen activation or through the
release of plasminogen bound to soluble FDPs [202, 203]. However, numerous
components are required for the functional assay which can lead to variability. Moreover,
none of the existing methods are suitable for the monitoring of TAFIa formation in realtime in the context of a clot. For this, a fluorogenic substrate for TAFIa is required, yet no
such compound for TAFIa (or any other carboxypeptidase) exists.
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1.10

Rationale, Hypothesis and Objectives
TAFI can be activated by thrombin, thrombin-TM and plasmin however, their

relative contribution in regulating the TAFI pathway in vivo is unknown. In order to
appreciate the physiological role of the TAFI pathway it is essential to understand how
TAFI is activated. The regulation of TAFI activation is dependent a variety of variables
including the site of thrombosis, the extent of activation of the coagulation and
fibrinolytic cascades, the vascular compartment, and different physiological and
pathophysiological conditions. The current studies were undertaken to examine the
structural basis for the regulation of TAFI activation and function. The structural insight
into the activation of TAFI will shed light on the molecular basis for its function in vivo.
The activation of TAFI by thrombin is greatly enhanced in the presence of TM. In
fact, accumulating evidence from several studies suggests that TM directly binds to TAFI
at sites remote from the activating cleavage site. At this point, however, it is not
completely understood how TM promotes TAFI activation by thrombin. The elements of
TAFI structure that allow accelerated activation of thrombin by TM have not been
completely identified. Based on the results of Wu and coworkers [204], it appears that the
residues on TAFI that displayed the strongest TM dependence are focused around the
activation domain. Therefore, it is possible that the activation domain of TAFI allows for
efficient interaction with TM to allow accelerated activation by thrombin.
Previous studies have shown that the presence of GAGs, such as heparin, is able to
accelerate TAFI activation by plasmin and stabilize TAFIa. However, the structural basis
for the effects of GAGs on plasmin-mediated TAFI activation or TAFIa stability is
unknown.
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It is apparent that the currently available methods to measure TAFIa activity and
assess its activation in real-time in plasma are not adequate. Indeed, the existing methods
are either not particularly sensitive or require numerous biological components which can
lead to variability in the performance of the assay.
The hypotheses to be addressed are: 1) TAFI interacts with TM such that the
enhancement of TAFI activation by the thrombin-TM complex is through binding at a site
or sites remote from the activation site; 2) the activation domain of TAFI is responsible
for the TM dependence of acceleration of activation by thrombin; 3) TAFI and TAFIa
possess GAG binding site(s) that are important in increased TAFI activation by plasmin
and/or increased thermal stability of TAFIa in the presence of heparin; and 4) a novel
fluorescence assay for the measurement of TAFIa activity will have increased sensitivity
compared to current methods and will allow for monitoring of TAFI activation in the clot
in real-time.
The research objectives of the current studies are as follows:
1) To determine the structural basis for the enhancement of TAFI activation by
thrombin in the presence of TM;
2) To evaluate the role of the activation domain of TAFI in activation by thrombinTM;
3) To assess the structural basis and functional significance of TAFI binding to
GAGs;
4) To develop a novel fluorescence assay to assess the function of activated TAFI in
real-time.
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2.1 Summary

Background: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a human plasma
zymogen that provides a molecular connection between coagulation and fibrinolysis.
TAFI is activated through proteolytic cleavage by thrombin, thrombin in complex with
the endothelial cell cofactor thrombomodulin (TM), or plasmin. Evidence from several
studies suggests that TM and TAFI make direct contact at sites remote from the activating
cleavage site to facilitate acceleration of thrombin-mediated TAFI activation. The
elements of TAFI structure that allow accelerated activation of thrombin by TM are
incompletely defined. Objectives: To identify TM interaction regions on TAFI that
mediate acceleration of activation by thrombin and therefore indicate TM binding sites on
TAFI. Methods: We mutated selected surface-exposed charged residues on TAFI to
alanine in order to identify sites that mediate acceleration of activation by TM. The
kinetics of activation of the mutants by thrombin in the presence or absence of TM as
well as their thermal stabilities and antifibrinolytic potentials were determined. Results:
TAFI variants R15A, E28A, K59A, D75A/E77A/D78A, E99A and E106A all exhibited
moderately reduced catalytic efficiencies (kcat/KM) of activation by thrombin-TM. TAFI
variants R377A and, particularly, R12A and R12A/R15A exhibited severely reduced
activation by thrombin-TM that was not explained by differences in activation by
thrombin alone. Conclusions: We have identified R12 and R377 as key residues for the
activation of TAFI by thrombin-TM. R12 likely directly binds to TM while R377 may
affect the thrombin-TAFI interaction specifically in the presence of TM.
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2.2 Introduction

Thrombin-activatable fibrinolysis inhibitor (TAFI) (also referred to as pro-CPU
and encoded by the gene CPB2) is a human plasma zymogen that provides a molecular
connection between the coagulation and fibrinolytic cascades [1, 2]. TAFI is activated
through proteolytic cleavage by thrombin, thrombin in complex with the endothelial cell
cofactor thrombomodulin (TM), or plasmin to generate the enzyme activated TAFI
(TAFIa) [3-5]. TAFIa possesses basic carboxypeptidase activity that down-regulates
fibrinolysis by removing carboxyl-terminal lysine and arginine residues from partially
degraded fibrin thereby attenuating positive feedback in the fibrinolytic cascade [6, 7].
Thrombin and plasmin are relatively weak activators of TAFI, however, while binding of
thrombin to TM increases the catalytic efficiency (kcat/KM) of TAFI activation by 1250fold compared to thrombin alone [4]. Structure/function studies of TAFI activation
suggest that a TAFI-TM interaction accounts for this acceleration [8-11]. However, the
elements of TAFI structure that allow accelerated activation of thrombin by TM have not
been completely identified.
TM is an integral plasma membrane protein on endothelial cells consisting of an
amino-terminal lectin-like domain, six epidermal growth factor (EGF)-like domains, a
serine/threonine-rich domain, a transmembrane domain and a short cytoplasmic tail [12].
Binding of thrombin to TM alters the substrate specify of thrombin from acting as a
procoagulant enzyme to possessing anticoagulant and antifibrinolytic properties [12]. The
only other known physiological substrate of the thrombin-TM complex is protein C (PC).
While TAFI and PC are similar with respect to kinetics of activation by the thrombin-TM
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complex [5], the structural requirements in TM differ between the two substrates. The
smallest primary structure of TM capable of efficiently activating PC requires the
residues of EGF-4 through EGF-6 plus the six residues connecting EGF-4 to EGF-3
whereas TAFI requires residues of the c-loop of EGF-3 through EGF-6 [8, 9]. The
importance of the residues within the c-loop of EGF-3 is exemplified by a report using
alanine scanning mutagenesis of TM showing that substitution of residues within this
region resulted in a 90% or greater reduction in TAFI activation but no effect on PC
activation [9].
It was previously thought that the accelerative effects of TM on PC activation
were due to the ability of TM to allosterically alter the conformation of the thrombin
active site in order to minimize the repulsive charge interactions that may exist between
thrombin and the P3 and P3’ residues of the PC scissile bond [13, 14]. However,
crystallographic studies of the thrombin-TM complex revealed that TM binding to
thrombin does not cause allosteric changes in its active site but instead suggested that TM
may bind directly to PC in order to optimally present the scissile bond to the thrombin
active site [15]. This mechanism likely applies also to TAFI since a study of the residues
immediately surrounding the scissile bond in TAFI showed that they do not determine the
TM dependence of TAFI activation [10].
Structural modeling of PC with the thrombin-TM complex revealed multiple
interactions between PC and TM partly mediated by the three consecutive lysine residues
in PC that enhance the binding to TM [15]. To determine whether a similar mechanism
occurs in TAFI, Wu and coworkers mutated several basic residues on the surface of
TAFI, including three consecutive lysine residues within the activation domain [11];
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however, these mutations had only a small (8-fold decrease) effect on TM cofactor
ability against TAFI compared to mutation of the analogous residues in PC (70 – 2000fold decrease) [16]. Furthermore, when the crystal structure of TAFI was docked onto the
thrombin-TM complex structure, the roles of specific residues on TAFI could not be
completely assessed as the charged residues of the c-loop of TM-EGF-3, required for
TAFI activation, are absent from this structure [11]. Most recently, Plug and coworkers
demonstrated that mutation of arginine 12 in TAFI to glutamine reduced the catalytic
efficiency of activation of TAFI by thrombin-TM by 54-fold [17]. Therefore, the residues
on TAFI responsible for the acceleration of TAFI activation by TM remain to be
completely characterized.
In the present study, mutation of selected surface-exposed charged residues on
TAFI to alanine was used to identify sites that mediate acceleration of activation by TM,
potentially indicating sites where TM binds to TAFI directly. The data identify two
residues crucial for activation of TAFI by thrombin-TM.
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2.3 Experimental Procedures

2.3.1

Materials
The synthetic carboxypeptidase substrate anisylazoformyl-arginine (AAFR) was

obtained from Bachem Americas, Inc. (Torrance, CA, USA). Hippuryl-L-arginine,
heparin sodium salt (from porcine intestinal mucosa), and potato tuber carboxypeptidase
inhibitor (PTCI) were obtained from Sigma-Aldrich Canada, Ltd. (Oakville, ON,
Canada). The plasmin inhibitor D-valylphenylalanyllysyl chloromethylketone (VFKck),
the

TAFIa

(Plummer’s

inhibitor
inhibitor)

DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic
and

the

thrombin

inhibitor

acid

D-phenylalanylprolylarginyl

chloromethylketone (PPAck) were purchased from Calbiochem (San Diego, CA, USA).
QuikChange® Site-directed Mutagenesis kit was from Stratagene (La Jolla, CA, USA).
DNA restriction and modification enzymes (T4 DNA Ligase and Q5 High-Fidelity DNA
Polymerase) were purchased from New England Biolabs (Mississauga, ON, Canada).
pcDNA™4A/myc-His mammalian expression vector was purchased from Invitrogen
Canada Inc. (Burlington, ON, Canada). Oligonucleotides for mutagenesis were purchased
from Integrated DNA Technologies, Inc. (Coralville, IA, USA). Dulbecco’s modified
Eagle’s

medium/nutrient

mixture

F-12,

Opti-MEM,

Trypsin-EDTA,

penicillin/streptomyocin/fungizone (PSF) were obtained from Invitrogen. Newborn Calf
Serum was obtained from Sigma-Aldrich. Effectene transfection reagent was purchased
from QIAGEN, Inc. (Toronto, ON, Canada). Methotrexate was purchased from Mayne
Pharma, Inc. and Zeocin™ was purchased from Invitrogen. Thrombin, rabbit-lung TM
and plasmin were obtained from Haematologic Technologies (Essex Junction, VT, USA).
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Recombinant tPA (Alteplase) was purchased from Kingston General Hospital Pharmacy.
Polyclonal sheep anti-human TAFI antibody was purchased from Affinity Biologicals
(Ancaster, ON, Canada) and polyclonal rabbit anti-sheep antibody was purchased from
ThermoFisher Scientific. (Ottawa, ON, Canada). The mouse-anti-human TAFI
monoclonal antibody MA-T4E3 was obtained from Dr. Ann Gils (Katholieke Universiteit
Leuven, Leuven, Belgium) and coupled to CNBr Activated Sepharose 4B (GE Healthcare
Life Sciences, Mississauga, ON, Canada) according to manufacturer’s instructions (2-6
mg antibody/mL resin). Ni Sepharose excel resin was purchased from GE Healthcare Life
Sciences (Mississauga, ON, Canada). The phospholipids L-α-phosphatidylcholine from
frozen egg yolk (Type XIII-E) and 1,2-diacyl-sn-glycero-3-phospho-L-serine from bovine
brain

were

purchased

from

Sigma-Aldrich.

Synthetic

phosphatidylcholine/phosphatidylserine vesicles (PC/PS, 80:20) were prepared by
modification of the methods of Barenholz et al. and Bloom et al. [18, 19].

2.3.2

Construction of TAFI Variants
Mutagenesis was carried out using the QuikChange mutagenesis kit (Stratagene)

according to the manufacturer’s instructions. The primers used are shown in the
Supplementary Table 2-1. In all cases, the template for the mutagenesis was TAFI-pNUT,
which contains human TAFI cDNA which contains threonine at positions 147 and 325
[20]. The presence of the mutations was verified by DNA sequence analysis. All variants
were expressed from the pNUT plasmid except the R12A and R12A/R15A variants.
The TAFI-R12A and TAFI-R12A/R15A variants, as well as wild-type TAFI, were
also inserted into the pcDNA4A/myc-His expression vector in order to generate
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recombinant proteins with a carboxyl-terminal 6× His tag. The sequences of the primer
pairs are follows: sense, 5’- AAA CTG CAG TTG GGA TGA AGC TTT GC -3’ (PstI
site underlined) and anti-sense, 5’- GGA CCG GTA ACATTC CTA ATG ACATGC
CAA G -3’ (AgeI site underlined). The cDNA wild-type TAFI, TAFI-R12A, and TAFIR12A/R15A was amplified by polymerase chain reaction and inserted into
pcDNA4A/myc-His digested with PstI and AgeI sites.

2.3.3

Expression and Purification of Recombinant TAFI Variants
Recombinant TAFI variants were purified from conditioned medium harvested

from Baby hamster kidney (BHK) cell lines stably expressing the variants. Variants
lacking the 6×His tag were purified by immunoaffinity chromatography as previously
described [21]. Variants containing the 6×His tag were purified by affinity
chromatography over Ni2+-Sepharose.

2.3.4

Kinetics of activation of TAFI variants by thrombin-thrombomodulin complex
Each TAFI variant at various concentrations (0.0156 – 1.0 μM) was incubated in

the presence of CaCl2 (5 mM), thrombin (1 nM) and rabbit-lung thrombomodulin (5 nM)
in HBST (20 mM HEPES pH 7.4, 150 mM NaCl, 0.01% (v/v) Tween 80) for 10 minutes
at 21°C, then reactions were stopped by the addition of a solution containing the thrombin
inhibitor

phenylalanylprolylarginyl

chloromethylketone

(PPAck;

1

μM

final

concentration) and TAFIa substrate hippuryl-L-arginine (1.2 mM final concentration).
Rates of substrate hydrolysis (measured by absorbance at 254 nm) were converted into
rates of TAFIa formation, and the data were fit to the Michaelis-Menten equation as
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previously described [10]. The kinetic constants obtained are considered “apparent” since
they were determined at one concentration of the cofactor TM.

2.3.5

Kinetics of activation of TAFI variants by thrombin
Each TAFI variant at various concentrations (0.1 – 2.0 μM) was incubated in the

presence of CaCl2 (5 mM), thrombin (100 nM) and potato tuber carboxypeptidase
inhibitor (PTCI) (20 μg/mL) in HBST for 15 minutes at 21°C. Thrombin activity was
then quenched by the addition of PPAck. Samples were analyzed by SDS-PAGE and
western blotting with a sheep anti-human TAFI polyclonal antibody. Blots containing
various known concentrations of TAFIa (3.125 – 100 nM) were prepared and analyzed
simultaneously with a given experiment to provide a standard curve. The TAFIa
concentrations formed in each kinetic experiment were determined by interpolating from
the TAFIa band densities on the standard curve. The standard curves were linear and the
TAFIa band densities fell within the rages of the standard curves. The concentration of
TAFIa was then converted to the rate of TAFIa formation and the slope of the
relationship between the rate and the TAFI concentration was determined to estimate the
catalytic efficiency (kcat/KM) [21].

2.3.6

Activation of TAFI variants by plasmin
For activation of TAFI by plasmin, TAFI variants (200 nM) were incubated with

plasmin

(25

nM)

and

Plummer’s

inhibitor

(DL-2-mercaptomethyl-3-

guanidinoethylthiopropanoic acid; Calbiochem) (150 μM) in the presence or absence of
heparin (0.2 U/μL) at 21ºC for 15 minutes. Plasmin activity was then quenched by the
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addition of valylphenylalanyllysyl chloromethylketone (VFKck) (to 1 μM). Samples were
analyzed by SDS-PAGE and western blotting to give the rates of TAFIa formation as
described above.

2.3.7

Thermal Stability Assay of the TAFIa variants
Purified recombinant TAFI variants (1 μM) were activated by incubation with

thrombin (25 nM), TM (100 nM), CaCl2 (5 mM) in HBST at 21°C for 15 min. Thrombin
activity was then quenched by the addition of PPAck (to 1 μM). Activated TAFI was
divided into aliquots corresponding to various time points and incubated at 37°C. At each
time point, the corresponding aliquots were removed and placed on ice. Residual TAFIa
activity was determined by measurement of the rate of hydrolysis of anisylazoformylarginine (AAFR) by monitoring the absorbance at 350 nm. Non-linear regression of the
data to an equation describing first-order exponential decay was used to determine decay
rate constants and thus half-lives of each TAFIa variant, as previously described [21].

2.3.8

Clot Lysis Assays
All clot lysis assays were performed in a final volume of 100 μL in microtitre

plates at 37°C. The TAFI deficient plasma (TdP), prepared from the plasma of healthy
human volunteers as previously described [10, 22], was diluted 1:3 in HBST and
supplemented with recombinant TAFI variants (50 nM) and synthetic phosphatidylcholine/phosphatidyl-serine (PC/PS) vesicles

(20 μM) in the presence of different

concentrations of TM (0.02 – 2 nM, final) before clotting was initiated by addition of the
assay mixture into the wells of microtitre plates containing small, separated aliquots of
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thrombin (6 nM, final), CaCl2 (5 mM, final) and tPA (2 nM, final). Clot lysis was
monitored by the change in turbidity of each reaction at 405 nm in a Spectramax Plus 384
plate reader (Molecular Devices, Sunnyvale, CA, USA) at 37°C and the time to 50% lysis
was determined graphically from the midpoint between maximum and minimum
turbidities of the clots.

2.3.9

Statistical Methods
Statistical analyses were performed with the use of SPSS software, version 22.0

(SPSS Inc., Chicago, Illinois). Comparisons between samples were performed by oneway ANOVA using a Tukey post-hoc analysis. Statistical significance was assumed at p
< 0.05.
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2.4 Results

2.4.1

Construction, expression, and purification of TAFI variants
To determine the elements of TAFI structure that mediate acceleration of

activation by TM we have mutated selected surface-exposed charged residues on TAFI to
alanine (Figure 2-1). The crystal structure of human TAFI and the model of TAFI docked
to the thrombin-TM complex guided the construction of these variants while we avoided
lysine and arginine residues previously reported by Wu and coworkers to partially reduce
the efficiency of TAFI activation [11, 23, 24].
Eleven mutants of human TAFI with alanine substituted for surface-exposed,
charged residues were constructed (Figure 2-1). In some cases, charged residues located
in close proximity were mutated in combination, yielding R12A/R15A, D54A/D56A,
D75A/E77A/D78A, and E112A/E116A. With the exception of R12A and R12A/R15A,
all variants including wild-type TAFI (T147/T325 isoform) were purified by
immunoaffinity chromatography. The R12A and R12A/R15A variants contain a
carboxyl-terminal 6×His tag for purification by affinity chromatography over Ni2+Sepharose. As a control for possible effects of the affinity tag, we also expressed wildtype TAFI with the 6×His tag. All variants were purified to homogeneity from
conditioned medium harvested from stably-expressing BHK cell lines (data not shown).
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Figure 2-1. Mutations analyzed in this study. Image was drawn using Polyview-3D and
the coordinates for chain B in pdb accession #3D66 [23]. The structure is rendered in
approximately the same orientation as TAFI in the TAFI-thrombin-TM model of Wu and
coworkers [11]. The arginine cleaved by thrombin and plasmin (R92) is shown in cyan.
Residues that have little or no impact on activation of TAFI by thrombin-TM are colored
green. Residues that have a moderate impact are colored yellow. Residues that have a
large impact are colored red. The grey sphere is the active site Zn2+ atom. Also shown are
K42/K43/K44, studied by Wu and coworkers [11], in blue.
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2.4.2

Kinetics of activation of TAFI variants by thrombin in the presence of TM
The kinetics of activation of the TAFI variants by thrombin (1 nM) in the presence

of TM (5 nM) were determined in order to examine whether any variants were resistant to
the effects of TM (Figure 2-2). The estimated Michaelis-Menten kinetic parameters are
summarized in Table 2-1, with kcat and KM cited as “apparent” because a single
concentration of TM was employed. The variants fell into three broad categories: those
whose activation by thrombin-TM was modestly affected, if at all (D54A/D56A and
E112A/E116A; Figure 2-2A), those whose activation was moderately decreased (R15A,
E28A, K59A, D75A/E77A/D78A, and E106A; Figure 2-2B), and those whose activation
was severely impaired (R12A, R12A/R15A, R377A; Figure 2-2C). The apparent catalytic
efficiency of wild-type TAFI and wild-type TAFI-6×His activation in the presence of
thrombin-TM complex is 2.61 µM-1s-1 and 1.22 µM-1s-1, respectively, a difference arising
because of a higher apparent KM for the latter (Table 2-1). The variant R377A showed a
dramatically lower catalytic efficiency in the presence of TM, compared to wild-type, an
effect mostly attributable to large increase in apparent KM. Under the conditions
employed to assess the activation by thrombin-TM of all the other variants, activation of
R12A and R12A/R15A could not be detected. Therefore, we used higher concentrations
of thrombin and TM (100 nM each) specifically for these mutants to assess whether they
are capable of being activated at all. Even under these conditions, the relationship
between activation rate and TAFI concentration was linear (Figure 2-2C), and so only the
kcat(app)/KM(app) could be estimated (Table 2-1).
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Figure 2-2. The kinetics of activation of TAFI variants by thrombin in the presence
of TM. The variants were incubated at different concentrations with 1 nM IIa, 5 nM TM
and 5 mM CaCl2 for 10 min at room temperature. The rate of TAFIa formation was
measured using the hydrolysis of the substrate hippuryl arginine (symbols). The data are
the means ± standard errors of the mean of 3 – 9 independent experiments. The data were
fit to the Michaelis-Menten equation by non-linear regression analysis; the lines are
drawn based on the mean kcat and KM for each variant. A: Variants showing little or no
difference in activation compared to wild-type TAFI. B: Variants showing moderate
differences in activation. C: Variants showing large differences in activation. The data for
wild-type TAFI (TAFI wt) are shown in each panel for comparison purposes.
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Table 2-1. Kinetic Parameters for Activation of TAFI variants by thrombin-TM or
thrombin alonea

thrombin-TM

Variant
kcat(app)
-1

TAFI wt
D54A/D56A
E112A/E116A
R15A
E28A
K59A
D75A/E77A/D78A
E99A
E106A
R377A
TAFI wt-6×His
R12A-6×His
R12A/R15A-6×His
a

KM(app)

thrombin

kcat(app)/KM(app)

p valueb

-1 -1

s

µM

µM s

0.30 ± 0.009
0.38 ± 0.025
0.27 ± 0.016
0.31 ± 0.011
0.21 ± 0.010
0.26 ± 0.022
0.24 ± 0.012
0.25 ± 0.010
0.22 ± 0.012
0.17 ± 0.010
0.31 ± 0.021
NAd
NA

0.11 ± 0.02
0.19 ± 0.01
0.16 ± 0.02
0.43 ± 0.02
0.29 ± 0.07
0.33 ± 0.03
0.25 ± 0.04
0.24 ± 0.04
0.24 ± 0.09
1.05 ± 0.23
0.25 ± 0.07
NA
NA

2.61 ± 0.47
1.95 ± 0.03
1.69 ± 0.20
0.71 ± 0.02
0.73 ± 0.18
0.80 ± 0.08
0.96 ± 0.12
1.03 ± 0.13
0.94 ± 0.22
0.15 ± 0.04
1.22 ± 0.10
0.00090 ± 0.0003e
0.000755 ± 0.0001e

kcat/KM

p value

Fold
enhancement

-1 -1

(µM s )
0.625
0.041
˂0.001
˂0.001
˂0.001
0.003
˂0.001
0.001
˂0.001
0.019
-

0.00129 ± 0.00017
0.00131 ± 0.00019
0.00081 ± 0.00007
0.00066 ± 0.00004
0.00107 ± 0.00010
0.00070 ± 0.00011
0.00016 ± 0.00002
0.00102 ± 0.00011
0.00121 ± 0.00010
0.00076 ± 0.00005
0.00027 ± 0.00002
0.00031 ± 0.00007
0.00039 ± 0.00003

1.000b
1.000b
0.058b
0.994b
0.029b
<0.001b
0.804b
1.000b
0.052b
<0.001b
0.886c
0.454c

2021
1487
2098
1068
682
1141
6114
1012
773
214
4550
3
2

Data are the means ± standard errors of the mean of 3-9 independent experiments
performed in triplicate
b
ANOVA versus TAFI wt
c
ANOVA versus TAFI wt-6×His
d
NA: no activation detected under these conditions
e
Experiment performed with higher concentrations of thrombin and TM
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2.4.3

Kinetics of activation of TAFI variants by thrombin
We next assessed if changes in the rate of activation of the variants by thrombin-

TM may be attributable to changes in their rate of activation by thrombin, by
measurement of their kinetics of activation by thrombin in the absence of TM. The rate of
activation was calculated following western blot analysis of the samples. The
relationships between rate and TAFI concentration were linear, indicating high KM values
(Figure 2-3). Therefore, the slopes of the rate data were used to estimate the catalytic
efficiencies (kcat/KM) of activation (Table 2-1). The catalytic efficiencies of activation of
variants E28A, D54A/D56A, E99A, and E106A are all comparable to wild-type. On the
other hand, the catalytic efficiencies of activation of variants R15A, K59A,
E112A/E116A, R377A and, most dramatically, D75A/E77A/D78A, are decreased
compared to wild-type. For all these variants, there is no apparent relationship between
the effects of the mutations on activation by either thrombin-TM or thrombin alone. This
is illustrated by comparing Figures 2-2 and 2-3 and Table 2-1, each of which are
organized by the effects of the mutations on activation by thrombin-TM. Most
interestingly, the catalytic efficiencies of R12A and R12A/R15A were similar to wildtype TAFI containing the 6×His tag (Figure 2-3), yet these variants are activated very
slowly by thrombin-TM (Figure 2-2). Table 2-1 shows the impact of each mutation on the
enhancement by TM of the catalytic efficiency of TAFI activation by thrombin.
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Figure 2-3. The kinetics of activation of TAFI variants by thrombin. The variants
were incubated at different concentrations with 100 nM IIa, 20 μg/mL PTCI and 5 mM
CaCl2 for 15 min at room temperature. The rates of TAFIa formation were calculated
using western blot analysis (symbols). The data are the means ± standard errors of the
mean of 3 – 9 independent experiments. The lines represent the mean slope for each
variant and are taken to be the catalytic efficiency (kcat/KM). A – C: Variants are
organized by their effect on activation by thrombin-TM, as in Figure 2-2. The data for
wild-type TAFI (TAFI wt) are shown in each panel for comparison purposes.
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2.4.4

Activation of TAFI variants by plasmin
The activation of the TAFI variants by plasmin in the absence and presence of

heparin was examined. Rates of activation at a single concentration of TAFI were
measured by western blot analysis and were normalized to wild-type TAFI minus heparin
(Figure 2-4). In general, heparin resulted in a 2 – 3-fold acceleration of plasmin-mediated
TAFI activation. Only in the case of R377A was activation by plasmin in the presence of
heparin significantly less than wild-type.
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Figure 2-4. Plasmin-mediated activation of TAFI variants. The TAFI variants (200
nM) were incubated with 25 nM plasmin and 150 μM Plummer’s inhibitor in the presence
or absence of 0.2 U/μL heparin for 15 minutes at room temperature. The extents of TAFI
activation were measured using western blot analysis. The extent of TAFIa formation was
normalized to wild-type TAFI in the absence of heparin. The data are the means ±
standard errors of the mean of 3 – 13 independent experiments.* and †: p < 0.05 versus
wild-type in the absence or presence of heparin, respectively, by ANOVA.
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2.4.5

Thermal Stabilities of the TAFI variants
The thermal stabilities of the TAFI(a) variants were determined by activation of

the zymogen by the thrombin-TM complex, followed by incubation at 37°C and
measurement of residual TAFIa activity by AAFR hydrolysis. Half-lives of each variant
were calculated from the resultant first-order decay rate constants (Table 2-2). The halflives of wild-type TAFI and wild-type TAFI-6×His were 7.0 ± 0.5 min and 6.9 ± 0.1 min,
respectively. Compared to wild-type TAFI, all the variants exhibited comparatively small
changes in their half-lives, as expected as all mutations are present either in the activation
domain or remote from regions of the catalytic domain that dictate stability [23, 25, 26].
The exceptions are R12A and R12A/R15A, which showed apparently markedly greater
half-lives. However, since the activation of these zymogens by thrombin-TM is extremely
inefficient, the enzymatic activities as measured using the AAFR substrate are very close
to background, likely affecting estimates of half-life. Moreover, we would not expect that
mutations in the activation domain would affect the stability of the enzyme after
activation.
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Table 2-2. Intrinsic Stability of TAFI variantsa
Variant

Half-life (min)
TAFI wt
7.0 ± 0.2
TAFI wt-6×His
6.9 ± 0.1
R12A-6×His
10.2 ± 1.3
R12A/R15A-6×His
18.5 ± 2.8
R15A
6.8 ± 0.1
E28A
6.7 ± 0.3
D54A/D56A
6.6 ± 0.1
K59A
5.1 ± 0.4
D75A/E77A/D78A
5.1 ± 0.1
E99A
5.2 ± 0.2
E106A
7.9 ± 0.3
E112A/E116A
6.4 ± 0.1
R377A
6.4 ± 0.1
a
Data are the means ± standard errors of the mean of 3-4 independent experiments
performed in triplicate
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2.4.6

Antifibrinolytic potential of TAFI variants
The antifibrinolytic potential of each variant using an in vitro plasma clot lysis

assay was determined at a constant concentration of added TAFI (50 nM), titrating TM
from 0.02 to 2 nM (Figure 2-5). As with the previous figures, we have grouped the
variants according to the catalytic efficiency of their activation by thrombin-TM (see
Figure 2-2, Table 2-1). In the presence of TM, the variants R12A and R12A/R15A
showed massive decreases in antifibrinolytic activity, as expected since their activation by
thrombin-TM is very slow. The other variant with substantially impaired activation by
thrombin-TM, R377A, also showed a much reduced antifibrinolytic effect. For the
remaining variants, there was a notable relationship between the catalytic efficiency of
thrombin-TM activation and their antifibinolytic potential in the presence of TM. The two
variants activated similarly to wild-type by thrombin-TM (D54A/D56A and
E112A/E116A) are very similar to wild-type in their antifibrinolytic activity in response
to TM (compare Figures 2-2A and 2-5A), whereas the variants with moderately reduced
activation by thrombin-TM are likewise observed to have moderately reduced
antifibrinolytic potential (compare Figures 2-2B and 2-5B).
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Figure 2-5. The antifibrinolytic potential of TAFI variants in the presence of TM.
TAFI-deficient plasma was diluted 1:3 and supplemented with TAFI variants (50 nM) in
the presence of 0.02 – 2 nM TM. The assay mixture was added into the wells of
microtitre plates containing small, separated aliquots of thrombin, CaCl2 and tPA to
initiate clot formation and subsequent lysis. The change in turbidity of the clots was
monitored at 405 nm at 37°C. The time to 50% lysis was determined graphically from the
midpoint between maximum and minimum turbidities of the clots. Each data point
represents the mean ± standard error of the mean of 3 – 4 independent experiments. A –
C: Variants are organized by their effect on activation by thrombin-TM, as in Figure 2-2.
The data for wild-type TAFI (TAFI wt) are shown in each panel for comparison purposes.
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2.5 Discussion

Thrombin-mediated activation of TAFI is dramatically accelerated by TM: an
over 1000-fold increase in catalytic efficiency (kcat/KM) has been reported [5]. The basis
for this increase in catalytic efficiency is unclear as early measurements of the kinetics of
TAFI activation by thrombin alone – showing a similar KM for TAFI activation either in
the presence or absence of TM – are likely incorrect [5]. In our hands and those of others
[11, 17, 21], measurement of kcat and KM for thrombin activation is practically impossible
as the relationship between TAFI concentration and rate of activation is linear over
achievable concentrations of TAFI. It is clear from such plots, however, that TM results
in a dramatic decrease in KM, an effect that implies an enhanced interaction between
substrate and cofactor-bound enzyme (compare Figures. 2-2 and 2-3, for example).
Indeed, accumulating evidence from several studies suggests that TM and TAFI make
direct contacts such that the enhancement of TAFI activation by TM results from binding
at sites remote from the activating cleavage site (Arg92-Ala93) [9-11]. By analogy with
the structural basis for the ability of TM to accelerate activation of protein C [15], TM
and TAFI likely interact through exosite interactions that present TAFI optimally as a
substrate for thrombin. However, the elements of TAFI structure that allow accelerated
activation of thrombin by TM are incompletely defined. We have identified a novel
residue (R377) that plays a key role in mediating enhanced activation of TAFI by TM,
and have clarified the role of R12, previously identified by Plug and co-workers [17].
The lysine and arginine residues on the catalytic domain and the triple lysine
residues within the activation domain reported by Wu and coworkers showed a reduced
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catalytic efficiency of TAFI activation by the thrombin-TM complex [11]. The maximal
decrease in catalytic efficiency was for mutation of K42/K43/K44: the observed 8-fold
decrease is much less than the total increase attributable to TM. However, mutation of
R377 results in a 17.4-fold decrease in catalytic efficiency (Figure 2-2; Table 2-1). Even
more dramatically, mutation of R12 decreases the cofactor activity of TM to the extent
that activation of TAFI is not even detectable at thrombin concentrations of 1 nM (data
not shown). In order to more directly assess the ability of TM to accelerate activation of
these mutants, we used 100 nM thrombin in the presence or absence of 100 nM TM.
Under these conditions, only a 2- to 3-fold increase in kcat/KM was observed for R12A or
R12A/R15A (Figure 2-2), strongly indicating that the R12A mutants are essentially
resistant to the accelerative effects of TM. This is the first report of such a mutant version
of TAFI.
R12 in TAFI is in the activation domain, close to K42/K43/K44 (Figure 2-1).
Molecular modeling by Wu and coworkers where the TAFI structure was docked to the
thrombin-TM EGF4-6 structure strongly indicated that the critical EGF-3 domain in TM
would be located in this vicinity [11]. It is tempting to speculate that R12 in TAFI
contacts key acidic residues in the EGF-3 domain, such as D341 or D343 located in the cloop of EGF-3; mutation of these residues abolishes the cofactor activity of TM [9]. A
very recent report by Plug and coworkers also identified R12 as a key residue mediating
TM-dependent activation of TAFI [17]. Mutation of R12 to glutamine resulted in a 54fold decrease in catalytic efficiency. In this work, R12 was also identified as a thrombin
cleavage site [17]; Plug and coworkers were thus left to speculate that either R12 is
involved in exosite interactions with TM that accelerate TAFI activation or prior cleavage
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at R12 accelerated thrombin-TM-mediated TAFI activation. Taking their data and our
data together, it is clear that the former explanation is most likely true. First, the kinetics
of cleavage at R12 are too slow to account for the ability of TM to accelerate TAFI
activation (see Figure 2 of [17]). Second, substitution of R12 for glutamine [17] or
alanine (current study) results in dramatically different activation kinetics by thrombinTM. Under conditions where activation of R12Q is detectable (1 nM thrombin, 1 – 8 nM
TM), we see no activation of R12A (Figure 2-2). If a lack of cleavage at R12 is the key
factor, we would not expect such a difference. It is possible that the glutamine residue at
position 12 is still capable of making some productive contacts with EGF-3 of TM.
As with purification of K42A/K43A/K44A with monoclonal antibody MA-T4E3
[11], variants R12A and R12A/R15A also could not be isolated using monoclonal
antibody MA-T4E3. This can be rationalized by examining the crystal structure of TAFI
[23], since residue R12 is located on a loop directly below and in close proximity to the
triple lysine residues which were not recognized by the antibody. Interestingly, another
monoclonal antibody (MA-T12D11) has been previously shown to prevent TAFI
activation by the thrombin-TM complex but not thrombin alone [27]. The key residue for
binding this antibody is G66, which is located on a loop in the immediate vicinity of R12
[23], again indicating that this region on the TAFI structure may be important for TM
binding. It is notable that the presence of the carboxyl-terminal histidine tag decreased the
activatability and antifibrinolytic activity of TAFI, as can be observed by comparison of
TAFIwt and TAFIwt-6×His. This finding is in agreement with previous results showing
that a nanobody directed against residues in this region inhibits thrombin-TM-mediated
activation of TAFI [28]. However, since we compared the effects of R12A mutations to
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TAFIwt-6×His, it is clear that the mere presence of the histidine tag does not explain
resistance of the R12A mutant to acceleration of thrombin activation by TM.
Mutation of additional surface-exposed charged residues had either little or no
effect on thrombin-TM-mediated activation of TAFI (D54A/D56A and E112A/E116A) or
decreased activation to a moderate extent (R15A, E28A, K59A, D75A/E77A/D78A,
E99A, E106A) (Table 2-1). It is notable that several of the latter category of mutations
are of negatively-charged residues, even though many of the residues on TM shown to be
important for TAFI activation are themselves negatively-charged [9]. We speculate that
these additional residues which we have identified map to a surface on TAFI that is
important for interaction with the thrombin-TM complex. Moreover, as R15A, E28A,
E99A and E106A show no significant difference in catalytic efficiency of activation by
thrombin alone (Table 2-1), these residues may specifically be involved in interaction
with TM.
The second mutation with dramatic effects on TAFI activation was R377A. This
residue is located in a completely different region of TAFI (Figure 2-1) where TM is not
anticipated to bind [11]. The R377A mutation decreased the catalytic efficiency of
activation by thrombin alone by less than two-fold but decreased that of thrombin-TM by
approximately 17-fold (Table 2-1). Upon examination of the model prepared by Wu and
coworkers, it is apparent that R377 is located approximately where the 149 loop of
thrombin contacts TAFI [11]. The 149 loop is one of two surface loops, the other being
the 60D loop, that reside on either side of the active site groove [29]. While the 60D loop
shows some structural alterations when bound by TM, the 149 loop is disordered in the
presence of TM (as it is in many other thrombin structures) while being in close
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proximity to TM EGF-5 [15]. It is possible that the 149 loop is positioned in such a way
by TM that brings it into productive contact with the surface helix in TAFI containing
R377.
In conclusion, we have identified two residues in TAFI, R12 and R377, that are
crucial for the ability of TM to accelerate TAFI activation by thrombin. R12 likely
directly contacts EGF-3 of thrombomodulin while R377 may be important for the TAFIthrombin interaction in the context of TM. The R12 mutation may be a useful tool to
probe the importance of TM in activation of TAFI both in in vitro and in vivo
experiments.
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2.9 Supporting information

Supplementary Table 2-1. Primer sequences for construction of TAFI Variantsa

Variant

Primer Sequence

TAFI-R12A

5’-AGTTCTAGCTGCTCTTCCTGCAACCTCTAGGCAAGTTCAA-3’

TAFI-R15A

5’-TAGCTGCTCTTCCTAGAACCTCTGCGCAAGTTCAAGTTCT-3’

TAFI-R12A/R15A

5’-GGCCAAGTTCTAGCTGCTCTTCCTGCAACCTCTGCGCAAGTTCAAGTTCTAC-3’

TAFI-E28A

5’-CTTACTACAACATATGCGATTGTTCTCTGGC-3’

TAFI-D54A/D56A

5’-CATTTTTTTGTAAATGCATCTGCTGTCGCCAATGTGAAAGCCC-3’

TAFI-K59A

5’-AAATGCATCTGATGTCGACAATGTGGCAGCCCATTTAAATGTGAGC-3’

TAFID75A/E77A/D78A

5’-GTGTCTTGCTGGCAGCCGTGGCAGCTCTTATTCAACAGCAG-3’

TAFI-E99A

5’-CTCCGCATCGTACTATGCACAGTATCCTACTCACTAAATG-3’

TAFI-E106A

5’-GAACAGTATCACTCACTAAATGCAATCTATTCTTGGATAGAATTTATAAC-3’

TAFI-E112A/E116A

5’-CTATTCTTGGATAGCATTTATAACTGCGAGGCATCCTGATATGCTTA-3’

TAFI-E116G

5’-CTTGGATAGAATTTATAACTGGCAGGCATCCTGATATGCTTACAAAAATCCAC3’

TAFI-R377A

5’-CATACGGATTCTTGCTGCCGGAGGCCTACATCAAACCCACC-3’

a

Sense strand sequences only are shown. Ala/Gly codons are double underlined; mutated
nucleotides are in boldface type.
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3.1 Summary

Background: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that
functions as a link between the coagulation and fibrinolysis pathways. TAFI is activated
through proteolytic cleavage by thrombin, thrombin in complex with the endothelial cell
cofactor thrombomodulin (TM), or plasmin. Several studies suggest that the activation
domain of TAFI plays an important role in its activation by the thrombin-TM complex.
One report has suggested that cleavage of TAFI after arginine-12 by thrombin accelerates
activation of TAFI by thrombin-TM. Objectives: To determine the effect of aminoterminal truncation of the activation domain on activation by thrombin in the presence of
TM. Methods: We generated several amino-terminal deletions of the activation domain of
TAFI including TAFIΔ1-6, TAFIΔ1-6, R12A, TAFIΔ1-11, and TAFIΔ1-12 in order to identify the
minimum length of the activation domain that is required to mediate acceleration of
activation by TM. The activation of the mutants by thrombin in the presence or absence
of TM was determined. Results: The variants were not detectably secreted from
mammalian cells but were all found to be expressed intracellularly. Activation of the
intracellular forms of the mutants could not be reliably detected. Conclusions: The results
from this study are inconclusive and further studies need to be performed to determine the
functionality of the amino-terminally truncated TAFI activation domain variants.
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3.2 Introduction

Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that
functions as an important regulator of the fibrinolytic system upon activation [1, 2]. The
mature TAFI protein is a 60 kDa procarboxypeptidase that consists of a 92-amino acid
activation domain (Phe1–Arg92) which is N-glycosylated at four sites (Asn22, Asn51,
Asn63, Asn86) and a 309-amino acid catalytic domain (Ala93–Val401) [3, 4]. TAFI is
activated through proteolytic cleavage at Arg92-Ala93 to generate the enzyme activated
TAFI (TAFIa) [5-7]. TAFIa possesses basic carboxypeptidase activity that efficiently
cleaves the carboxyl-terminal lysine and arginine residues from partially-degraded fibrin,
thus yielding a form of fibrin that possesses almost no cofactor activity [8]. Thus, the
TAFI pathway attenuates fibrinolysis by interfering with positive feedback in the
fibrinolytic cascade that is essential for plasminogen activation [9, 10]. Thrombin and
plasmin alone are relatively weak activators of TAFI however, when thrombin binds to
the endothelial cell cofactor TM, the catalytic efficiency (kcat/KM) of TAFI activation is
accelerated by over 1000-fold compared to thrombin alone [6, 7].
Several studies have revealed clues as to the structural basis for the acceleration of
TAFI activation by thrombin in the presence of TM. A study by Wu and coworkers
showed that substitution of the consecutive lysine residues in the activation domain of
TAFI, Lys42/Lys43/Lys44, with alanine exhibited an 8-fold reduced catalytic efficiency
of TAFI activation by the thrombin-TM complex [11]. In addition, Plug and coworkers
identified Arg12 in the activation domain as an important residue in TM-mediated
activation of TAFI. When Arg12 was mutated to a glutamine a 54-fold decrease in
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catalytic efficiency was observed [12]. However, in a recent study by our group we have
found that mutation of Arg12 with alanine resulted in a mutant form of TAFI that is
essentially resistant to the accelerative effects of TM [13]. A deletion mutant of TAFI
constructed by Zhou and coworkers where the first 73 amino acids of the activation
domain are absent failed to exhibit full cleavage by thrombin-TM even following
extended incubation periods [14]. Notably, all these studies have emphasized the
important role of the activation domain of TAFI in its activation by the thrombin-TM
complex. Therefore, we hypothesize that the activation domain of TAFI makes contacts
with TM, therefore constituting an exosite which affects the rate of cleavage. Moreover,
Arg12 is a key residue in this exosite.
Interestingly, Plug and coworkers found that Arg12 is a novel cleavage site
recognized by thrombin and plasmin [12]. That the Gln12 variant was more slowly
activated by thrombin-TM prompted them to speculate that cleavage after Arg12 results
in a form of TAFI that is more efficiently activated by thrombin-TM. On the other hand,
their work also showed that the kinetics of cleavage at Arg12 are too slow to account for
the effect of TM on thrombin cleavage at Arg92 [12]. In order to address this question in
a more definitive way, we have constructed and expressed several amino-terminal
deletions of the activation domain of TAFI including TAFIΔ1-6, TAFIΔ1-6, R12A, TAFIΔ1-11,
and TAFIΔ1-12. The activation of the mutants by thrombin in the presence or absence of
TM was determined.
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3.3 Experimental Procedures

3.3.1

Materials
DNA restriction and modification enzymes (T4 DNA Polymerase and T4 DNA

Ligase) were purchased from New England Biolabs (Mississauga, ON, Canada).
pcDNA™4A/myc-His mammalian expression vector was purchased from Invitrogen
Canada Inc. (Burlington, ON, Canada). Dulbecco’s modified Eagle’s medium/nutrient
mixture F-12, Opti-MEM, Trypsin-EDTA, penicillin/streptomyocin/fungizone (PSF)
were obtained from Invitrogen. Newborn Calf Serum was obtained from Sigma-Aldrich
Canada, Ltd. (Oakville, ON, Canada). MegaTran 1.0 transfection reagent was purchased
from Origene (Atlanta, GA, USA). RNeasy Plus Midi Kit was purchased from QIAGEN,
Inc. (Toronto, ON, Canada). RQ1 (RNA Qualified) RNase-Free DNase was purchased
from Promega (Madison, WI, USA). Diethyl pyrocarbonate (DEPC) was obtained from
Sigma-Aldrich. iTaq Universal SYBR Green One-Step Kit was purchased from BioRad
(Mississauga, ON, Canada). Thrombin and rabbit-lung thrombomodulin was obtained
from Haematologic Technologies (Essex Junction, VT, USA). The thrombin inhibitor Dphenylalanylprolylarginyl chloromethylketone (PPAck) was purchased from Calbiochem
(San Diego, CA, USA). Polyclonal sheep anti-human TAFI antibody was purchased from
Affinity Biologicals (Ancaster, ON, Canada) and polyclonal rabbit anti-sheep antibody
was purchased from ThermoFisher Scientific (Ottawa, ON, Canada).
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3.3.2

Construction of TAFI Activation Domain Deletion Mutants
The activation domain deletion mutants TAFIΔ1-6, TAFIΔ1-6, R12A, TAFIΔ1-11, and

TAFIΔ1-12 were generated in the wild-type TAFI- pcDNA4A/myc-His vector. cDNA
sequences encoding the activation domain deletion mutants were obtained from
GenScript custom gene synthesis services in the pUC57 vector (Piscataway Township,
NJ, USA) such that sequences encoding the native TAFI secretion peptide were fused
with sequences encoding the amino-terminally truncated activation domain.
These fragments were then transferred into the wild-type TAFI- pcDNA4A/mycHis expression vector, which was previously described and contains human TAFI cDNA
containing threonine at positions 147 and 325 and encodes a carboxyl-terminal 6×-His tag
[4, 13]. The wild-type TAFI- pcDNA4A/myc-His vector contains two BglII restriction
sites, one in the vector backbone and one within the TAFI coding sequence. To allow
utilization of BglII in the cloning of the deletion mutants into the wild-type TAFIpcDNA4A/myc-His vector the BglII site in the vector backbone was removed. This was
done by limiting digestion of the vector through titration of the BglII enzyme. The
digestion products were resolved on an agarose gel, and the singly-digested vector
fragment was excised from the gel. The BglII ends were made blunt using the T4 DNA
Polymerase and ligated, since BglII (recognition sequence AGATCT) leaves a 5’overhang, the ligation products (AGATCGATCT) would not be able to be digested by
this enzyme. To determine which of the BglII sites was eliminated by this maneuver,
clones were digested with PstI and BglII and those yielding ~5.95 kb and 300 bp bands
(reflecting cleavage of the BglII site in the TAFI cDNA) were selected. The resulting
wild-type TAFI- pcDNA4A/myc-HisΔBglII vector was digested with PstI and BglII, and
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the respective truncation mutant fragments that had been excised from pUC57 were
inserted. The presence of the truncation mutations was verified by DNA sequence
analysis.
The activation domain deletion mutants TAFIΔ1-6, TAFIΔ1-6, R12A, TAFIΔ1-11, and
TAFIΔ1-12 were also generated in the context of the TAFI-CIIYQ variant. Each truncation
mutant expression vector was digested with BglII and AgeI and the wild-type fragment
was substituted with the corresponding fragment encoding the CIIYQ mutation as well as
the carboxyl-terminal 6×-His tag, which had been excised from the TAFI-CIIYQpcDNA4A/myc-His expression vector digested with these enzymes.

3.3.3

Transient Transfection of TAFI Activation Domain Deletion Mutants
Baby hamster kidney (BHK) cells were cultured in Dulbecco’s modified Eagle’s

medium/F-12 nutrient mixture (1:1) (DMEM/F-12) containing 5% (v/v) newborn calf
serum (NCS) and 1% (v/v) PSF in a humidified incubator at 37°C in a 95% air/5% CO2
atmosphere. Expression plasmids encoding the respective TAFI mutants were transfected
into cells using MegaTran 1.0 transfection reagent (10 μg plasmid DNA in a 100 mm
plate of cells, 0.75 μg plasmid DNA in a 6-well plate of cells) with a 3:1 ratio of reagent
to DNA as per the manufacturer’s instructions. After 24 hour incubation with the
transfection mixture, the media was removed and the transiently expressing lines were
cultured in Opti-MEM containing 1% (v/v) PSF. Conditioned medium was collected at 72
hour post-transfection and the cells in the 100 mm plate were then lysed with 1 mL lysis
buffer (50 mM Tris pH 8.0, 1% NP-40, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM
EDTA, 0.1% SDS). Harvested conditioned medium was centrifuged at 3000 × g for 5
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minutes, supplemented with Tris-HCl, pH 8.0 (to 5 mM) and phenylmethanesulphonyl
fluoride (PMSF) to (2 μM) and stored at -20°C.

3.3.4

Activation of TAFI Mutants and Western blot analysis
For activation of TAFI, 75 μL of conditioned medium or lysate corresponding to

each TAFI variant was incubated in the presence of CaCl2 (5 mM) and thrombin (25 nM)
in the presence or absence of rabbit-lung thrombomodulin (100 nM) in HBST for a final
volume of 100 μL for 10 minutes at 21°C. Thrombin activity was then quenched by the
addition of PPAck (to 1 μM) before the mixture was placed on ice. SDS-PAGE sample
buffer (0.2 M Tris-HCl, 8% SDS, 40% Glycerol, 0.08% bromophenol blue) was added to
the samples. Samples were analyzed by SDS-PAGE and western blotting analysis.
Following SDS-PAGE on 12% polyacrylamide gels, proteins were transferred
onto a an Immobilon-P transfer membrane (Millipore) and blocked in blocking buffer
consisting of 6% (w/v) non-fat milk in 1× NET (150 mM NaCl, 5 mM EDTA, 50 mM
Tris pH 7.4, and 0.05% Triton X-100) for at least 1 hour at room temperature. The blots
were then incubated overnight at 4°C with the sheep anti-human TAFI polyclonal
antibody (Affinity Biologicals) (1:5,000 dilution) in blocking buffer containing 3% (v/w)
non-fat milk. The blots were washed with 1× NET (three times for 10 minutes each) then
incubated with horseradish peroxidase-conjugated rabbit anti-sheep IgG secondary
antibody (Pierce Biochemical) (1:15,000 dilution) in blocking buffer containing 3% (v/w)
non-fat milk at room temperature for 1 hour. The membranes were then washed with 1×
NET as described above. The immunoreactive bands were visualized using SuperSignal

103

West Femto Maximum Sensitivity Substrate (Pierce Biochemical) and a FluorChem Q
Gel Imaging System (Alpha Innotech).

3.3.5

RNA Extraction and DNase Treatment of RNA
Total RNA was extracted from transiently transfected cells (grown in 6-well

plates) using the RNeasy Plus Midi Kit according to the manufacturer’s protocol.
Subsequently, RNA was DNase treated using RQ1 RNase-free DNase for 2 hours at
37°C. Following DNase treatment, the RNA samples were phenol/chloroform extracted,
precipitated, and re-suspended in DEPC-treated H2O. RNA concentrations were measured
using a Nanodrop 2000 spectrophotometer (Thermo Scientific).

3.3.6

Real-time quantitative RT-PCR
Determination of mRNA expression corresponding to the recombinant variants

was assessed through iTaq™ Universal SYBR® Green One-Step kit (Bio-Rad) on a
BioRad CFX96 Real-Time thermal cycler system. The following primers were used:
TAFI forward 5’ -GCT GCC GGA GCG TTA CAT- 3’; TAFI reverse 5’ -CAT TCC
TAA TGA CAT GCC AAG CT- 3’; GAPDH forward 5’ -GGA GCC AAA AGG GTC
ATC ATC- 3’; GAPDH reverse 5’ -GTT CAC ACC CAT GAC GAA CAT G- 3’.
Thermocycling conditions used for all samples were as follows: reverse transcription at
50°C for 15 minutes, activation of Taq polymerase at 95°C for 7 minutes, 42 cycles of
denaturation at 95°C for 15 seconds, annealing at 60°C for 40 seconds. Relative
quantification of mRNA encoding the variants was performed by normalization of the
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threshold cycle for each sample with that of GAPDH from the same reaction well using
Bio-Rad CFX Manager software version 3.1 (Bio-Rad).
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3.4 Results

3.4.1

Expression of N-terminal deletion TAFI variants
Amino-terminal truncation mutants of TAFI (Figure 3-1) were expressed both in

the context of the wild-type TAFI amino acid sequence as well as the previously reported
stable TAFI variant, TAFI-S305C-T325I-T329I-H333Y-H335Q (TAFI-CIIYQ). This
variant contains mutations in the dynamic flap region that stabilize the region and
increase the half-life of TAFIa approximately 180-fold [15]. The expression and
activation of the truncated activation domain TAFI protein variants was examined using
western blotting analysis. Expression vectors encoding the amino-terminal activation
domain deletion variants as well as the full-length wild-type TAFI and TAFI-CIIYQ
forms and the control empty pcDNA4a vector were transiently transfected into BHK
cells. The conditioned medium was collected from each variant and incubated with
thrombin alone and thrombin-TM (Figure 3-2A). Immunoreactive bands were observed in
the conditioned medium of cells expressing the full-length variants. The full-length TAFI
variants migrated at approximately 65 kDa and were activated by thrombin-TM, indicated
by the 35 kDa band, as expected. Of particular note, the sizes of the zymogen bands are
slightly larger than expected, likely due to the presence of the 6× His tag on the carboxylterminus. Activation of wild-type TAFI by thrombin alone was not detectable since a low
concentration of thrombin was used (25 nM) and the activation period was short (10
minutes). In contrast, none of the truncation mutants, either in the context of wild-type
TAFI or TAFI-CIIYQ, were detectable in the conditioned media.
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The lysates from the transient transfections were also collected and incubated with
thrombin alone and thrombin-TM (Figure 3-2B). Immunoreactive bands were observed
on western blot analysis of the lysates at approximately 45-48 kDa for all variants tested
(Figure 3-2C), although those for TAFIΔ1-6,

R12A

and all the truncation mutants in the

context of TAFI-CIIYQ were considerably less abundant. Immunoreactive bands of 65
kDa were observed for full-length wild-type TAFI and TAFI-CIIYQ. The wild-type TAFI
and TAFI-CIIYQ present in lysate was activated by thrombin-TM shown by the
appearance of a faint 35 kDa band and the diminution or disappearance of the 65 kDa and
45-48 kDa bands (Figure 3-2B). Interestingly, the 45-48 kDa form of TAFI-CIIYQ
appeared to be activated more efficiently by thrombin-TM than the 45-48 kDa form of
wild-type TAFI (Figure 3-2B). As the abundance of the truncation variants in the lysates
is low, activation of these variants could not be reliably ascertained from the western blot
analysis (Figure 3-2B).
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Figure 3-1. TAFI amino-terminal deletion mutants. The full length TAFI protein
consists of a 92-amino acid activation domain (dark blue) and a 309-amino acid catalytic
domain (light blue). The TAFI amino-terminal deletion mutants constructed are: TAFIΔ16, TAFIΔ1-6, R12A, TAFIΔ1-11, and TAFIΔ1-12 which were made in the context of wild-type
and CIIYQ. The variant TAFIΔ1-73 was only made in the context of CIIYQ. The location
of residue R12 is indicated by the yellow star.
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B
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Figure 3-2. Activation of TAFI amino-terminal deletion mutants. BHK cells were
transiently transfected with the expression plasmids empty pcDNA4a, wild-type TAFI,
and TAFI-CIIYQ and the following variants in the context of wild-type and CIIYQ:
TAFIΔ1-6, TAFIΔ1-6, R12A, TAFIΔ1-11, and TAFIΔ1-12 and the variant TAFI-CIIYQΔ1-73. A)
Conditioned media and B) lysate samples were collected from the mutants. The samples
were activated by thrombin alone (25 nM) and thrombin-TM (25 nM, 100 nM,
respectively) as indicated and subjected to western blot analysis. C) Non-activated lysate
samples for all variants. The position of TAFI (solid) and TAFIa (dashed) are indicated
by arrow heads, non-specific bands are indicated by asterisks, and intracellular forms of
TAFI are indicated by square brackets.
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The expression of the truncated activation domain TAFI variants was also
examined through measurement of their mRNA and was assessed using qRT-PCR
(Figure 3-3). The results show that all the TAFI variants were expressed in BHK cells.
TAFI-CIIYQ showed the highest mRNA expression of CPB2 being approximately 2- to
70- fold higher compared to the rest of the variants. The next highest expression is from
TAFIΔ1-12 CIIYQ followed by wild-type TAFI each with comparable expression being
approximately 1-fold less than TAFI-CIIYQ. The variants TAFIΔ1-6 wild type, TAFIΔ1-11
wild type, and TAFIΔ1-11 CIIYQ all have similar magnitude of expression with 2-fold less
expression compared to wild-type TAFI while these variants TAFIΔ1-6 CIIYQ, TAFIΔ1-6,
R12A

CIIYQ, and TAFIΔ1-12 wild-type are 3-fold less. The lowest expressed variants are

TAFIΔ1-6, R12A wild-type possessing 7-fold less expression and variant TAFIΔ1-73 CIIYQ
with 34-fold less expression compared to wild-type TAFI.
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Figure 3-3. Quantification of amino-terminal deletion mutants expression. BHK cells
were transiently transfected with the expression plasmids empty pcDNA4a,wild-type
TAFI, and TAFI-CIIYQ and the following variants in the context of wild-type and
CIIYQ: TAFIΔ1-6, TAFIΔ1-6, R12A, TAFIΔ1-11, and TAFIΔ1-12 and the variant TAFI-CIIYQΔ173. The expression of the respective mRNAs was analyzed by quantitative real-time RTPCR. The data shown are the mean of one experiment performed in triplicate. The error
bars represent the standard errors of the mean.
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3.5 Discussion

The truncation mutants of the activation domain of TAFI were constructed to
address the possibility that cleavage of TAFI by thrombin or plasmin at Arg12 might
accelerate activation of TAFI by thrombin-TM, as recently suggested by Plug and
coworkers [16]. Evidence from several studies suggests the importance of the activation
domain of TAFI in its activation by the thrombin-TM complex. Plug and coworkers
demonstrated that mutation of Arg12 to Gln residue resulted in a 54-fold decrease in
catalytic efficiency (kcat/KM) of TAFI activation by thrombin-TM [12] while a recent
study from our group showed that mutation of Arg12 to an Ala resulted in almost
complete resistance of acceleration of TAFI activation by thrombin in the presence of
TM. Furthermore, mutations within the activation domain caused a decrease in the
catalytic efficiency of activation in the presence of TM [13]. Adding to the evidence is the
study by Zhou and coworkers showing that a mutant version of TAFI-CIIYQ where the
first 73 residues of the activation domain are absent was unable to be cleaved by
thrombin-TM despite the extended activation periods [14]. Molecular modeling of the
interaction of TAFI with thrombin-TM suggests that the key structure in TM for
promoting TAFI activation – epidermal growth factor-like domain 3 – is likely to contact
TAFI in the activation domain in the vicinity of Arg12. Clearly, Arg12 is an important
residue in the activation of TAFI by thrombin-TM, but the question remains to be
addressed if removal of residues 1 through 12 influences TAFI activation by thrombinTM.
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In the current study we have attempted to address this question by constructing
mutant variants of TAFI with N-terminal deletions of the activation domain of TAFI
including TAFIΔ1-6, TAFIΔ1-6,

R12A,

TAFIΔ1-11, and TAFIΔ1-12.We initially constructed

these activation domain truncated mutants of TAFI in the context of wild-type TAFI.
However, preliminary studies showed that the truncation variants were not secreted into
the medium of transfected cells. Therefore, we also constructed the truncation variants in
the context of the stable TAFI-CIIYQ variant. The rationale for this is that Zhou and
coworkers expressed the more extensive truncation variant TAFIΔ1-73 in this context
[16]. It has been postulated that the activation domain contributes to the stabilization of
the dynamic flap in the TAFI zymogen therefore, it is possible that the truncated forms of
activation domain of TAFI do not support stabilization of the enzyme domain. The
CIIYQ mutations in the dynamic flap stabilize the enzyme domain [15].
Expression plasmids encoding all of the truncation variants as well as full-length
wild-type TAFI and TAFI-CIIYQ were transiently transfected into BHK cells and
activation of the TAFI protein in the conditioned medium was assessed through western
blotting analysis. Our results show that wild-type and TAFI-CIIYQ were able to be
secreted and activated by thrombin-TM indicating successful transfection. However, none
of the variants, either in the wild-type or CIIYQ form, were secreted from cells.
At this time it is not fully clear why the mutants were not secreted. The study by
Zhou and coworkers demonstrated the Δ1-73 TAFI-CIIYQ mutant is able to be secreted,
with and without an amino-terminal 6×-His tag. Our mutants are in-frame (as verified by
sequence analysis) and each contained an intact signal peptide. One difference between
the studies of Zhou and the current work is the mammalian expression system utilized;
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Zhou and coworkers utilized, human embryonic kidney (HEK293) cells versus the BHK
cells used here. However, both BHK cells and HEK293 cells have been used to express
recombinant TAFI [4, 11, 14, 17-19]. The most likely explanation is the presence of the
carboxyl-terminal 6×-His tag in this study. It is notable that our previous work has shown
the carboxyl-terminal 6×-His tag does materially affect the functional properties of TAFI,
including its activation and antifibrinolytic effect [13]. How the presence of the tag
affects the folding and ultimate secretion of the truncation variants is unclear, but
certainly this could be overcome by constructing and expressing a new generation of
truncation variants with an amino-terminal 6×His tag, as was done by Zhou and
coworkers [14] and also by Marx and coworkers for the purpose of producing
recombinant TAFI for crystallization [20].
The lysates from the transient transfections were also analyzed and a species
presumably corresponding to a hypoglycosylated, intracellular form of TAFI
(approximately 45-48 kDa) was detectable for all the variants tested (Figure 3-2C), albeit
in greatest abundance for the secretable full-length forms of TAFI. We speculate that
these forms represent incompletely folded and/or glycosylated forms of TAFI that are
present in the endoplasmic reticulum. In the case of the truncated variants, the protein is
never properly folded and/or glycosylated and so is unable to exit the endoplasmic
reticulum and proceed through the secretory pathway. In this respect, they are analogous
to lower molecular-weight forms of TAFI expressed from naturally-occurring
alternatively spliced CPB2 transcript [21]. It is notable that the TAFI-CIIYQ intracellular
form is efficiently activated by thrombin-TM while the corresponding form of wild-type
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TAFI is not (Figure 3-2B). This may relate to the greater stability, and hence more
efficient folding, of the CIIYQ form.
Using qRT-PCR analysis, we did verify that each of the expression plasmids was
transfected into the BHK cells and mRNA corresponding to the variants expressed.
Although there were notable differences in the abundance of these mRNAs, they do not
fully explain the differences in the intracellular or extracellular abundance of the
respective TAFI variants.
At this time, it is not possible to definitively conclude whether amino-terminal
truncation of the TAFI activation domain affects cleavage of TAFI by thrombin-TM.
However, it is likely that loss of a significant number of residues in the 1-12 sequences
will profoundly affect the conformation of the activation domain, and may even have
affected the ability of the truncation variants to be expressed. Residues 1-12 form a βstrand that is an internal strand in a four-strand antiparallel β-sheet that is a key part of the
open-faced α/β-sandwich activation domain tertiary structure (Figure 3-4). Loss of these
residues is likely to negatively impact the thermodynamic stability of this β-sheet and
hence of the activation domain itself. Loss of proper folding of the activation domain
would likely prevent secretion of the protein. Interestingly, the TAFIΔ1-73 variant
completely lacks the open-faced α/β-sandwich moiety, perhaps accounting for the
secretability of this variant. Construction of variants without the carboxyl-terminal 6×-His
tag will likely shed light on the importance of the activation domain not only for
activation of TAFI by thrombin-TM but also folding and secretion of TAFI.

116

Figure 3-4. Structure of the activation domain of TAFI. This image was rendered
using Polyview (http://polyview.cchmc.org/polyview3d.html), using the coordinates of
the crystal structure of human recombinant TAFI (PDB ID 3D66; chain B) [19]. The
activation domain (Residues 1-92 is coloured: Residues 1-12 are in red (with the side
chain of Arg12 shown in red), residues 13-73 are in green, and residues 74-92 are in cyan
(with the side chain of Arg92 shown in cyan).
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This is the outcome of joint research
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4.1 Summary

Background: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a human plasma
zymogen that provides a molecular link between coagulation and fibrinolysis. TAFI is
activated through cleavage at Arg92 by thrombin, thrombin in complex with the
endothelial cell cofactor thrombomodulin (TM), or plasmin. Studies have shown that the
presence of glycosaminoglycans (GAGs) is able to accelerate TAFI activation by plasmin
and stabilize TAFIa. The elements of TAFI structure that allow these effects are
unknown. Objectives: To identify heparin interaction regions on TAFI that mediates
acceleration of activation by plasmin and contributes to stabilization of TAFIa. Methods:
Based on crystallographic studies and homology to heparin-binding proteins, we
performed mutagenesis of surface-exposed charged residues on TAFI that putatively
constitute heparin-binding sites. The ability of the mutants to bind to heparin, kinetics of
activation by plasmin in the presence or absence of heparin, the thermal stability and
antifibrinolytic potential of each variant was determined. Results: Mutagenesis of Lys211
and Lys212 did not impair heparin binding or the effects of heparin on activation by
plasmin and TAFIa stability but had a general effect on the ability of TAFI to be activated
by plasmin. Mutagenesis of Lys306 did not impair heparin binding or any of the effects of
heparin on TAFI/TAFIa function. Mutation of His308 did not impair heparin binding but
this mutation generally had a severe negative effect on TAFI/TAFIa function. Mutation of
Arg320 and Lys324 in combination markedly decreased heparin binding but had no effect
on heparin-mediated acceleration of TAFI activation by plasmin while somewhat
decreasing TAFIa stabilization by heparin. Finally, mutagenesis of Lys327 and Arg330
decreased (but did not eliminate) heparin binding while decreasing the ability of heparin
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to accelerate plasmin-mediated TAFI activation, to stabilize TAFIa, and to increase the
antifibrinolytic ability of TAFI/TAFIa. Conclusion: We conclude that Lys327 and
Arg330 define a functionally-relevant heparin binding site, but that additional sites may
be present on the TAFI structure.
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4.2 Introduction

Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that
provides a molecular link between the coagulation and fibrinolytic cascades [1, 2] as well
as between coagulation and inflammation [3]. Activated TAFI (TAFIa) possesses basic
carboxypeptidase activity: the ability to remove carboxyl-terminal lysine and arginine
residues from protein and peptide substrates. Accordingly, TAFIa down-regulates
fibrinolysis by removing carboxyl-terminal lysine and arginine residues from partially
degraded fibrin thereby attenuating positive feedback in the fibrinolytic cascade [4, 5].
TAFIa can also regulate pericellular plasmin formation by removal of carboxyl-terminal
lysine residues from cellular plasminogen receptors [6], thereby regulating cell migration
[7] and possibly other inflammatory responses. Indeed, deficiency of TAFI in mouse
models influences a wide spectrum of inflammatory and fibrotic disorders [3, 8].
Two mechanisms exist to regulate the elaboration of active TAFI (TAFIa): control
of the rate of TAFI activation and control of the rate of TAFIa inactivation. TAFIa is
formed through cleavage at Arg92 by thrombin, thrombin in complex with the endothelial
cell cofactor thrombomodulin (TM), or plasmin [9-11]. Thrombin and plasmin alone are
relatively poor activators of TAFI but binding of thrombin to TM increases the catalytic
efficiency (kcat/KM) of TAFI activation by 1250-fold [10]. It has been shown that the
presence of glycosaminoglycans (GAGs), such as heparin, is able to accelerate TAFI
activation by plasmin [11] such that the catalytic efficiency of the reaction is only ~10fold lower than that exhibited by thrombin-TM. With respect to TAFIa inactivation, the
enzyme has the unusual property of being metastable [12]: its activity spontaneously
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decays with a half-life of 8 – 15 minutes at body temperature in the absence of any further
proteolytic cleavage [13]. Biophysical and structural studies have attributed the loss of
activity to profound structural changes in the enzyme [13-16]. Interestingly, GAGs are
able to stabilize TAFIa, causing a 2.3-fold increase in its half-life at 25°C from 74 to 170
min [11]. However, the elements of TAFI structure that mediate the effects of GAGs on
TAFI activation and TAFIa stability are unknown.
In a report on the crystal structure of bovine TAFI, Anand and coworkers
described 22 bound sulfate molecules in the model [16]. These bound sulfates may
represent potential GAG-binding sites and were clustered in three regions: near the socalled “dynamic flap” on the enzyme domain where it interfaces with the activation
domain, at the top of the activation domain, and within the active site cleft. Only the first
potential site seemed a reasonable possibility to account for the effects of GAGs:
following activation of TAFI, heparin bound to the activation domain would not affect the
stability of TAFIa, heparin bound in the active site cleft would prevent catalytic activity
by blocking substrate access [16]. A putative GAG-binding site was identified by Mao
and coworkers through sequence homology with heparin-binding sequences in GAGbinding

proteins.

A

region

in

TAFI

spanning

Trp210

through

Ser221

(WKKMRMWRKNRS, where the underlined residues are basic) is homologous to the
heparin-binding sequence motif (–XBBXBX–, where B and X represent basic amino acids
and hydrophobic acids, respectively) in GAG-binding proteins [11].
Although plasmin is a weak activator of TAFI, it is a relevant activator. Studies by
Gils and coworkers in vitro using monoclonal antibodies that inhibit plasmin-mediated
TAFI activation showed that plasmin is a relevant TAFI activator during clot formation
124

and lysis in the context of plasma clot lysis assays [17]. Furthermore, when the
monoclonal antibody MA-TCK26D6 – which inhibits TAFI activation specifically by
plasmin – was injected into a mouse thromboembolism model, decreased fibrin
deposition in the lungs was observed indicating an acceleration of fibrinolysis [18].
Plasmin-mediated TAFI activation would dominate at sites of vascular injury which
expose an abundance of GAGs present in the extracellular matrix near the fibrin rich clot
[11]. Additionally, as these injury sites would lack thrombomodulin, in the presence of
GAGs TAFI activation by plasmin may therefore play a significant role in stabilizing the
clot [11].
In this study, we constructed recombinant TAFI variants containing mutations in
the “dynamic flap” instability region as well as the region spanning Trp210-Ser221 which
are two sites predicted to interact with heparin. We assessed the ability of these variants
to bind heparin, measured their kinetics of activation by plasmin in the presence or
absence of heparin, and determined their thermal stabilities and antifibrinolytic potential.
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4.3 Experimental Procedures

4.3.1

Materials
The synthetic carboxypeptidase substrate anisylazoformyl-arginine (AAFR) was

obtained from Bachem Americas, Inc. (Torrance, CA, USA). Heparin sodium salt and
heparin-agarose type I saline suspension (from porcine intestinal mucosa), and potato
tuber carboxypeptidase inhibitor (PTCI) were obtained from Sigma-Aldrich Canada, Ltd.
(Oakville,

ON,

chloromethylketone

Canada).
(VFKck),

The
the

plasmin

inhibitor

D-valylphenylalanyllysyl

TAFIa

inhibitor

DL-2-mercaptomethyl-3-

guanidinoethylthiopropanoic acid (Plummer’s inhibitor) and the thrombin inhibitor Dphenylalanylprolylarginyl chloromethylketone (PPAck) were purchased from Calbiochem
(San Diego, CA, USA). QuikChange® Site-directed Mutagenesis kit was from Stratagene
(La Jolla, CA). DNA restriction and modification enzymes were purchased from New
England Biolabs (Mississauga, ON, Canada). Oligonucleotides for mutagenesis were
purchased from Integrated DNA Technologies, Inc. (Coralville, IA, USA). Dulbecco’s
modified

Eagle’s

medium/nutrient

mixture

F-12,

Opti-MEM,

Trypsin-EDTA,

penicillin/streptomyocin/fungizone (PSF) were obtained from Invitrogen. Newborn Calf
Serum was obtained from Sigma-Aldrich. Effectene transfection reagent was purchased
from QIAGEN, Inc. (Toronto, ON, Canada). Methotrexate was purchased from Mayne
Pharma, Inc. Thrombin, rabbit-lung thrombomodulin and plasmin were obtained from
Haematologic Technologies (Essex Junction, VT, USA), Inc. Recombinant batroxobin
was purchased from Cedarlane (Burlington, ON, Canada). Recombinant tPA (Alteplase)
was purchased from Kingston General Hospital Pharmacy. Polyclonal sheep anti-human
TAFI antibody was purchased from Affinity Biologicals (Ancaster, ON, Canada) and
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polyclonal rabbit anti-sheep antibody was purchased from ThermoFisher Scientific.
(Ottawa, ON, Canada). The mouse-anti-human TAFI monoclonal antibody MA-T4E3
was obtained from Dr. Ann Gils (Katholieke Universiteit Leuven, Leuven, Belgium) and
coupled to CNBr Activated Sepharose 4B (GE Healthcare Life Sciences, Mississauga,
ON, Canada) according to manufacturer’s instructions (2-6 mg antibody/mL resin). The
phospholipids L-α-phosphatidylcholine from frozen egg yolk (Type XIII-E) and 1,2diacyl-sn-glycero-3-phospho-L-serine from bovine brain were purchased from SigmaAldrich. Synthetic phosphatidylcholine/phosphatidylserine vesicles (PC/PS, 80:20) were
prepared by modification of the methods of Barenholz et al. and Bloom et al. [19, 20].

4.3.2

Construction of TAFI Variants
Mutagenesis was carried out using the QuikChange mutagenesis kit (Stratagene)

according to the manufacturer’s instructions. The mutagenic primers used are shown in
Table 4-1. In all cases, the template for the mutagenesis was TAFI-pNUT, which contains
human TAFI cDNA which contains threonine at positions 147 and 325 [13]. The presence
of the mutations was verified by DNA sequence analysis.
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Table 4-1. Primer sequences for mutagenesis of TAFIa

Variant

Primer Sequence

TAFI-K306A

5’-CCTATACACGAAGTAAAAGCGCAGACCATGAGGAACTGTCTC-3’

TAFI-H308F

5’-ACACGAAGTAAAAGCAAAGACTTTGAGGAACTGTCTCTAGTAGC-3’

TAFI-K212A

5’-GTTATGACTACTCATGGAAAGCGAATCGAATGTGGAGAAAG-3’

TAFIK211Q/K212Q

5’-GTGGACGGTTATGACTACTCATGGCAACAGAATCGAATGTGGAGAAAGAACCG-3’

TAFIR320A/K324A

5’-ACTGTCTCTAGTAGCCAGTGAAGCAGTTGCTGCTATTGAGGCAACTAGTAAAAATACC-3’

TAFI-K327A

5’-TTCGTGCTATTGAGAAAACTAGTGCAAATACCAGGTATACACATGGCC-3’

TAFIK327A/R330A

5’-TTCGTGCTATTGAGAAACTAGTGCAAATACCGCGTATACACATGGCCATGGCTCAG-3’

a

Sense strand sequences only are shown. Ala/Phe/Gln codons are double underlined;
mutated nucleotides are in boldface type
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4.3.3

Expression and purification of recombinant TAFI variants
Baby hamster kidney (BHK) cells were cultured in Dulbecco’s modified Eagle’s

medium/F-12 nutrient mixture (1:1) (DMEM/F-12) containing 5% (v/v) newborn calf
serum (NCS) and 1% (v/v) PSF in a humidified incubator at 37°C in a 95% air/5% CO2
atmosphere. Expression plasmids encoding the respective TAFI variants were transfected
into cells using Effectene transfection reagent (2 μg plasmid DNA and 60 μL of
transfection reagent per 100 mm plate of cells). After 24 hour incubation with the
transfection mixture, the cells were then cultured in DMEM/F-12 containing 5% NCS and
1% PSF supplemented with 400 μM methotrexate for approximately 2 weeks, with the
medium changed every other day, for the selection of stable cell lines expressing the
respective recombinant TAFI variants. For recombinant TAFI production, stably
expressing lines were cultured in triple flasks (500 cm2; Nunc) in Opti-MEM containing
1% (v/v) PSF and 40 μM ZnCl2. Conditioned medium was collected at 48 hour intervals
and replaced with fresh medium. Harvested conditioned medium was centrifuged at 3000
× g for 5 minutes, supplemented with Tris-HCl, pH 8.0 (to 5 mM), reduced glutathione
(to 0.5 mM) and phenylmethanesulphonyl fluoride (PMSF) (to 2 μM) and stored at 20°C.
To purify the recombinant TAFI variants, conditioned medium was passed
through a 0.22-μm filter prior to affinity chromatography over a 1-mL MA-T4E3Sepharose column at 4°C as previously described [21]. Protein containing fractions were
pooled and then were concentrated and exchanged into HBST (20 mM HEPES pH 7.4,
150 mM NaCl, 0.01% (v/v) Tween 80) using Amicon ultra-4 centrifugal filter units,
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MWCO 10 kDa. Purified TAFI was quantified by measurement of absorbance at 280 nm
and 320 nm (ε1%, 280 = 26.4; Mr= 60,000), aliquoted and stored at -70°C.

4.3.4

Binding of TAFI to heparin
A 1-mL heparin-agarose column was prepared by equilibrating the column with

10 column volumes of HBST. TAFI (0.25 µg) was applied to the column, after which a
wash was performed (0.2 column volumes of HBST × 12) followed by elution (0.2
column volumes of HBST containing 193 U/mL heparin). The TAFI content in each
fraction was analyzed by SDS-PAGE and western blotting using a polyclonal antibody
raised against human TAFI.

4.3.5

Kinetics of activation of TAFI variants by plasmin
Each TAFI variant at various concentrations (0.01 – 0.1 μM) was incubated with

plasmin (25 nM), and Plummer’s inhibitor (150 μM) in the presence or absence of
heparin (200 U/mL) at 21ºC for 12 minutes. Plasmin activity was then quenched by the
addition of VFKck (to 1 μM) before the mixture was placed on ice. SDS-PAGE sample
buffer (0.2 M Tris-HCl, 8% SDS, 40% Glycerol, 0.08% bromophenol blue) was added to
the samples. Samples were analyzed by SDS-PAGE and western blotting with the sheep
anti-human TAFI polyclonal antibody. A TAFIa standard was prepared along with each
kinetic experiment. The TAFIa standard was prepared by activating wild-type TAFI
(1μM) by incubating with thrombin (25 nM), thrombomodulin (100 nM) and CaCl 2 (5
mM) at 21 ºC for 10 minutes and then placed on ice. Known amounts of TAFIa (3 – 37.5
nM) were subjected to SDS-PAGE and western blotting along with the kinetic samples.
130

For the poorly activated TAFI variants H308F, K211Q/K212Q, and K327A/R330A, a
smaller TAFIa standard range was used (0.2 – 9.6 nM). For a given experiment, all blots
containing standards and samples were processed simultaneously for visualization of
immunoreactive bands. The density of the 35 kDa TAFIa and 25 kDa TAFIai bands were
quantified using AlphaView SA software. The standard was constructed by plotting the
density of each standard TAFIa sample versus concentration of TAFIa. The TAFIa
concentrations formed in each kinetic experiment were determined by interpolating from
the densities on the standard curve. The concentration of TAFIa was then converted to the
rate of TAFIa formation, v (mol of TAFIa formed /mol of plasmin /second). The data
were fit to the Michaelis-Menten equation (Sigmaplot 11.0, SPSS Inc., Chicago, IL).

4.3.6

Thermal stability of the TAFIa variants
Purified recombinant TAFI variants (1 μM) were activated by incubation with

thrombin (25 nM), TM (100 nM), CaCl2 (5 mM) in HBST at 21°C for 15 min. Thrombin
activity was then quenched by the addition of PPAck (to 1 μM) before the mixture was
placed on ice. The activated TAFI was dispensed into aliquots corresponding to various
time points in the presence or absence of heparin (312 U/mL final) and incubated at 37°C.
Following the final time point, 15 μL of each aliquot was mixed with 35 μL HBST and 50
μL of 240 μM synthetic carboxypeptidase substrate AAFR (120 μM, final) in a microtiter
plate which had been pre-treated (overnight) with HBS/1% Tween 80 and thoroughly
rinsed with deionized distilled water. The initial rates of AAFR hydrolysis were measured
at 350 nm in a SpectraMax Plus 384 plate reader (Molecular Devices, Sunnyvale, CA,
USA). The amount of residual TAFIa activity relative to the initial residual TAFIa
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activity was plotted as a function of time, and the data were fit by non-linear regression to
the first-order exponential decay equation (SigmaPlot 11.0, SPSS Inc., Chicago, IL). The
first-order decay constant k was obtained and used to determine the half-life of each TAFI
variant.

4.3.7

Barium Adsorbed TAFI-Deficient Plasma
Barium adsorbed plasma (BAP) was prepared as described previously [9] and was

subsequently made TAFI-deficient (TdBAP). To prepare TAFI-deficient plasma, 50 mL
of BAP was passed over a 1-mL MA-T4E3-Sepharose column at room temperature. The
plasma was passed over the column repeatedly, and between each pass the column was
washed with HBST. After each pass, TAFI was eluted from the column with 0.2 M
glycine, pH 3. An aliquot of the plasma was then used for an in vitro clot lysis assay (in
the absence of added TAFI) in the presence or absence of 10 nM TM [22]. The plasma
was considered to be TAFI-deficient when no difference was observed between clot lysis
times in the presence or absence of TM.

4.3.8

Clot Lysis Assays
All clot lysis assays were performed in a final volume of 100 µL in microtitre

plates at 37°C. The TdBAP was diluted 1:3 in HBST and supplemented with synthetic
phosphatidylcholine/phosphatidylserine vesicles (PC/PS) (20 μM) as well as different
concentrations of TAFI variants either as zymogen (0 – 100 nM) or as TAFIa (0 – 50 nM;
following activation by thrombin-TM as described above). The mixtures also contained
no heparin or one of two difference concentrations (25 or 100 U/mL) of heparin. Clotting
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was initiated by addition of the assay mixtures into the wells of microtitre plates
containing small, separated aliquots of batroxobin (0.5 ug/mL), CaCl2 (5 mM) and tPA (2
nM). Clot lysis was monitored by the change in turbidity of each reaction at 405 nm in a
SpectraMax Plus 384 plate reader (Molecular Devices, Sunnyvale, CA, USA) and the
time to 50% lysis was determined graphically from the midpoint between maximum and
minimum turbidities of the clots.

4.3.9

Statistical Methods
Statistical analyses were performed with the use of SPSS software, version 22.0

(SPSS Inc., Chicago, Illinois). Comparisons between different variants for a given assay
parameter were performed by one-way ANOVA using a Tukey post-hoc analysis.
Statistical significance was assumed at p < 0.05. Differences between individual variants
in the absence or presence of heparin were determined using an unpaired Student’s t-test.
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4.4 Results

4.4.1

Construction, expression, and purification of TAFI variants
To identify the GAG interaction site(s) on TAFI we have expressed TAFI variants

containing mutations of residues that are predicted to interact with heparin in the
instability region as well as in the region spanning Trp210-Ser221 (Figure 4-1). The latter
region was hypothesized to function as a heparin-binding sequence based on homology
with heparin-binding proteins [11]. Specifically, this region contains two repeats of the –
XBBXBX– consensus, where B = Lys or Arg and X = hydrophobic amino acids. In the
bovine crystal structure of TAFI, however, only one out of 22 sulfate molecules were
bound to the Trp210-Ser221 region: at Lys212 [16]. We therefore mutated Lys212 and
the neighbouring Lys211. None of the other basic residues in this region are surfaceexposed (Figure 4-2). The variant with both lysines mutated to Ala did not express, and
so the two lysines were together mutated to Gln.
In the instability region, there are three sulfates bound in the bovine crystal
structure [16]. One is bound at His308, Ser312 and Arg313; of these, only His308 is
conserved in human; we therefore mutated this residue as well as the spatially close
Lys306 residue. When His308 was mutated to Ala, the protein did not express so we
mutated this residue to Phe. Another sulfate is bound to His326 and Arg327, neither of
which is conserved in human. Therefore we mutated the Lys at position 324 and the
spatially close Arg320 residue (Figure 4-2). The final sulfate is bound at Arg330. We
mutated this residue along with the spatially close Lys327 residue (Figure 4-2).
Altogether, seven variants were constructed (Figure 4-2).
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Figure 4-1. Putative glycosaminoglycan binding sites on TAFI. The ribbon diagram of
bovine TAFI [16] on the left (superposition of three independent TAFI molecules) shows
both the activation domain and the catalytic domain and four N-linked glycans. The
bound sulfates on the structure represent potential heparin-binding sites and are clustered
in three regions: near the dynamic flap (gold) where it interfaces with the activation
domain (orange sulfates), at the prodomain (blue sulfates), and within the active site cleft
(pink sulfates). The last set of sulfates is unlikely to represent a relevant heparin-binding
site as it would block substrate access to the active site. The ribbon representation on the
right of human TAFI, prepared from the crystallographic data from [15] (PDB accession
#3D66), indicates the position Arg92 (side chain in red) and a putative GAG-binding site
identified by through sequence homology with heparin-binding proteins. The region
spanning Trp210 through Ser221 contains the heparin-binding sequence motif –
XBBXBX–, where B and X represent basic amino acids (side chains in cyan) and
hydrophobic acids (side chains in green), respectively.
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Figure 4-2. Mutations of Potential heparin binding sites on TAFI. The crystal
structure of TAFI is rendered based on PDB #3D66 [15] using Polyview
(http://polyview.cchmc.org/polyview3d.html). The activation domain is in red and the
side chain of Arg92 is magenta. Side chains of residues that were mutated are labeled and
shown in green. Surrounding side chains of note are also shown in cyan (Tyr208 –
Lys218; Lys304 – Glu310; Ala318 – Thr332). The active site Zn2+ is shown as a sphere.
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4.4.2

Binding of TAFI variants to heparin-agarose
We examined the ability of the variants to bind GAGs by utilizing a heparin-

agarose column. The protein was applied to the column and the column was then given a
buffer wash followed by elution using buffer containing heparin. The TAFI content in the
fractions was evaluated using western blot analysis. Wild-type TAFI was eluted almost
exclusively in the heparin-containing fractions (Figure 4-3), demonstrating specific
binding of TAFI to heparin immobilized on the column. In a control experiment using an
agarose column lacking covalently linked heparin, TAFI eluted completely in the buffer
wash (Figure 4-3), again consistent with specific binding between TAFI and heparin on
the column.
Variants H308F and K212A displayed similar elution profiles to wild-type
whereas variants K306A and K211Q/K212Q were not as tightly bound compared to wildtype, indicated by the fact that slightly more of the protein was eluted in the wash (Figure
4-3). The variants R320A/K324A, K327A, and K327A/R330A exhibited the lowest
affinity for the heparin-agarose; the majority of R320A/K324A and K327A eluted in the
wash fractions while for K327A/R330A, an approximately equal amount of protein was
present in the wash and elution fractions (Figure 4-3).
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Figure 4-3. Binding of TAFI variants to heparin-agarose. Purified recombinant TAFI
variants were applied to a heparin-agarose column. The column was washed with 2.4
column volumes of buffer (over 12 fractions) and eluted with 2.4 column volumes of
buffer containing heparin (over 12 fractions). Each fraction was subjected to western blot
analysis using a polyclonal anti-TAFI antibody. A control experiment to evaluate nonspecific binding of TAFI to the column was conducted using the same agarose resin that
was not derivatized with heparin (wt TAFI (control)). The data are representative of at
least 3 independent experiments.
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4.4.3

Kinetics of activation of TAFI variants by plasmin in the absence and presence of
heparin
The kinetics of activation of various concentrations of the TAFI variants by

plasmin in the absence and presence of heparin were determined (Figure 4-4). If a
reduced accelerative effect of heparin was observed, this would imply that the mutated
residues were important for the effect of heparin in this context. The estimated MichaelisMenten kinetic parameters in the absence and presence of heparin are summarized in
Tables 4-2 and 4-3, respectively. Our values for kcat and KM are in the same range as was
reported by Mao and coworkers using a similar western blot-based method (kcat = 0.00044
s-1; KM = 55 nM) [11]. We observe a 3.5-fold increase in kcat upon addition of heparin,
which compares favourably with the 5.9-fold increase observed by Mao and coworkers.
However, while they observed a decrease in KM upon addition of heparin, we observed an
increase, which reduced the increment in catalytic efficiency (kcat/KM) in our data set.
Nonetheless, it is clear that heparin has a notable effect on plasmin activation in our
hands, most particularly at the highest concentrations of TAFI tested, which correspond to
the physiological concentrations of the zymogen [23]. All the TAFI variants, to varying
degrees, displayed accelerated activation in the presence of heparin, with K306A and
R320A/K324A showing profiles most similar to wild-type (Figure 4-4). Several of the
variants, however, displayed greatly impaired activation by plasmin that was
superimposed on the effects of the mutations on acceleration by heparin. In particular,
H308F, K211Q/K212Q, and K327A/R330A showed much reduced rates of activation that
were little changed in the presence of heparin. K212A showed in intermediate effect, with
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moderately reduced rates of activation and a moderate decrease in the effect of heparin
(Figure 4-4).
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Figure 4-4. Effect of heparin on the kinetics of activation of the TAFI variants by
plasmin. TAFI activation by plasmin was measured at various concentrations of TAFI
and in the absence (filled circles) or presence (open circles) of heparin. The rate of TAFI
activation was determined by western blot analysis. The symbols are the means ±
standard error of the mean of at least 3 independent experiments. The lines are regression
lines based on the mean values of kcat and KM obtained from at least 3 independent
experiments.
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Table 4-2. Kinetic parameters for activation of TAFI variants by plasmin in the
absence of heparin
Variant

kcat
KM
kcat/KM
s-1
µM
µM-1s-1
TAFI wt
0.000684 ± 0.00012 0.0142 ± 0.005 0.0481 ± 0.0051
K306A
0.001157 ± 0.00010 0.0265 ± 0.002 0.0436 ± 0.0050
H308F
0.000623 ± 0.00016 0.1458 ± 0.019 0.0043 ± 0.0006
K212A
0.001323 ± 0.00010 0.0610 ± 0.018 0.0217 ± 0.00001
K211Q/K212Q 0.000179 ± 0.00003 0.0157 ± 0.002 0.0114 ± 0.0022
R320A/K324A 0.001793 ± 0.00058 0.0901 ± 0.017 0.0199 ± 0.0024
K327A
0.001502 ± 0.00016 0.1328 ± 0.038 0.0113 ± 0.0024
K327A/R330A 0.000142 ± 0.00002 0.0199 ± 0.004 0.0071 ± 0.0009
Data are the means ± standard error of the mean of 3-9 independent experiments

Table 4-3. Kinetic parameters for activation of TAFI variants by plasmin in the
presence of heparin
Variant

kcat
KM
kcat/KM
-1
s
µM
µM-1s-1
TAFI wt
0.002422 ± 0.00036 0.0391 ± 0.002
0.0619 ± 0.0095
K306A
0.002762 ± 0.00020 0.0391 ± 0.002
0.0706 ± 0.0046
H308F
0.000488 ± 0.00009 0.0484 ± 0.007
0.0101 ± 0.0022
K212A
0.001508 ± 0.00031 0.0360 ± 0.008
0.0418 ± 0.0131
K211Q/K212Q 0.000391 ± 0.00004 0.0164 ± 0.002
0.0239 ± 0.0025
R320A/K324A 0.003614 ± 0.00058 0.0392 ± 0.005
0.0922 ± 0.0018
K327A
0.001065 ± 0.00019 0.0521 ± 0.015
0.0204 ± 0.0076
K327A/R330A 0.000172 ± 0.00003 0.0121 ± 0.007
0.0142 ± 0.0052
Data are the means ± standard error of the mean of 3-9 independent experiments
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4.4.4

Thermal Stabilities of the TAFI variants in the absence and presence of heparin
Mao and coworkers [11] previously established that the half-life of TAFIa at 25˚C

was increased from 74 min to 170 min in the presence of heparin. The thermal stability of
each variant in the presence and absence of heparin was determined to examine whether
this stabilizing effect is also observed at 37˚C. Half-lives of each variant were calculated
from the resultant first-order decay rate constants (Table 4-4). The half-life of wild-type
TAFIa was increased 1.5-fold by heparin. Many of the variants have a different stability
to wild-type in the absence of heparin, and this is not unexpected given the results of
previous mutagenesis studies [13, 24]. However, H308F, R320A/K324A, K327A, and
(especially) K327A/R330A each showed decreases in the degree to which they were
stabilized by heparin (Figure 4-5; Table 4-4).

144

Table 4-4. Intrinsic Stability of TAFI variants in the absence and presence of
heparin
Variant

Half-life (min)
minus heparin
plus heparin

fold increase

TAFI wt
5.3 ± 0.5
7.9 ± 0.6
1.5
K306A
4.3 ± 0.3
8.1 ± 0.4
1.9
H308F
1.3 ± 0.1
1.7 ± 0.1
1.3
K212A
5.4 ± 0.6
9.1 ± 0.9
1.7
K211Q/K212Q
4.1 ± 0.2
6.8 ± 0.5
1.7
R320A/K324A
7.0 ± 0.9
8.9 ± 0.7
1.3
K327A
4.7 ± 0.6
5.8 ± 0.7
1.3
K327A/R330A
3.0 ± 0.04
3.1 ± 0.05
1.0
Data are the means ± standard error of the mean of 3-5 independent experiments
performed in triplicate
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Figure 4-5. Effect of heparin on the stabilities of the TAFIa variants. Each variant
was quantitatively activated by incubation with thrombin-TM. After quenching of the
thrombin, the TAFIa was incubated at 37°C in the presence (filled circles) or absence
(open circles) of heparin and timed aliquots removed and placed on ice. The residual
TAFIa activity was measured using a TAFIa substrate and is expressed relative to the
TAFIa activity present before incubation at 37°C. The symbols are the means ± standard
error of the mean of at least 3 independent experiments. The lines are regression lines
based on the mean first-order rate constants for TAFIa decay obtained from at least 3
independent experiments.

147

4.4.5

Antifibrinolytic potential of TAFI variants
We determined the antifibrinolytic potential of the variants in the absence and

presence of heparin using plasma clot lysis assays. We set up two different types of
assays in order to separately evaluate the effects of heparin on plasmin-mediated
activation and on stability of TAFIa.
In the first type of lysis assay, the system was manipulated such that the plasmin
that was generated during lysis is the sole TAFI activator, by using TAFI-deficient,
barium-adsorbed plasma and initiating clot formation using batroxobin. No thrombin
would be generated during clot formation or lysis under these conditions, and it was
previously shown by Mao and coworkers that addition of heparin to stimulate plasminmediated TAFI activation was required to observe a TAFI-dependent antifibrinolytic
effect [11]. We varied the concentration of recombinant TAFI variants added to the clots
and used two different concentrations of heparin (Figure 4-6). Wild-type TAFI exhibited
the greatest antifibrinolytic potential with increased heparin concentration, with variants
K212A and K306A also having a notable response to heparin. Heparin resulted in a small
increase in lysis time at the highest concentrations of K211A/K212A, R320A/K324A,
K327A, and K327A/R330A, while H308F showed very little antifibrinolytic effect that
was essentially resistant to heparin (Figure 4-6).
In the second type of clot lysis assay, we quantitatively activated the TAFI
variants using thrombin-TM prior to addition to the clot lysis assay. This allowed us to
specifically interrogate the role of heparin-mediated TAFIa stabilization during lysis,
since the maximal extent of fibrinolysis inhibition (i.e. the plateau) is a direct function of
the intrinsic stability of TAFIa [13, 25]. Wild-type TAFI displays an increase in stability
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in the presence of heparin and therefore an increase in the plateau lysis time, as expected
(Figure 4-7). Variants K306A, K211Q/K212Q, and R320A/K324A each exhibited
increases in the plateau lysis times due to heparin that were comparable to wild-type
TAFIa (Figure 4-7). K212A showed a moderately decreased increase in plateau lysis
time, while lysis time of H308F, K327A, and K327A/R330A were largely resistant to the
effects of heparin (Figure 4-7). Notably, K327A/R330A and H308F are both much less
stable than wild-type TAFIa and show correspondingly reduced antifibrinolytic potential
(i.e. plateau lysis time).
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Figure 4-6. Effect of heparin on the antifibrinolytic potential of the TAFI variants.
Clots were assembled from barium-adsorbed TAFI-deficient plasma and supplemented
with various concentrations of TAFI variants in the absence of heparin (filled circles) or
in the presence of 25 U/mL (open triangles) or 100 U/mL (open circles) heparin. Clotting
was initiated with batroxobin and lysis was initiated with tPA. Clot formation and lysis
was allowed to proceed at 37°C and lysis was monitored by measurement of absorbance
at 405 nm. The time to 50% clot lysis (defined as the midpoint between the maximum and
minimum absorbances) was determined and plotted relative to the clot lysis times
observed in the absence of TAFI. The data are the means ± standard error of the mean of
at least three independent experiments.
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Figure 4-7. Effect of heparin on the anfibrinolytic potential of the TAFIa variants.
TAFI was quantitatively activated by incubation with thrombin-TM, and the resultant
TAFIa (in different concentrations) was included in clots assembled from bariumadsorbed TAFI-deficient plasma and either lacking (filled circles) or containing (open
circles) 100 U/mL heparin. Clotting was initiated with batroxobin and lysis was initiated
with tPA. Clot formation and lysis was allowed to proceed at 37°C and lysis was
monitored by measurement of absorbance at 405 nm. The time to 50% clot lysis (defined
as the midpoint between the maximum and minimum absorbances) was determined. The
data are the means ± standard error of the mean of at least three independent experiments.
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4.5 Discussion

It has been reported that GAGs, such as heparin, accelerate activation of TAFI by
plasmin and stabilize TAFIa [11]. However, the number and location of the heparinbinding sites on TAFI that mediate these effects are unknown. The report on the bovine
crystal structure of TAFI identified several bound sulfate ions which may predict
potential heparin-binding sites on TAFI. The sulfate ions bound to the instability region
appeared as the most probable heparin-binding site as this would explain the increased
half-life of TAFIa in the presence of heparin [16]. In addition, a potential GAG-binding
site was identified by sequence homology with heparin-binding proteins [11], although
only one of them is present on the surface of the protein and hence accessible for heparinbinding. It is important to consider that binding of individual sulfates may not necessarily
represent bona fide heparin-protein interactions, since heparin itself is a polymer of
varying lengths consisting of sulfated glycosidic units. Therefore, it is possible that some
of the residues that are associated with a sulfate ion in the crystal structure do not
represent actual heparin-binding sites. Nevertheless, the predicted sites give us clues to
begin to identify the TAFI-heparin interaction.
We constructed a series of TAFI variants with mutations in surface-exposed basic
residues suggested to be heparin-binding residues. We then measured heparin binding of
the TAFI variants and the effect of heparin on their plasmin-mediated activation, enzyme
stability, and antifibrinolytic function. Our findings show that no mutation completely
eliminated heparin binding, and that Lys327 and Arg330 may represent a functional
heparin binding site.
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The binding of the variants to the heparin-agarose column indicated that mutations
in the instability region of TAFI result in a reduced affinity for heparin since at least half
of the protein eluted in the wash fractions. We do not believe that our findings represent
fractions of the protein that are or are not capable of binding heparin since if we pool the
TAFI in the non-binding fraction and reapply it to the column, a similar fraction does not
bind to the column (data not shown).
Although the K306A variant displays slightly reduced affinity for heparin, we do
not appear to observe this reflected in the functional properties of the protein, as heparin
normally accelerated its activation by plasmin and stabilizes its enzyme form. It does
appear to be less potent in inhibiting fibrinolysis than wild-type TAFI both in the
presence and absence of heparin, however. This may be a consequence of the slightly
reduced stability of the enzyme in the absence of heparin. The H308F variant binds
heparin normally but is activated very poorly by plasmin and is far less stable than wildtype TAFIa. It also has almost no antifibrinolytic effect under any of the conditions we
employed. In fact, it could be argued that its apparent resistance to the effects of heparin
actually reflect its essential lack of functionality. Therefore, it can be concluded that
Lys306 and His308 do not constitute a heparin-binding site.
Mutation of Lys211 and/or Lys212 does not significantly impact the heparin
affinity of TAFI. It also does not notably alter the stability of the TAFIa variants or the
effect of heparin on stability. Differences are observed in the extent of plasmin activation,
however. K212A has a much increased KM value compared to wild-type, whereas
K211Q/K212Q has a much reduced kcat value compared to wild-type, although the
catalytic efficiency of both variants is increased by heparin to a similar extent. These
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effects are reflected in the reduced potency of the respective variants in lysis assays where
the antifibrinolytic effect is sensitive to plasmin-mediated TAFI activation (Figure 4-6).
Overall, the data with these variants are more consistent with them influencing activation
by plasmin than affecting heparin binding.
To date there are few studies characterizing the plasmin-TAFI interaction. A
report by Mishra and coworkers identified a monoclonal antibody that specifically
inhibits plasmin-mediated TAFI activation: MA-TCK11A9 with the major epitope
binding residues Lys268, Ser272 and Arg276 [17]. The MA-TCK22G2 and MATCK27A4 were found to inhibit plasmin and thrombin mediated activation and plasmin,
thrombin, and thrombin-TM activation, respectively. The residues important for binding
MA-TCK22G2 are Thr147 and Ala148 and MA-TCK27A4 additionally binds Phe113
[17]. None of these residues are close to Lys211/212. However, Lys211/212 is on the
same side of the protein as Arg92, suggesting that they may be contacted either by the
protease domain of plasmin or its lysine-binding kringles.
The mutations in the instability region (dynamic flap) of TAFI had the greatest
effect on TAFI binding to heparin. The weakest binding was observed with
R320A/K324A. Interestingly, this variant exhibited normal activation by plasmin and
acceleration of that activation by heparin. However, this result was not reflected in clot
lysis assays with plasmin as the activator, where inhibition of fibrinolysis was very much
impaired compared to wild-type. The reason for this observation is not clear. Although
the R320A/K324A enzyme was stabilized to a lesser extent by heparin, clot lysis assays
using pre-activated TAFIa showed that heparin could raise the plateau lysis time of this
enzyme. Interestingly, while an R320Q variant is very unstable compared to wild-type
156

[13], the variant studied here is actually slightly more stable than wild-type, and has a
correspondingly higher plateau lysis time in the absence of heparin. Our observations
with the R320A/K324A variant raise the possibility of more than one heparin-binding site
on TAFI, with one of the sites being “cryptic” and only exposed upon TAFI activation. It
is possible that Arg320, Lys324, Lys327 and Arg330 are all involved in this site, as the
dynamic flap is located close enough to the activation domain for its molecular motion to
be constrained in the context of the zymogen.
Mutation of Lys327 and Arg330 provides the strongest evidence for the existence
of a functional heparin-binding site that influences both TAFI activation and TAFIa
inactivation. Both mutations abolish the increase in kcat for plasmin activation seen in
response to heparin, although the double mutation results in a profound impairment in
plasmin-mediated activation. These effects are reflected in the clot lysis assays with
plasmin as the activator; both mutants, particularly the double mutant, show a much
reduced response to the addition of heparin. The K327A results in a decreased
stabilization of the enzyme, while the K327A/R330A double mutant is both very unstable
compared to wild-type and is completely resistant to stabilization by heparin. Both these
enzymes show a similar plateau lysis time either in the presence or absence of heparin,
and the plateau lysis times of the double mutant are much lower owing to the fact that this
enzyme is relatively unstable.
Altogether, the results of this study shed new light on the nature of the TAFIheparin interaction. Connections can be made between impaired heparin-binding, reduced
effects of heparin on activation or stabilization, and changes in antifibrinolytic potential.
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The data suggest that TAFI possesses multiple heparin-binding sites which may
contribute to the different functions of heparin in regulating TAFI activity.
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Chapter 5
A novel fluorescent assay for the measurement of activated
Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) activity
Chapter 5 A novel fluorescent assay for the measurement of activated ThrombinActivatable Fibrinolysis Inhibitor (TAFIa) activity
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5.1 Summary

Background: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase
present in plasma that acts as a molecular connection between the coagulation and
fibrinolysis pathways. TAFI is activated to form TAFIa through proteolytic cleavage by
thrombin, thrombin in complex with the endothelial cell cofactor thrombomodulin (TM),
or plasmin. Various assays are available to measure the carboxypeptidase activity of
TAFIa however, the methods currently available suffer one or more disadvantages
including low sensitivity, labour intensivity and complexity. Additionally, none of the
available assays are able to monitor the activation of TAFI in real-time during clot
formation and dissolution. Objectives: To develop a novel fluorescence assay to monitor
the process of TAFI activation in real-time. Methods: We have developed a novel
fluorescence based assay for the measurement of the basic carboxypeptidase activity of
TAFIa. A synthetic peptide substrate was designed composed of four amino acids (GlyAla-Gly-Arg) modified with an amino-terminal tetramethylrhodamine (TAMRA)
fluorophore. An anionic quencher interacts electrostatically with the positively charged
carboxyl-terminal arginine side chain in the substrate allowing quenching of the TAMRA
fluorescence. The cleavage of the carboxyl-terminal arginine by TAFIa results in the
release of the substrate causing an increase in fluorescence. Results: The fluorescent
quencher dye Evans Blue was determined as the most optimal quencher for the TAMRAGAGR synthetic peptide substrate and the interaction between the substrate and quencher
is not affect by chloride concentration. The sensitivity of the TAMRA-GAGR substrate is
far superior to the sensitivity of commonly employed carboxypeptidase B substrates. Due
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to its sensitive nature, the activation of TAFI in vitro was able to be monitored in realtime and is detectable at TAFIa concentrations as low as 100 pM. Conclusions: We have
devised a novel fluorescence based assay to assess the function of activated TAFI. The
assay is a promising means of monitoring TAFIa activity during clot formation and lysis
in real-time.
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5.2 Introduction

Thrombin-activatable fibrinolysis inhibitor (TAFI) is plasma procarboxypeptidase
that functions as a molecular link between the coagulation and fibrinolysis pathways [1,
2]. The activation of TAFI through proteolytic cleavage by thrombin, thrombin in
complex with the endothelial cell cofactor thrombomodulin (TM), or plasmin generate the
activated form of the zymogen called activated TAFI (TAFIa) [3-5]. TAFIa possesses
basic carboxypeptidase activity and functions by catalyzing the removal of carboxylterminal arginine and lysine residues from proteins or peptide substrates [6, 7].
TAFI is an important regulator of the fibrinolytic pathway. TAFIa attenuates
fibrinolysis by interfering with the positive feedback in the fibrinolytic cascade.
Specifically, TAFIa removes the newly-exposed carboxyl-terminal basic amino acid
residues from partially degraded fibrin which are essential for maximally efficient
plasminogen activation [6, 7]. A characteristic that differentiates TAFIa from other
carboxypeptidases is its intrinsic thermal instability. TAFIa is unstable at body
temperature, possessing a half-life of approximately 8-15 minutes. TAFIa undergoes a
conformational change that is associated with the loss of its enzymatic activity [8-11].
Several methods have been reported for measuring the carboxypeptidase activity
generated upon activation of TAFI. Hydrolysis of synthetic substrates such as hippurylarginine or -lysine (Hipp-Arg/Hipp-Lys) and anisylazoformyl-arginine or -lysine
(AAFR/AAFK) is monitored spectrophotometrically at wavelengths 350 nm and 254 nm,
respectively. While this approach can be used to quantify TAFIa levels in a purified
system [10, 12-14], it is not possible to directly detect TAFIa activity in plasma. This is
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primarily due to turbidity induced interference with absorbance measurements resulting
from the formation of a fibrin clot and the high protein concentration present in the
plasma milieu. In addition, spectrophotometric detection of cleavage of these substrates
suffers limited sensitivity. Highly sensitive methods to detect Hipp-Arg cleavage that
involves either detection of the products by HPLC [15] or a coupled redox fluorescencebased assay [16] have also been described, but these assays are not capable of monitoring
TAFIa generation in situ. Likewise, a highly sensitive assay for TAFIa with a detection
limit between 1-2 pM has been described that utilizes electrochemiluminescence [17].
Another sensitive assay for measurement of TAFIa takes advantage of its ability to
remove basic residues from soluble fibrin degradation products and measures the release
of plasminogen therefore indirectly measuring the concentration of TAFIa in plasma.
However, the requirement for the preparation of numerous biomolecular components for
the assay is cumbersome and can lead to variability [18].
In the present study, we have developed a novel fluorescence assay for the
measurement of TAFIa activity with picomolar sensitivity. The synthetic substrate
designed for the assay, termed TAMRA-GAGR, is a peptide composed of four amino
acids (Gly-Ala-Gly-Arg) modified with an amino-terminal tetramethylrhodamine
(TAMRA) fluorophore. An anionic quencher interacts electrostatically with the positively
charged carboxyl-terminal arginine in the substrate, thereby quenching the fluorescence
of the bound TAMRA fluorophore. Cleavage of the carboxyl-terminal arginine by TAFIa
causes the release of the associated quencher resulting in a measurable increase in
fluorescence, indicative of TAFIa activity and thus allowing the concentration of TAFI in
the sample to be quantified.
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5.3 Experimental Procedures

5.3.1

Materials
The synthetic TAFIa substrate TAMRA-GAGR was synthesized by CanPeptide

Inc. (Pointe-Claire, Quebec, Canada) and was purified by HPLC. The quenching dye,
Evans Blue, was purchased from Tocris Bioscience (Bristol, UK), Rose Bengal and
Trypan Blue from Sigma-Aldrich Canada, Ltd. (Oakville, ON, Canada), Acid Green 27
from Tokyo Chemical Industry (Kita-Ku, Toyko, Japan), and Ponceau S from BioShop
Canada Inc. (Burlington, ON, Canada). The synthetic carboxypeptidase substrate
anisylazoformyl-arginine (AAFR) was obtained from Bachem Americas, Inc. (Torrance,
CA, USA). Hippuryl-L-arginine was obtained from Sigma-Aldrich. The thrombin
inhibitor D-phenylalanylprolylarginyl chloromethylketone (PPAck) was purchased from
Calbiochem (San Diego, CA, USA). Dulbecco’s modified Eagle’s medium/nutrient
mixture F-12, Opti-MEM, Trypsin-EDTA, penicillin/streptomyocin/fungizone (PSF)
were obtained from Invitrogen Canada Inc. (Burlington, ON, Canada). Newborn Calf
Serum was obtained from Sigma-Aldrich. Effectene transfection reagent was purchased
from QIAGEN, Inc. (Toronto, ON, Canada). Methotrexate was purchased from Mayne
Pharma, Inc. (Salisbury, SA, Australia). Carboxypeptidase B (CPB), isolated from
porcine pancreas, was purchased from Worthington Biochemical Company (Lakewood,
NJ, USA). Thrombin, rabbit-lung thrombomodulin and plasmin were obtained from
Haematologic Technologies (Essex Junction, VT, USA). The mouse-anti-human TAFI
monoclonal antibody MA-T4E3 was obtained from Dr. Ann Gils (Katholieke Universiteit
Leuven, Leuven, Belgium) and coupled to CNBr Activated Sepharose 4B (GE Healthcare
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Life Sciences, Mississauga, ON, Canada) according to manufacturer’s instructions (2-6
mg antibody/mL resin).

5.3.2

Recombinant Wild-type TAFI and TAFI-CIIYQ
The expression plasmid is wild-type TAFI-pNUT vector, which contains human

TAFI cDNA which contains threonine at positions 147 and 325 [10]. The stable TAFI
variant, TAFI-S305C-T325I-T329I-H333Y-H335Q (TAFI-CIIYQ), contains mutations in
the dynamic flap region that stabilize the region and increase the half-life of TAFIa
approximately 180-fold [19].

5.3.3

Expression and Purification of Recombinant Wild-type TAFI and TAFI-CIIYQ
Baby hamster kidney (BHK) cells were cultured in Dulbecco’s modified Eagle’s

medium/F-12 nutrient mixture (1:1) (DMEM/F-12) containing 5% (v/v) newborn calf
serum (NCS) and 1% (v/v) PSF in a humidified incubator at 37°C in a 95% air/5% CO2
atmosphere. An expression plasmid encoding wild-type TAFI and TAFI-CIIYQ was
transfected into cells using Effectene transfection reagent (2 μg plasmid DNA and 60 μL
of transfection reagent per 100 mm plate of cells). After 24 hour incubation with the
transfection mixture, the cells were then cultured in DMEM/F-12 containing 5% NCS and
1% PSF supplemented with 400 μM methotrexate for approximately 2 weeks, with the
medium changed every other day, for the selection of stable cell lines expressing
recombinant wild-type TAFI and TAFI-CIIYQ. For recombinant wild-type TAFI and
TAFI-CIIYQ production, a stably expressing line was cultured in triple flasks (500 cm 2,
Nunc, Roskilde, Denmark) in Opti-MEM containing 1% (v/v) PSF and 40 μM ZnCl2.
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Conditioned medium was collected at 48 hour intervals and replaced with fresh medium.
Harvested conditioned medium was centrifuged at 3000 × g for 5 minutes, supplemented
with Tris-HCl, pH 8.0 (to 5 mM), reduced glutathione (to 0.5 mM) and
phenylmethanesulphonyl fluoride (PMSF) to (2 μM) and stored at -20°C.
To purify wild-type TAFI and TAFI-CIIYQ expressed from the pNUT vector,
conditioned medium was passed through a 0.22-μm filter prior to affinity chromatography
over a 1-mL MA-T4E3-Sepharose column at 4°C as previously described [14]. Protein
containing fractions were pooled and then were concentrated and exchanged into HBST
(20 mM HEPES pH 7.4, 150 mM NaCl, 0.01% (v/v) Tween 80) using Amicon ultra-4
centrifugal filter units, MWCO 10 kDa. Purified TAFI was quantified by measurement of
absorbance at 280 nm and 320 nm (ε1%, 280 = 26.4; Mr= 60,000), aliquoted and stored at 70°C.

5.3.4

Spectrophotometric Measurements
The absorbance spectrum, fluorescence excitation spectrum and emission

spectrum of the TAMRA-GAGR peptide substrate was obtained with a Spectramax M5e
plate reader (Molecular Devices, Sunnyvale, CA, USA). The TAMRA-GAGR peptide
substrate was dissolved in water to a final concentration of 1000 µM, aliquoted and stored
at -20°C. A 200 µL sample of 1000 µM TAMRA-GAGR sample was analyzed in a clear
UV sensitive microtitre plate (Corning) or black microtitre plate (Dynatech) for
absorbance or fluorescence measurements, respectively. All measurements were
determined at 21°C.
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5.3.5

Screening quencher dyes of TAMRA-Gly-Ala-Gly-Arg substrate
The quencher dyes Evans Blue, Ponceau S, Acid Green 27, Rose Bengal, and

Trypan Blue were dissolved in water to a final concentration of 10 mM and stored in an
opaque container at 21°C. The fluorescence intensity of TAMRA-GAGR was measured
as a function of quencher dye concentration to determine the optimal dye concentration
required to obtain maximal quenching of TAMRA-GAGR. The quencher dye was titrated
(0-80 µM) with a fixed concentration of TAMRA-GAGR (5 µM) in an HBST (20 mM
HEPES pH 7.4, 150 mM NaCl, 0.01% (v/v) Tween 80) buffer solution. The fluorescence
intensity was measured at 550 nm excitation and 590 nm emission wavelengths, with a
cut-off filter at 580 nm at 21°C. A black microtitre plate was used and a final well volume
of 100 µL was maintained for each assay.
The dissociation constant between each quencher dye and TAMRA-GAGR
substrate was determined based on its relative fluorescence. The relative fluorescence was
calculated using the equation shown below.

Eq. 1

Where Imax is the fluorescence of a solution containing 0 µM quencher, I is the
fluorescence of each solution of varying quencher concentration, and Imin is the
fluorescence of a solution containing 80 µM quencher. A plot of relative fluorescence
versus quencher concentration was generated for each quencher using these calculated
values. The complete data set was fit to the ligand binding equation for one-site saturation
by non-linear regression analysis (Sigmaplot 10, SPSS Inc., Chicago, IL) to determine the
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dissociation constant. The plots appeared sigmoidal, and so the data were fit to the Hill
equation to find the Hill constant (n) and the dissociation constant Kd. The Hill equation is
shown below.

(

)

[ ]

Eq. 2

Where R is the relative fluorescence quenching, n is the Hill constant, Q is the
concentration of the quencher, and Kd is the dissociation constant.

5.3.6

Determination of the Effect of Chloride concentration on TAMRA-Gly-Ala-GlyArg substrate and quencher interaction
The NaCl concentration was varied (0-150 mM) with TAMRA-GAGR (5 µM

final concentration) and Evans Blue (40 µM final concentration) in a HEPES buffer
solution (20 mM HEPES pH 7.4, 0.01% (v/v) Tween 80). The fluorescence intensity was
monitored as described above.

5.3.7

Determination of the Effect of Evans Blue quencher concentration on detection of
enzymatic activity
The Evans Blue quencher dye was varied (0-80 µM final concentration) with a

fixed concentration of TAMRA-GAGR (5 µM final concentration) in HBST buffer
solution in a volume of 95 µL. The fluorescence intensity was monitored for a short time
period then 5 µL of TAFIa or CPB was added to 1 nM final concentration in a final well
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volume of 100 µL. The fluorescence intensity continued to be monitored as described
above.

5.3.8

Thermal Stability and Activity of Wild-type TAFIa
Purified recombinant wild-type TAFI (1 μM) was activated by incubation with

thrombin (25 nM), TM (100 nM), CaCl2 (5 mM) in HBST at 21°C for 15 min. Thrombin
activity was then quenched by the addition of PPAck (to 1 μM) before the mixture was
placed on ice. The activated TAFI was divided into aliquots corresponding to various
time points in the presence of TAMRA-GAGR (5 μM) or Evans Blue (40 μM) alone or in
combination and incubated at 37°C. At each time point, the corresponding aliquots were
removed and placed on ice. Residual TAFIa activity was determined by measurement of
the rate of hydrolysis of AAFR by monitoring the absorbance at 350 nm. Non-linear
regression of the data to an equation describing first-order exponential decay was used to
determine decay rate constants and thus half-live of wild-type TAFIa, as previously
described [14].

5.3.9

Generating a Standard Curve for Measuring TAFIa Concentration
Wild-type TAFI (1μM) was completely activated by incubating with thrombin (25

nM), TM (100 nM) and CaCl2 (5 mM) at 21 °C for 10 minutes. The reaction was stopped
by the addition of the thrombin inhibitor PPAck (1 μM final concentration) and placed on
ice. Activated TAFI was diluted to obtain known amounts of TAFIa (0 – 250 nM) and
10 µL was added into a 90 µL solution containing TAMRA-GAGR (5 µM final
concentration) and Evans Blue (40 µM final concentration) in HBST and fluorescence
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was monitored as described above. A standard curve was constructed by plotting the
initial rates of hydrolysis of TAMRA-GAGR versus the concentration of activated TAFI.
A standard curve was constructed for TAFIa-CIIYQ in the same manner. A standard
curve was constructed for CPB as follows: a 10 µL solution of known amounts of CPB (0
– 15.6 nM) was added into a 90 µL mixture of TAMRA-GAGR (5 µM) and Evans Blue
(40 µM) in HBST and fluorescence was monitored as described above.

5.3.10 Measuring TAFI activation in real-time
The activation of TAFI in real-time was examined utilizing the TAMRA-GAGR
substrate and Evans Blue quencher. An 87.5 µL solution consisting of TAMRA-GAGR
(5 µM final), Evans Blue (40 µM final), CaCl2 (5 mM final) and varying TAFI
concentrations (0-200 nM final) in HBST was added to the wells of a black microtitre
plate. Then a 12.5 µL mixture of thrombin (25 nM final) and thrombomodulin (100 nM
final) was added to the wells and the fluorescence was immediately monitored. From the
linear portion of the initial rate of substrate hydrolysis the RFU/min2 was calculated and
plotted versus the concentration of TAFI zymogen.

5.3.11 Activity of TAFIa toward synthetic substrates
Various concentrations of TAFIa (0 – 22 nM), generated as described above, were
added into a solution containing the synthetic carboxypeptidase substrate hippuryl-Larginine (HR) (1.2 mM final) or AAFR (120 μM final) to achieve a final volume of
100 μL. All reactions were performed in the wells of a microtiter plate which had been
pre-treated (overnight) with HBS/1% Tween 80 and thoroughly rinsed with deionized
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distilled water. Absorbance was monitored at 254 nm (HR) or 350 nm (AAFR) using a
SpectraMax Plus 384 plate reader (Molecular Devices, Sunnyvale, CA, USA). The initial
rates of hydrolysis of HR or AAFR were determined from the slope of the absorbance
versus time relationship. At the same concentrations of TAFIa, the activity towards
TAMRA-GAGR was monitored under the same conditions described above. The initial
rate of TAMRA-GAGR hydrolysis was determined from the slope of the RFU versus
time relationship.
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5.4 Results

5.4.1

TAMRA-Gly-Ala-Gly-Arg substrate Assay Concept
A schematic representation of the assay is presented in Figure 5-1. The future

application of this assay is to be able to detect TAFIa activity in real-time as it becomes
activated during lysis assays since currently there is no simple method for measuring
TAFIa activity in this manner.
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A

B

C

D
Figure 5-1. Schematic representation of the fluorescent carboxypeptidase assay. A)
The synthetic peptide substrate is composed of four amino acids conjugated to the
fluorophore TAMRA (TAMRA-Gly-Ala-Gly-Arg). B) An anionic quencher in solution
will interact with the positively charged carboxyl-terminal arginine in the substrate. C)
Addition of TAFIa, a basic carboxypeptidase, will result in cleavage of the carboxylterminal arginine. D) Dissociation of arginine and the associated quencher from the
substrate will result in a measurable increase in TAMRA’s fluorescence.
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5.4.2

Spectral Properties of TAMRA-Gly-Ala-Gly-Arg substrate
To determine the maximum excitation and emission wavelength prior to

performing fluorescence assays, the excitation spectrum and emission spectrum of the
TAMRA-GAGR substrate was obtained. The excitation spectrum of the intact TAMRAGAGR substrate is bell-shaped with a maximum at 550 nm. The emission spectrum of the
substrate possesses a similar shape with a maximum at 590 nm. The absorbance spectrum
possesses a broad peak between 450 and 650 nm. The fluorescence and absorbance
spectra of the intact TAMRA-Gly-Ala-Gly-Arg substrate is presented in Figure 5-2.
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Figure 5-2. Spectral properties of TAMRA-Gly-Ala-Gly-Arg substrate. The
absorbance spectrum (blue), excitation (black) and emission (red) spectrum of the
TAMRA-GAGR peptide substrate. The substrate (1000 µM) was dissolved in water.
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5.4.3

Fluorescence quenching of TAMRA-Gly-Ala-Gly-Arg substrate by binding of
quencher
The extent of fluorescence quenching of the TAMRA-GAGR substrate by

different quencher dye molecules was examined in order to identify the best quencher of
the TAMRA fluorescent moiety and to determine the optimal ratio of quencher to 5 µM
TAMRA-GAGR substrate to use for the fluorescence assays. The following quencher
dyes were screened against TAMRA-GAGR to identify the optimal quencher: Evans
Blue, Ponceau S, Acid Green 27, Rose Bengal, and Trypan Blue (Figure 5-3). Quenching
of the fluorescence of TAMRA-GAGR by Evans Blue is readily observable under
ultraviolet light (Figure 5-4).The fluorescence quenching of the substrate by the quencher
dyes was evaluated by titrating the TAMRA-GAGR substrate with different
concentrations of quencher and monitoring the fluorescence. The fluorescence quenching
of TAMRA-GAGR by the quencher dye molecules from most to least pronounced is as
follows: Evans Blue, Ponceau S, Trypan Blue, Rose Bengal and Acid Green 27 (Figure 55). As the binding curves appeared to be sigmoidal in shape, the quenching data were fit
to the Hill equation (Figure 5-6), which showed positive cooperativity was occurring (Hill
constants > 1; Table 5-1). The extent of positive cooperativity was consistent at all
concentrations of quencher in all cases except for Evans Blue, where the Hill constant
was observed to increase at the higher concentrations of quencher (Figure 5-6). The
concentration of Evans Blue to use in the fluorescence assays was chosen to be the
concentration at the beginning of the plateau where the substrate becomes significantly
quenched (40 µM), but before the large increase in positive cooperativity.
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Figure 5-3. Structure of components of the fluorescent assay. This assay involves A) a
synthetic peptide, Gly-Ala-Gly-Arg with an amino-terminal fluorophore, TAMRA.
Various quencher dyes were analyzed for their ability to quench TAMRA’s fluorescence
including: B) Ponceau S, C) Evans Blue, D) Acid Green 27, E) Trypan Blue, F) Rose
Bengal.
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A

B

Figure 5-4. Visualization of Evans Blue titration with TAMRA-Gly-Ala-Gly-Arg
substrate. Titertubes containing varying concentrations of Evans Blue (titrated from 0-80
uM, left to right) into 5 µM TAMRA-GAGR and HBST buffer were imaged in A) visible
light and B) ultraviolet light.
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Figure 5-5. Quencher titration of TAMRA-Gly-Ala-Gly-Arg substrate. The
concentration of the TAMRA-GAGR peptide substrate was fixed at 5 µM in HBST buffer
and varying concentrations of quencher were titrated from 0-80 uM and the fluorescence
was monitored. The quenchers are indicated: Evans Blue (black), Ponceau S (red), Acid
Green 27 (green), Rose Bengal (magenta), and Trypan Blue (blue).
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Figure 5-6. Hill plot of TAMRA-Gly-Ala-Gly-Arg substrate with quenchers. The
quencher titration data was fit using the Hill equation log(R/(1-R)) = nlog([Q]) - nlog(Kd),
where R is the relative fluorescence quenching, n is the Hill constant, Kd is the
dissociation constant, and [Q] is the quencher concentration. The slope of the curve
represents the Hill constant and the intercept with the x-axis provides nlog(Kd). The
quenchers are indicated: Evans Blue (black), Ponceau S (red), Acid Green 27 (green),
Rose Bengal (magenta), and Trypan Blue (blue).
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Table 5-1. Dissociation constant and Hill constant between quencher and substratea

Quencher

Kd

Hill constant

µM

n

Evans Blue

2.2 ± 0.1

3.18

Ponceau S

4.2 ± 0.1

1.94

Acid Green 27

9.8

1.80

Rose Bengal

6.1

1.98

Trypan Blue

5.4

1.83

a

Data are the means ± standard errors of the mean of 1-3 independent experiments
performed in triplicate
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5.4.4

Influence of Chloride on TAMRA-Gly-Ala-Gly-Arg substrate and quencher
interaction
The influence of sodium chloride concentration on the interaction between the

TAMRA-GAGR substrate and Evans Blue quencher was evaluated by varying the
sodium chloride concentration and evaluating the fluorescence intensity. Although there
was a slight increase in the fluorescence intensity as a function of chloride concentrations,
the fluorescence intensity remained quenched relative to the absence of quencher at 150
mM NaCl (Figure 5-7).
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Figure 5-7. Effect of NaCl on TAMRA-Gly-Ala-Gly-Arg substrate and quencher
interaction. The NaCl concentration was varied and the initial fluorescence intensity was
evaluated to assess the interaction between the TAMRA-GAGR substrate and Evans Blue
quencher. The first bar on the left represents the initial intensity of the TAMRA-GAGR
substrate in the absence of quencher (Q) but in buffer containing 150 mM NaCl. The
subsequent bars indicate the initial intensity of TAMRA-GAGR and Evans Blue in buffer
containing varying NaCl concentrations. The data are the means ± standard errors of the
mean of three independent experiments.
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5.4.5

Influence of Evans Blue on detection of enzymatic activity
The effect of the concentration of the Evans Blue quencher on the detection of

wild-type TAFIa or CPB enzyme activity towards the TAMRA-GAGR substrate was
examined by varying the concentration of the quencher in an HBST buffer solution with a
constant TAMRA-GAGR concentration while monitoring the fluorescence intensity over
time. Upon addition of the enzyme, the rate of TAMRA-GAGR hydrolysis increased with
increased Evans Blue concentration and reached a maximum at 40 µM and 25 µM Evans
Blue for wild-type TAFIa (Figure 5-8A) and CPB (Figure 5-8B), respectively, and then
the rate of hydrolysis gradually decreased.
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Figure 5-8. Effect of Evans Blue on detection of enzymatic activity. The Evans Blue
quencher concentration was varied (0-80 µM) at a fixed concentration of TAMRAGAGR (5 µM) in HBST buffer and fluorescence intensity was monitored. Following
addition of 1 nM enzyme, A) wild-type TAFIa and B) CPB to buffer containing varying
Evans Blue concentrations the fluorescence intensity continued to be monitored.
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5.4.6

Standard Curves
Standard curves were created for wild-type TAFIa, TAFIa-CIIYQ and CPB to

determine whether a relationship exists between the concentration of the enzyme and the
rate of hydrolysis of the TAMRA-GAGR substrate to enable quantitative analysis. The
enzymes were serially diluted to various known concentrations then added to the
TAMRA-GAGR and Evans Blue substrate mixture and fluorescence intensity was
monitored over time. An example of the fluorescence profiles of wild-type TAFIa,
TAFIa-CIIYQ and CPB that demonstrate increase in fluorescence due to the cleavage of
TAMRA-GAGR by the respective enzymes is shown in Figure 5-9. Standard curves were
constructed by plotting the initial rates of hydrolysis of TAMRA-GAGR versus the
concentration of enzyme (Figure 5-10). The limit of detection for wild-type TAFIa and
TAFIa-CIIYQ is 0.0977 nM and for CPB is 0.0061 nM (Figure 5-10). Additionally, to
determine whether the TAFI zymogen would have activity toward the TAMRA-GAGR
substrate a standard curve was generated using the same concentrations of zymogen. No
activity was observed when the TAFI zymogen was used (data not shown).
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Figure 5-9. Standard fluorescence progress curves. Known concentrations of enzyme
were added to a TAMRA-GAGR and Evans Blue substrate mixture and the hydrolysis of
the substrate was monitored over time. Representative standard progress curves are
shown for A) wild-type TAFIa, B) TAFIa-CIIYQ, and C) CPB.
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Figure 5-10. Standard curve plots. Standard curves were constructed by plotting the
initial rate of hydrolysis of TAMRA-GAGR versus the concentration of enzyme.
Standard curve plots are shown for A) wild-type TAFIa and TAFIa-CIIYQ. The inset is
the magnification of the plot at the 0 - 2 nM concentration. B) A standard curve plot for
CPB with the inset magnifying the plot at the 0 – 0.2 nM concentration. The data are the
means ± standard errors of the mean of three independent experiments.
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5.4.7

Thermal Stability and Enzymatic Activity of Wild-type TAFI in the absence or
presence of assay components
The thermal stability and enzymatic activity of wild-type TAFI in the presence

and absence of TAMRA-GAGR or Evans Blue alone or in combination was determined
to examine whether any of the assay components affect the stability or activity of TAFIa,
respectively. The half-life was calculated from the resultant first-order decay rate
constants (Table 5-2). None of the assay components either alone or in combination had
an observable effect on the stability or activity of TAFIa.
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Table 5-2. Intrinsic Stability and activity of Wild-type TAFIa in the absence and
presence of assay componentsa

Half-life (min)

Activity (mOD/min)b

TAFIa wt

7.0 ± 0.2

1.97 ± 0.0483

TAFIa wt plus TAMRA-GAGR

7.0 ± 0.2

1.79 ± 0.0536

TAFI wt plus Evans Blue

7.0 ± 0.3

2.02 ± 0.0214

7.1 ± 0.2

1.50 ± 0.0926

Variant

TAFI wt plus TAMRA-GAGR & Evans
Blue
a

Data are the means ± standard errors of the mean of 2-3 independent experiments
performed in triplicate
b
Data are the initial rates of substrate hydrolysis following activation of wild-type TAFI
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5.4.8

Monitoring Activation of TAFI in real-time
The activation of wild-type TAFI by the thrombin-TM complex was detected

upon incubation with the TAMRA-GAGR and Evans Blue substrate mixture. The
conversion of TAFI to the activated TAFIa enzyme results in hydrolysis of the TAMRAGAGR substrate and an increase in fluorescence intensity (Figure 5-11A). An apparent
linear relationship exists between the RFU/min2 versus the concentration of TAFI
zymogen (Figure 5-11B).
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Figure 5-11. Activation of TAFI progress curve. A) Wild-type TAFI of varying
concentrations was incubated with an activation mixture (25 nM thrombin, 100 nM TM
and 5 mM CaCl2) and the TAMRA-GAGR and Evans Blue substrate mixture at 21°C.
The rate of TAFIa formation was assessed by monitoring the hydrolysis of the substrate
over time. B) A plot of RFU/min2 versus zymogen TAFI concentration was constructed.
The data are the means ± standard errors of the mean of three independent experiments.
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5.4.9

TAFIa activity toward synthetic substrates
The enzymatic activity of wild-type TAFIa toward the available carboxypeptidase

B substrates AAFR and HR was compared to the fluorescent TAMRA-GAGR substrate.
The same concentrations of TAFI (1-22 nM) were incubated with each of the substrates
and the absorbance or fluorescence was monitored over time (Figure 5-12). A plot was
constructed of the rate of substrate hydrolysis versus the concentration of TAFIa and the
slope represented the efficiency of detection of substrate hydrolysis by TAFIa per
nanomolar of TAFIa (Figure 5-12D). The TAMRA-GAGR substrate is almost 1000 times
more sensitive than AAFR and almost 14,000 times more sensitive than HR (Table 5-3).
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Figure 5-12. Enzymatic activity of wild-type TAFIa toward synthetic
carboxypeptidase B substrates. Wild-type TAFIa (1-22 nM) was incubated with the
substrates A) TAMRA-GAGR, B) AAFR, and C) HR at 21°C and their hydrolysis was
monitored over time. D) A plot of initial rate of substrate hydrolysis versus TAFIa
concentration was constructed to assess the efficiency of detection. The data are the
means ± standard errors of the mean of three independent experiments.
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Table 5-3. TAFIa Activity toward substrates

Substrate

Equation of a Line

TAMRA-

y = 0.02174 + 0.05284

Efficiency of Detection

GAGR

2

R = 0.98
y = 0.00002213 – 0.00005463

AAFR

983
2

R = 0.97
y = 0.00000156 + 0.00007766
HR

13,924
2

R = 0.97
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5.5 Discussion

In the present study, we have designed a novel fluorescence based assay for
measuring the basic carboxypeptidase activity of TAFIa. This is the first fluorogenic
substrate of any kind to be reported for the detection of TAFIa activity. The assay consists
of a synthetic peptide substrate composed of four amino acids (Gly-Ala-Gly-Arg)
modified with an amino-terminal TAMRA fluorophore. The basis of this assay method is
the ability of the TAMRA moiety to be quenched through electrostatic interaction
between an anionic quencher and the positively charged carboxyl-terminal arginine in the
substrate. The ability of activated TAFI to catalyze the cleavage of the carboxyl-terminal
arginine in the substrate causes the release of the quencher from the proximity of the
fluorophore and results in an increase in fluorescence which can be monitored using a
fluorescence plate reader. The assay was inspired by an assay system for arginine
deaminases developed by Wang and coworkers [20], where conversion of arginine to
citrulline results in elimination of the positive charge of the gaunidinium functional group
of arginine and loss of interaction with the anionic quencher.
The ability of several anionic quencher dyes to quench the fluorescence of the
TAMRA-GAGR substrate was assessed. The study by Wang and coworkers [20]
demonstrated the fluorescence quenching of TAMRA-containing substrates using
numerous quencher dyes. The dyes that were reported to have the greatest quenching
ability were Acid Green 27, Evans Blue, Ponceau S, Rose Bengal and Trypan Blue.
Therefore, these were candidate anionic quenchers used to test against the substrate.
Evans Blue (followed closely by Ponceau S) was determined as the most optimal
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quenchers for the TAMRA-GAGR synthetic peptide substrate. Evans Blue had a slightly
lower Kd compared to Ponceau S and therefore was chosen as the optimal quencher with a
ratio of 1:8 for the fluorescent assays. Moreover, preliminary investigations with TAFIa
showed that Evans Blue resulted in the greatest increase in fluorescence following
substrate hydrolysis (data now shown).
Interestingly, all of the quenchers showed positive cooperativity in their
interaction with the TAMRA-GAGR substrate. The basis for this behaviour is not
immediately evident from the chemical structures of the substrate and quenchers. It is
possible that there is some degree of self-association between molecules of TAMRAGAGR that is disrupted by the quencher, thus facilitating binding of additional TAMRAGAGR molecules by quencher. In any event, we see no evidence that this cooperative
binding has a serious impact on the assay. For example, standard curves constructed with
varying concentrations of TAFIa or CPB are consistently linear (Figure 5-9).
On the other hand, the assay was shown to be quite sensitive to the
substrate:quencher ratio. Ratios higher or lower than the optimal (approximately 1:8
substrate:quencher) result in underestimation of the TAFIa or CPB activity present
(Figure 5-8). Therefore, it is reasonable to conclude that the assay performs the best when
a relatively small proportion of the substrate is hydrolyzed by TAFIa/CPB. As such, the
rates of hydrolysis should be measured early in the time course and dilution of the
enzyme may be required to ensure it falls within the linear range.
Indeed, some unusual behavior of the assay was observed in the case, most
notably, of wild-type TAFIa. We often observed that the plots of fluorescence versus time
deviated from linearity at extended times, apparently reaching a premature plateau in
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some cases. This is evident, for example, by comparing panels A and C of Figure 5-9.
Since this behavior seemed somewhat restricted to wild-type TAFIa, we suspected that
some component of the assay was destabilizing the enzyme, especially since the plateau
effect was occurring far earlier than might be explained by the half-life of wild-type
TAFIa (approximately 2 hours at room temperature). However, direct assessment of this
possibility using a different TAFIa substrate appeared to rule out an effect on stability
(Table 5-2). Thus, the reason for the plateau effect with TAFIa remains to be determined,
although the measures described in the previous paragraph should be sufficient to
mitigate these effects.
Since the quencher and substrate interact electrostatically to form a fluorescently
quenched complex it was assessed whether this interaction is disrupted by the chloride
concentration in the buffer. At all chloride concentrations tested, however, the interaction
was minimally perturbed (Figure 5-7). This indicates the chloride concentration in the
buffer used for the assays is not sufficient to dissociate the quencher from the substrate
and therefore, the quencher is able to quench the substrate despite the presence of only a
single arginine residue. Therefore, any increase in fluorescence is attributable to TAFIa
cleavage of substrate, not random dissociation of the quencher from the substrate.
One of the major advantages of the TAMRA-GAGR substrate is its high
sensitivity compared to other commonly used TAFIa substrates such as AAFR and HR.
This fluorescence assay is sensitive for detecting concentrations of TAFIa as low as 100
pM. The future application of this assay is to be able to detect TAFIa activity in real-time
as it becomes activated during clot formation and dissolution assays, in a manner
analogous to how the endogenous thrombin potential is determined during plasma
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clotting in the presence of a fluorogenic thrombin substrate [21, 22]. Currently, there is no
method for measuring TAFIa activity in this manner. We are able to monitor the
activation of TAFI in buffer in real-time however further optimization is required to begin
to examine the activation of TAFI in the context of plasma/clot. Indeed, preliminary
experiments in the presence of plasma (data not shown) showed that sensitivity of the
assay is much decreased, perhaps because of competition for binding to the anionic
quencher by other elements in plasma.
This study provides a platform to begin to optimization of this fluorescence based
assay. Before we begin to fully quantitate the concentration of TAFIa with high accuracy
and reliability the limitations of the substrate and quencher need to be addressed. First,
the substrate only contains a single arginine residue that is susceptible to quenching.
Designing a substrate with more than one positively charged residue that can be removed
by TAFIa will allow improved ability to quench the substrate and will generate an
enhancement in the fluorescence generated upon exposure to an enzyme thereby
increasing the signal to noise ratio. Moreover, as with many fluorescence based assays the
fluorescent substrate suffers from inner-filter effects as determined from the absorbance
spectrum showing the absorbance at the excitation and emission wavelength exceeding
0.1. This causes the measured fluorescence intensity and the substrate concentration to
deviate from linearity resulting in an underestimation of the fluorescence signal.
Therefore, a correction factor for the inner-filter effect needs to be taken into account
when using different substrate concentrations [23]. As well, the intra- and interassay
variability must be determined to assess the reproducibility of the assay.
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The full potential of this assay method has yet to be completely explored and
appreciated. One research application of the assay will be to study the time course of
TAFIa activation during clot formation and lysis. The assay can also be used as a
sensitive method to routinely measure the activity of TAFIa and other basic
carboxypeptidases such as CPB. In addition, due to the simplicity and sensitivity of the
assay it could ultimately be used as a tool in clinical settings to identify individuals with
heamostatic diseases based on the variation in TAFIa generation or altered TAFIa
activation and function.
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The balance of the coagulation and fibrinolytic systems is in part mediated by the
activation of the thrombin-activatable fibrinolysis inhibitor (TAFI) pathway [1, 2]. TAFI
is activated by thrombin alone, thrombin in complex with thrombomodulin (TM), or
plasmin. The thrombin-TM complex greatly accelerates the activation of TAFI to
activated TAFI (TAFIa) in comparison to the weak activators thrombin and plasmin [35]. However, the structural basis for the acceleration of TAFI activation by thrombin in
the presence of TM has been relatively elusive. In Chapter 2, we mutated surface-exposed
charged residues on TAFI to alanine to determine the sites on TAFI that allow the
acceleration of activation by TM. We determined that Arg12 is essential and Arg377 is
very important for the activation of TAFI by the thrombin-TM complex. We speculate
that residue Arg12 directly binds to TM whereas residue Arg377 could affect the
interaction between thrombin and TAFI, particularly in the presence of TM. Additionally,
during our study we identified that the activation domain of TAFI is an important region
influencing its accelerated activation by the thrombin-TM complex, as evidence by the
effect of additional mutations beyond Arg12. In Chapter 3, the potential role of cleavage
of TAFI after Arg12 on activation by thrombin-TM was tested by constructing aminoterminal truncation mutants in the activation domain of TAFI. At this time, however, the
results of the study are inconclusive since the proteins were not secreted. Plasmin is a
poor activator of TAFI but the presence of glycosaminoglycans (GAGs) is able to
accelerate its activation as well as stabilize the thermally unstable TAFIa enzyme.
However, the structural basis of these effects is unknown. In Chapter 4, we identified
residues Lys327 and Arg330 as part of a heparin-binding site on TAFI that allows GAGs
to mediate their effect on TAFI function. Finally, in Chapter 5, we designed a novel
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fluorescence assay for the measurement of TAFIa activity which has significantly
increased sensitivity compared to the commonly used carboxypeptidase B (CPB)
substrates hippuryl-arginine or -lysine (Hipp-Arg/Hipp-Lys) and anisylazoformylarginine or -lysine (AAFR/AAFK).

6.1 The interaction between TAFI and thrombomodulin

Based on several studies to date it is becoming increasingly evident that the
mechanisms by which TM meditates the enhancement of TAFI and protein C (PC)
activation by thrombin feature both similarities and differences. Previous studies have
focused on comparing TAFI and PC because they have similar kinetics of activation.
They are both weakly activated by thrombin and in the presence of TM their rate of
activation is greatly accelerated by over 1000-fold [5]. In both cases it is thought that
EGF-5 and EGF-6 bind to thrombin with high affinity while upstream EGF-like domains
interact with the substrate (either TAFI or PC) to present it optimally to thrombin for
cleavage [6, 7]. Although crystallographic analysis of the thrombin-TM structure
appeared to rule out previously-hypothesized allosteric effects of TM acidic residues in
the thrombin active site [6], subsequent reports have suggested some allosteric effects of
TM including relieving a Ca2+-dependent clash between basic residues in thrombin and
PC [8], altering the conformation of the PC activation domain [9], and altering the
conformation of the thrombin active site [10]. Whether these or analogous allosteric
effects play a role in TAFI activation by thrombin-TM has not been explored.
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Most relevant to the work in this dissertation, however, is the fact that TAFI and
PC require different structural elements of TM to allow efficient activation. The smallest
primary structure of TM that allows efficient activation of PC requires the residues of
EGF-4 through EGF-6 plus the six residues connecting EGF-4 to EGF-3 whereas TAFI
requires residues of the c-loop of EGF-3 through EGF-6 [11, 12]. In particular, the
residues within the c-loop of EGF-3 are essential for TAFI activation. A report by Wang
and coworkers identified residues in the c-loop of EGF-3 that are required for TM
cofactor function for TAFI activation. They used alanine scanning mutagenesis of TM
and demonstrated that residues within the c-loop of TM-EGF-3 including Val340,
Asp341, Glu343 and Asp349 are essential for the cofactor function of TM in TAFI
activation but not PC activation. As well, mutation of residues Tyr337, Asp338, Leu339,
Val345 within the c-loop of TM-EGF-3 and residues Glu346 and Val348 within the
interdomain region between EGF-3 and EGF-4 resulted in significantly reduced
activation of TAFI [12]. This study indicated that the residues within the c-loop of TMEGF-3 that are essential for TAFI activation are primarily negatively charged. In Chapter
2, we elected to focus our study on mutating surface-exposed charged residues on TAFI
to alanine in order to identify the regions on TAFI that influence TM-dependent
activation. We did find that the greatest effects on thrombin-TM-dependent activation of
TAFI were observed when basic residues were mutated, consistent with the role for acidic
residues in TM. It is important to note that the interaction between TAFI and TM is not
exclusively mediated through ionic interactions. There are likely also some hydrophobic
and polar uncharged residues on TM that mediate its interaction on the surface of TAFI
through hydrophobic interactions or hydrogen-bonding interactions, respectively. Future
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studies should be aimed at validating the TM interaction surface on TAFI with reciprocal
mutations in the putative region in TM.
In Chapter 2, we identified residue Arg12 as critical for the interaction between
TAFI and TM. Indeed, this residue’s involvement in the interaction confirmed an earlier
report by Plug and coworkers [13] however, our R12A mutant was essentially resistant to
the accelerative effects of TM which is the first mutation of TAFI to be reported with
such an effect. The mutation reported by Plug and coworkers, R12Q, did not yield such a
dramatic effect on TM likely due to the fact that the mutant of TAFI is most likely still
able to make some productive contact with TM [13]. Our mutant, R12A, is novel in that it
essentially disrupted the interaction between TAFI and the cofactor ability of TM. The
location of residue Arg12 on the crystal structure of TAFI is on a surface exposed loop
directly below and in close proximity to the Lys42/Lys43/Lys44 residues within the
activation domain that was reported by Wu and coworkers which had only an 8-fold
reduced catalytic efficiency (kcat/KM) of TAFI activation by the thrombin-TM complex
[14]. It would be interesting to mutate other surface exposed residues in the vicinity of
Arg12 in order to examine this TM binding region on the surface of TAFI.
In addition, TAFI and PC each require different structural elements of thrombin
for activation. A study by Hall and coworkers, using a collection of thrombin mutants
where polar or charged surface residues were mutated to an alanine, found that three
mutants were able to specifically decrease the activation of TAFI without affecting
activation of PC [15]. The thrombin mutations that affected TAFI activation mapped to a
region on thrombin above the active site cleft. Also, thrombin mutations were found that
specifically affected PC activation but had no effect on TAFI activation, and these were
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located below the active site cleft. This study therefore showed that thrombin interaction
with its substrates, TAFI and PC, is through distinct domains [16]. In Chapter 2, we also
identified residue Arg377 as important for the activation of TAFI by the thrombin-TM
complex. Mutant R377A showed a 17-fold reduced catalytic efficiency of TAFI
activation by the thrombin-TM complex but a less than two-fold decreased activation by
thrombin alone. Examining the model of TAFI docked to the thrombin-TM structure [14],
this residue appears in close proximity to where thrombin binds to TAFI. We therefore
speculated that Arg377 of TAFI interacts with thrombin most consequentially in the
ternary complex containing TM, and hence this finding suggests that TAFI interacts with
thrombin in a subtly different manner in the presence and absence of TM. It would be
interesting to determine through mutagenesis and biochemical studies whether Arg377 of
TAFI contacts the region in thrombin above the active site cleft; the binding of TM to
thrombin may position the enzyme active site and the region of TAFI Arg377 in a manner
that causes a tighter interaction between the thrombin-TM complex and TAFI.
Moreover, in Chapter 2, we identified residues within or in close proximity to the
activation domain of TAFI (Arg15, Glu28, Lys59, Glu99 and Glu106) that exhibited a
decreased catalytic efficiency of activation by the thrombin-TM complex and little
difference in catalytic efficiency of activation by thrombin alone. These results indicate
that the variants that showed the strongest TM dependence were focused around the
activation domain which would be near where the c-loop of TM-EGF-3 would interact
with TAFI [14]. The crystal structure of human α-thrombin bound to TM-EGF-4-6, which
is the smallest structure of TM that is capable of activating PC, has been determined and
has been a useful tool in evaluating the structural basis for the acceleration of PC
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activation by TM through the modeling of PC with the complex [6]. Wu and coworkers
docked the crystal structure of TAFI onto this thrombin-TM complex structure, however,
the charged residues of the c-loop of TM-EGF-3 required for TAFI activation are absent
from this structure [14]. This model as well as the crystal structure of TAFI aided in the
selection of residues on TAFI to study in Chapter 2 to assess its interaction with TM
however, the location of TM-EGF-3 relative to the TAFI structure is relatively unknown.
To date, however, a crystal structure of the complex between thrombin and EGF-3-6 of
TM has not been reported. Such a structure would allow additional insights to be gained
regarding the interaction between the TAFI activation domain and thrombin-TM. One
reason for the absence of a crystal structure might be that the extended structure of EGF3-6, compared to EGF-4-6, inhibits crystallization. It would be worthwhile to try and
overcome this effect by attempting to crystallize thrombin-TM in the presence of TAFI,
because TAFI would bind to and perhaps conformationally stabilize the extended EGF-34 region of TM. Such a structural model would be a valuable tool in elucidating the
mechanism by which TM enhances the acceleration of TAFI activation by thrombin.
As the results of Chapter 2 were being prepared for submission, a paper was
published that identified Arg12 as important for the acceleration of TAFI activation by
thrombin-TM [13]. Intriguingly, Arg12 was also reported to be a cleavage site (albeit an
inefficient one) for thrombin and plasmin. The authors speculated that the reason why
their Arg12 to Gln12 mutation was impaired as a substrate for thrombin-TM was because
thrombin cleavage at Arg12 yields a form of TAFI that is a better substrate for thrombinTM. However, the slow kinetics of Arg12 cleavage did not support such a scenario, and
the authors acknowledged that they could not rule out that Arg12 formed a TM-binding
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exosite. The results in Chapter 2 firmly put to rest the notion that cleavage of TAFI at
Arg12 accelerated its activation: cleavage should be equally affected by mutation of
Arg12 to Gln and Ala, yet the mutation to Ala has a much more profound effect on
thrombin-TM activation. Nonetheless, to attempt to more directly address the role of
Arg12 cleavage, we undertook the studies in Chapter 3, with the construction of aminoterminal truncation mutants of the activation domain of TAFI. We attempted to express
the respective recombinant TAFI variants to examine their ability to be activated by the
thrombin-TM complex. Unfortunately, it is difficult to conclude with certainty whether
removal of residues 1-12 has functional consequences since the mutant proteins were not
secreted. Analysis of the crystal structure of TAFI indicates that these residues are likely
crucial for folding of the activation domain, which is likewise probably required to
stabilize the enzyme domain during folding of the protein in the ER lumen. We
speculated that the carboxyl-terminal 6×-His tag may have prevented folding and
secretion of the truncated variants, since studies of a perhaps analogous variant lacking
residues 1-73 showed that this variant could be secreted in the context of an aminoterminal 6×-His tag (or no His tag) and the CIIYQ mutations [17]. We did not observe
secretion of the Δ1-73-CIIYQ variant with a carboxyl-terminal 6×-His tag, although
expression of the mRNA for this variant was greatly diminished compared to the other
variants. Future studies will involve construction of amino-terminally His-tagged versions
of these truncation variants of TAFI.
Although we utilized soluble forms of TM in all our studies, it should be noted
that TM is a transmembrane protein that is expressed on the luminal surface of
endothelial cells [18-20]. Therefore, TAFI activation occurs on the surface of endothelial
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cells and indeed its activation has been demonstrated on human umbilical vein endothelial
cells [7, 21]. However, TM expression has been detected in a variety of other cell types
including human blood monocytes, neutrophils, and smooth muscle cells [22-24]. Studies
have shown that the level of cellular TM antigen increases upon differentiation of the
monocytic cell line THP-1 [25]. TM has also been found in human platelets present at
approximately 60 molecules per platelet whereas approximately 30,000 to 100,000
molecules are found on the endothelial cell surface [20]. These cell surfaces are all likely
to play a role in the activation of TAFI in vivo and should be evaluated in further studies.
As well, soluble TM is found in plasma due to proteolysis of the protein or damage to
endothelial cells due to infections, sepsis, and inflammation [26-31]. Therefore, the
contribution of soluble TM to promoting TAFI activation should be assessed. Soluble TM
has been shown to promote activation of TAFI in the context of in vitro clot lysis assays
[21].

6.2 The interaction between TAFI and Heparin

Although plasmin is a relatively weak activator of TAFI, its activity against TAFI
has been shown to be markedly enhanced in the presence of heparin and other GAGs [4].
Therefore, plasmin may be an important activator at vascular injury sites which expose an
abundance of GAGs present in the extracellular matrix. Additionally, these injury sites
will be comparatively deficient in TM, therefore in the presence of GAGs, plasmin
mediated TAFI activation may dominate thereby contributing to stabilizing the fibrin rich
clot. A study by Mao and coworkers also demonstrated that the presence of GAGs is able
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to stabilize the active enzyme TAFIa causing a 2.3-fold increase in its half-life at 25°C. A
putative GAG-binding site in TAFI was identified by sequence homology with heparinbinding proteins spanning Trp210 through Ser221 [4]. Anand and coworkers later
identified several bound sulfate molecules in the crystal structure of bovine TAFI and
postulated that the sulfates evidenced the existence of a heparin-binding site. The bound
sulfates were found in three locations: at the activation domain, within the active site
cleft, and near the instability/dynamic flap region where it interfaces with the activation
domain [32]. These studies suggested the existence of an interaction between TAFI and
heparin; however, the elements of TAFI structure that interact with heparin to impart
these characteristics remained to be definitively identified.
In Chapter 4, to identify the GAG-binding site(s) on TAFI and assess their
function in regulating TAFI activity, we have expressed recombinant TAFI variants
containing mutations in basic (i.e. positively charged) residues in the predicted regions
that might participate in ionic interactions with the highly anionic GAGs. We chose to
focus on the instability region, since it was the most relevant region to explain the
increased stabilization of TAFIa, as well as the heparin-binding protein-homologous
region spanning Trp210-Ser221 which are predicted to interact with heparin.
Interestingly, many of the residues implicated on bovine TAFI are not conserved in
human TAFI, so we had to either not mutate some residues or mutate other nearby
positively-charged residues. We identified the instability region of TAFI as an important
heparin interaction site on the structure since mutations within this area resulted in the
weakest binding interaction to heparin. In particular, residues Lys327 and Arg330 within
the instability region were identified as part of a functionally-relevant heparin-binding
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site and nearby residues Arg320 and Lys324 may also be involved. The results of TAFI
mutant R320A/K324A hinted at the existence of more than one heparin binding site
present on the TAFI structure due to the weak binding of this variant to heparin, yet its
normal sensitivity to the effects of heparin during plasmin activation and TAFIa
stabilization indicates that these residues are not functionally relevant.
Our study was based on the individual bound sulfates in the crystal structure of
bovine TAFI and therefore each bound sulfate does not necessarily represent a heparinTAFI interaction since GAGs are long, unbranched polysaccharide polymers of varying
lengths containing variable amounts of sulfate or carboxyl groups on their sugars [33, 34].
In addition, GAG-binding consensus sequences do not exist in all heparin-protein
interactions indicating that several factors determine the interaction between GAGs and
proteins including length, anionic character and stereochemistry of the polysaccharide,
and conformation of the protein structure [35, 36]. Yet, our study provided clues into the
interaction between TAFI and heparin. Future studies should be aimed at identifying
other heparin-binding regions on TAFI through mutagenesis studies. The TAFI structure
contains several exposed positively charged surface patches which may provide
interaction sites with heparin since its interaction with proteins is primarily mediated
through ionic interactions. In addition, we used only a semi-quantitative method for
assessment of heparin binding to TAFI through the use of an affinity chromatography
approach. A previous graduate student in our group had attempted to measure the binding
of TAFI to heparin by measurement of the intrinsic fluorescence of TAFI or by using
fluorescently-labeled heparin. No binding was revealed by these methods, which indicates
that if binding was occurring, perhaps it did not influence the quantum yield of the
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intrinsic or extrinsic fluorophores. Another possible method to measure binding would be
surface plasmon resonance. Importantly, this technique would readily be able to detect the
presence of multiple binding sites for heparin on TAFI as well as their respective
affinities.
To date, the structural basis for the interaction of plasmin with TAFI is relatively
uncharacterized. However studies by Mishra and coworkers utilizing monoclonal
antibodies have identified some important residues on TAFI for interaction with plasmin
including residues Lys268, Ser272, Arg276, Thr147, Ala148 and Phe113 [37].

In

Chapter 4 we identified residues Lys212 and Lys211 as potentially participating in
plasmin binding to TAFI. The position of residues Lys212 and Lys211 on the threedimensional structure of TAFI is located on the surface near the scissile bond (Arg92Ala93). Plasmin’s protease domain or lysine-binding kringles may interact with residues
near Arg92 which would explain why these variants showed an increase in KM as well as
reduced plasmin activation in the absence of heparin compared to wild-type.
Additionally, whether the exposed positively charged surface patches on TAFI are
sites for interacting with the kringle domains of plasmin is unknown since residues near
the scissile bond may not be the only determinants of substrate specificity. Activation of
plasminogen to plasmin, gives the protease a more open conformation which may allow it
to stretch out to these regions on the surface of the TAFI protein allowing it cleave the
scissile bond while being bound to lysine-containing exosites elsewhere on the substrate.
As a compounding effect, the impaired interaction with plasmin could possibly impair the
ability of heparin to elicit its effects. For example, in the case of thrombin inhibition by
antithrombin, heparin catalyzes the reaction by binding to both thrombin and
219

antithrombin [38, 39]. Therefore, it is possible that heparin binds to both plasmin and
TAFI, thus allowing heparin’s accelerating effect on TAFI activation by plasmin. In that
case, impaired binding of TAFI to plasmin would also affect heparin binding to TAFI. To
investigate this possibility, a truncated form of plasmin can be used. Microplasmin lacks
all 5 kringles, but has an active catalytic domain [40], thus it could still activate TAFI.
This approach may give insight on whether heparin can still elicit its catalyzing effect on
plasmin-mediated activation of TAFI in a kringle-independent manner. To fully
appreciate the accelerating effects of heparin on TAFI activation by plasmin we need to
understand how plasminogen/plasmin interacts with TAFI. Until then it will be difficult
to differentiate heparin interaction sites on TAFI that promote activation and heparin
interaction sites that promote stability. On a more fundamental level, the mechanism
underlying the effect of heparin on plasmin-mediated activation of TAFI remains unclear.
Importantly, heparin has been shown to bind to kringle 5 of plasminogen [41]. This
suggests that heparin could act as a bridge to promote an encounter complex between
plasmin and TAFI. Further kinetic and mutagenesis studies will be required to address
this possibility.
As expected, mutations in the dynamic flap region of TAFI had the greatest effect
on stabilization of TAFIa by heparin. The dynamic flap is held in place in the zymogen
(whose potential activity is stable) through interactions with the activation domain. Upon
removal of the activation domain, the dynamic flap is proposed to undergo a structural
transition that alters the position of the catalytically critical Glu363 residue present where
the dynamic flap re-enters the core of the enzyme [42]. The spontaneous loss of TAFIa
activity is associated with a substantial (almost 50%) decrease in the intrinsic
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fluorescence of the enzyme [43, 44] as well as a markedly decreased solubility [45, 46]. It
is difficult to imagine that these effects could be accounted for by a change in the
conformation of the dynamic flap alone. Presumably, movement of the dynamic flap
triggers additional structural changes, evidence for which has been found in fluorescence
[43] and antibody-binding studies [47]. The structure of “inactive” TAFIa is unknown. In
any event, movement of the dynamic flap certainly is the key step in TAFIa inactivation.
We speculate that the ability of heparin to bind in this region reduces the conformational
freedom of the dynamic flap thus stabilizing the enzyme. Crystallization of TAFI/TAFIa
in the presence of heparin (or, more likely, a homogenous GAG analogue such as
fondaparinux) should shed light on this issue.
Mao and coworkers also demonstrated that other GAGs/proteoglycans such as
chondroitin sulfate, dermatan sulfate, and high concentrations of heparan sulfate and
keratan sulfate are capable of stimulating plasmin-mediated TAFI activation [4].
However, the study only showed semi-quantitatively the efficacy of the different GAGs
in plasmin activation and it is unknown how these GAGs affect stabilization of TAFIa.
Further studies should determine the effects of the different GAGs on TAFI activation by
plasmin through kinetic analysis as well as on TAFIa stabilization. In addition, it has been
shown that GAGs can inhibit the activation of TAFI by the thrombin-TM complex
however the structural basis of these effects is not known [48]. The K327A and
K327A/R330A variants constructed in Chapter 4 could be used as tools to assess the
activation of TAFI by the thrombin-TM complex in the presence of heparin since they
bind very poorly to heparin. It is important to determine the molecular basis for these
effects since TM and GAGs do not exist in isolation physiologically. Moreover, the role
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of cell surface and extracellular matrix GAGs on TAFI activation by thrombin-TM and
plasmin should be investigated. The loss of function mutants that have been generated
and characterized in this dissertation would be very useful for this task. It essential to try
to understand the how the activation of TAFI is regulated by these factors as it will give
us clues into how the TAFI pathway is regulated in vivo.

6.3 Monitoring TAFIa activity with a Fluorescence-based assay

Many methods have been described for measuring the carboxypeptidase activity
of the TAFIa enzyme. Synthetic substrates such as Hipp-Arg/Hipp-Lys and AAFR/AAFK
are able to detect TAFIa activity in a purified system through spectrophotometric means
[44, 49-51]. However, these substrates cannot be used to detect TAFIa activity in the
context of plasma since they suffer from low sensitivity and absorbance detection will not
be possible during clot lysis assays. Other, indirect, assays have been reported to detect
TAFIa activity; however, they either require many components that are not readily
available or are time-consuming due to the complexity of the assay method [52-54]. No
matter how sensitive, no indirect method can measure the accumulation (and
disappearance) of TAFIa in real-time in the context of a clot.
In Chapter 5, we describe the development of a novel fluorescence assay to detect
TAFIa activity utilizing a fluorescent substrate. This is the first direct fluorogenic
substrate system ever described for TAFIa or any other carboxypeptidase. The basis of
the assay is the ability of TAFIa to catalyze the removal of carboxyl-terminal arginine
residues from a synthetic peptide substrate modified with an amino-terminal
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tetramethylrhodamine (TAMRA) fluorophore.

The carboxyl-terminal arginine in the

synthetic substrate electrostatically interacts with the anionic quencher, Evans Blue, to
allow fluorescence quenching of the TAMRA fluorophore. The cleavage of the carboxylterminal arginine by TAFIa results in the release of the synthetic substrate bound to the
quencher thus producing an increase in fluorescence. This assay was shown to be
detectable at TAFIa concentrations as low as 100 pM. The fluorescence based assay has
advantages over the existing substrates used to measure TAFIa activity including its
greatly increased sensitivity compared to the currently available carboxypeptidase B
substrates Hipp-Arg/Hipp-Lys and AAFR/AAFK and the simplicity of the assay method.
We undertook various strategies to optimize the assay, most notably by comparing
and titrating various anionic quenchers. Such optimization is crucial in the context of this
assay for the maximization of the signal-to-noise ratio of the assay and for ensuring that it
faithfully reports the concentration of TAFIa at all time points. One reason why careful
optimization is necessary is the dynamic equilibrium that exists between the anionic
quencher and the arginine side chain in the substrate. If the quencher is too abundant, then
insufficient “free” carboxyl-terminal arginine is available at any time to be recognized by
TAFIa. If the quencher is too scarce, an insufficient degree of quenching of the TAMRA
moiety would result and the sensitivity of the assay would suffer. In addition, the
equilibrium would be perturbed as the assay proceeds and the substrate is consumed,
which might affect the rate of substrate cleavage and/or residual quenching. In our first
attempts at running the assay, we used TAFIa, and observed that the fluorescence
plateaued at a different level depending on the concentration of TAFI present (see Figure
5-9A and C, for example). We speculated that either the equilibrium perturbation was
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having an effect, or that TAFIa activity was being prematurely quenched in the context of
the assay. When we used stable TAFIa-CIIYQ and, particularly, CPB, however, these
plateau effects were either greatly diminished or absent. This would tend to rule out an
effect arising from perturbation of quencher binding equilibrium. On the other hand, we
could see no effect of the assay components on the specific activity or the stability of
TAFIa. Another possibility is some sort of product inhibition that specifically affects
TAFIa. In any event, these effects underscore the need to carefully optimize the assay and
to measure rates of hydrolysis when substrate consumption is linear.
At this point in time there is no assay available that is able to continuously
measure the enzymatic activity of TAFI in the context of plasma as it becomes activated
during lysis assays. The preliminary experiments conducted thus far provide a starting
point for beginning the optimization of this assay in a plasma containing system. We are
able to detect the activation of TAFI in vitro in real-time in a purified system however,
further studies require the optimization of the assay to be able to measure the activation of
TAFI in plasma. Future studies require the determination of correction factors for the
inner-filter effects in the context of a purified and plasma system. As well, the intra- and
interassay variability needs to be assessed to determine the reproducibility of the assay.
Following future optimization, this assay may provide a means to examine TAFIa
generation in real-time within clots which will provide insight into the regulation of TAFI
activity.
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6.4 Concluding Remarks

It is essential that a balance exists between the activities of the coagulation and
fibrinolytic pathways. Imbalances lead to excessive blood loss as well as inappropriate
thrombus formation. Excessive activation of plasma TAFI poses a risk factor for the
development of thrombotic diseases whereas inefficient activation of plasma TAFI is
detrimental to the formation of a stable fibrin clot. This dissertation was generally focused
on analysis of the control of the elaboration of TAFIa activity. The identity of the
activators of TAFI in particular physiological and pathophysiological contexts remains
largely unexplored. Other groups have utilized antibodies that specifically prevent TAFI
activation by one or more activators to probe this question. Our approach is distinct but
complementary: to generate specific loss-of-function variants that are resistant to
activation by specific activators or modulation of activation. The findings in this
dissertation as well as prior work from our group [51] has resulted in a “tool-kit” of wellcharacterized variants that can be brought to bear on these questions. Future studies
should therefore be aimed at assessing the relative contribution of each of the activators in
activating TAFI as well as determine the activator of TAFI in various physiological and
pathophysiological contexts. This could be done both in vitro with recombinant protein or
even in vivo with mutations knocked into mice or rats using genome editing approaches.
The R12A variant, in particular, with a specific and profound defect in thrombin-TM
mediated activation, would be a particularly attractive candidate in this context.
The studies described provide insight into the elements of structure required for
the activation of TAFI by the thrombin-TM complex and well as the structural basis for
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the acceleration of plasmin-mediated TAFI activation by GAGs and the stabilization of
the TAFIa enzyme. These studies will aid in further propelling the determination of the
mechanism of TAFI activation by the respective activators. They may also provide the
rationale for the development of therapeutics aimed at manipulating the activity of the
TAFI pathway. For instance, activation of TAFI has been shown to decrease the efficacy
of thrombolytic therapy [55]. Promotion of TAFI activation, however, would be a
potential strategy to ameliorate the propensity for bleeding that is observed in hemophilia
and other bleeding diatheses.
Finally, the fluorescence-based TAFIa assay described could provide a useful tool
for examining the regulation of the TAFI pathway in different settings in the vasculature
and for the continuous measurement of TAFIa generation during clot formation and lysis
assays, respectively. Previous studies have shown a donor-dependent difference in the
functional elaboration of TAFIa activity that was associated with risk for ischemic stroke
[56]. Our assay could be applied clinically to identify subjects with impaired or
accelerated TAFI activation thus reflecting dysfunction of the fibrinolytic system.
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